



# CONGRESS PROGRAM

# Friday, 8 October 2010

13.00–14.00 **Turquoise Hall 2**  
**Masterclass lunch**

14.00–17.00 **Turquoise Hall 2**

## Young Oncologist Masterclass

### The importance of conducting well-designed clinical trials

Co-Chairs: Susana N. Banerjee, London, UK and

Marina C. Garassino, Milan, Italy

Session Shooters: Raffaele Califano, Manchester, UK,

Konstantinos Kamposioras, Haidari, Attica, Athens, Greece,

Christophe Massard, Villejuif, France

14.00 Statistical issues and how to use biomarkers as surrogates  
in the 21<sup>st</sup> century

Marc Buyse, Ottignies Louvain-la-Neuve, Belgium

14.50 Coffee break

15.10 Biobanking in clinical trials: What, when and  
how should I collect samples?

Maria Grazia Daidone, Milan, Italy

16.00 Break

16.10 Stopping a cancer trial early: is it really for the benefit of  
patients? What about the quality of data?

Pinuccia Valagussa, Milan, Italy

18.30–20.00 **Gold Hall**

## Opening Ceremony

18.30 ESMO Presidential address

David J. Kerr, Oxford, UK

18.55 Congress Local Committee Welcome

Umberto Veronesi, Milan, Italy and

Roberto Labianca, Bergamo, Italy

19.05 Welcome to Lombardy

Roberto Formigoni, President of Lombardy Region (TBC)

19.15 Welcome to Milan

Letizia Moratti, Mayor of Milan

19.25 Scientific address

Rolf A. Stahel, Zurich, Switzerland, Scientific Chair

19.35 ESMO Award to Alberto Costa

19.40 Performance: “The best of Italian Opera”

20.00 Welcome Reception in the Gold Foyer

# Saturday, 9 October 2010

08.00–08.45 **Turquoise Hall 2**

## Young Oncologist Breakfast

### How to write an outstanding manuscript

David J. Kerr, Oxford, UK

08.00–09.00 **Yellow Hall 1**

## Challenge Your Expert session

### Cancer of unknown primary site (CUP): 20 questions to be answered

Nicholas Pavlidis, Ioannina, Greece

08.00–09.00 **Yellow Hall 2**

## Challenge Your Expert session

### Mesothelioma

Walter Weder, Zurich, Switzerland

08.00–09.00 **Yellow Hall 3**

## Challenge Your Expert session

### Genetic counselling for hereditary predisposition to ovarian and breast cancer

James Mackay, London, UK

08.00–09.00 **Green Hall 3**

## Challenge Your Expert session

### Osteosarcoma

Stefan Bielack, Stuttgart, Germany

08.00–09.00 **Green Halls 1+2**

## Patient Cases session

### Team work in palliative care

Co-Chairs: Philip J. Larkin, Dublin, Ireland and

Lukas Radbruch, Bonn, Germany

08.00 What nurses contribute

Philip J. Larkin, Dublin, Ireland

08.10 What doctors contribute

Lukas Radbruch, Bonn, Germany

08.20 Discussion

08.00–09.00 **Orange Halls 2+3**

## Patient Cases session

### Hepatocellular carcinoma: A multi-step therapeutic approach

Co-Chairs: Jordi Bruix, Barcelona, Spain and

Jean-Luc Raoul, Rennes, France

08.00 An early-stage HCC

Jordi Bruix, Barcelona, Spain

08.10 An intermediate case of HCC

Jean-Luc Raoul, Rennes, France

08.20 Discussion

08.00–09.00 **Orange Hall 1**

### Multidisciplinary Interactive session (MIS)

#### Optimal integration of chemotherapy and radiotherapy in small cell lung cancer

Co-Chairs: Fiona Blackhall, Manchester, UK and Corinne Faivre-Finn, Manchester, UK

- 08.00 Radiotherapy  
Corinne Faivre-Finn, Manchester, UK
- 08.15 Medical Oncology  
Fiona Blackhall, Manchester, UK
- 08.30 Discussion

09.00–10.30 **Gold Hall**

### Educational session

#### Diagnostic and management issues in metastatic breast cancer

Chairs: Fabrice André, Villejuif, France and José Baselga, Boston, MA, USA

- 09.00 What can the pathologist offer for optimal treatment choice?  
Giuseppe Viale, Milan, Italy
- 09.30 Treatment of triple negative breast cancer  
Fabrice André, Villejuif, France
- 10.00 Treatment of Her2-overexpressing breast cancer  
José Baselga, Boston, MA, USA

09.00–10.30 **Violet Hall**

### Educational session

#### New therapeutic opportunities in urological cancer

Chair: Joaquim Bellmunt, Barcelona, Spain  
Co-Chair: Vesa Kataja, Kuopio, Finland

- 09.00 New hormonal agents in the treatment of advanced prostate cancer  
Johann de Bono, Sutton, UK
- 09.30 New agents for bladder cancer  
Joaquim Bellmunt, Barcelona, Spain
- 10.00 How to select targeted therapy in renal cancer  
Bernard Escudier, Villejuif, France

09.00–10.30 **Pink Hall**

### Educational session

#### How much do we know about cancer cells?

Chair: Carlos Cordon-Cardo, New York, NY, USA  
Co-Chair: Marco A. Pierotti, Milan, Italy

- 09.00 The epithelial-mesenchymal transition (EMT) phenomenon  
Pierre Savagner, Montpellier, France
- 09.30 Cancer stem cells  
Carlos Cordon-Cardo, New York, NY, USA
- 10.00 Circulating cancer cells  
Dimitrios Mavroudis, Heraklion, Greece

09.00–10.30 **Blue Hall**

### Educational session

#### Advances in neuroendocrine tumors

Chair: William Travis, New York, NY, USA  
Co-Chair: George Pentheroudakis, Kardamitsia, Greece

- 09.00 Lung neuroendocrine  
William Travis, New York, NY, USA
- 09.30 Gastrointestinal neuroendocrine tumors  
Kjell Oeberg, Uppsala, Sweden
- 10.00 Merkel tumors  
Jürgen Becker, Würzburg, Germany

09.00–10.30 **Silver Hall**

### Proffered Paper session

#### Supportive and palliative care

Chair: Jørn Herrstedt, Odense, Denmark  
Co-Chair: Fausto Roila, Terni, Italy

- 09.00 **12340** – Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS)  
Clelia Madeddu, Cagliari, Italy
- 09.15 **12350** – A randomized controlled trial of antimicrobial prophylaxis infusion after gastric cancer surgery (OGSG0501)  
Yukinori Kurokawa, Osaka, Japan
- 09.30 Invited Discussant, Abstracts 12340 and 12350  
Simon Van Belle, Ghent, Belgium
- 09.45 **11810** – First randomized trial comparing balloon kyphoplasty (BKP) to non-surgical management among cancer patients with vertebral compression fractures  
Leonard Bastian, Leverkusen, Germany

- 10.00 12360** – Control of nausea with palonosetron versus granisetron both combined with dexamethasone in patients undergoing cisplatin (CDDP) – or anthracycline plus cyclophosphamide (AC/EC)-based regimens  
Kaoru Kubota, Tokyo, Japan
- 10.15** Invited Discussant, Abstracts 11810 and 12360  
Fausto Roila, Terni, Italy

**09.00–10.30 Red Hall**

### Special Symposium

#### ESMO/CSCO Joint Symposium. Personalised medicine:

#### Do ethnic differences matter?

Co-Chairs: David J. Kerr, Oxford, UK and Shu-Kui Qin, Nanjing, China

- 09.00** Pharmogenomic and SNP in diverse ethnicity  
Howard McLeod, Chapel Hill, NC, USA
- 09.20** Hepatocellular carcinoma (HCC)  
Shu-Kui Qin, Nanjing, China
- 09.40** Personalized management of lung cancer:  
EGFR mutation and beyond  
Tony S. K. Mok, Hong Kong, China
- 10.00** Colorectal cancer  
David J. Kerr, Oxford, UK
- 10.20** Conclusions

**09.30–10.30 Orange Hall 1**

### Multidisciplinary Interactive session (MIS)

#### Locally advanced pancreatic cancer

Co-Chairs: Christophe Louvet, Paris, France and Hanno Riess, Berlin, Germany

- 09.30** Medical Oncology  
Hanno Riess, Berlin, Germany
- 09.45** Medical Oncology  
Christophe Louvet, Paris, France
- 10.00** Radiotherapy  
Florence Huguet, Paris, France
- 10.15** Discussion

**11.00–12.30 Gold Hall**

### Educational session

#### Treatment of PT1N0 breast cancer

Chair: Angelo Di Leo, Prato, Italy

Co-Chair: Fatima Cardoso, Lisbon, Portugal

- 11.00** Multigene predictors to assess risk of relapse  
Christos Sotiriou, Brussels, Belgium

- 11.30** Benefits and adverse effects of endocrine therapy  
Marco Colleoni, Milan, Italy
- 12.00** Chemotherapy with or without trastuzumab  
Angelo Di Leo, Prato, Italy

**11.00–12.30 Violet Hall**

### Educational session

#### Advances in the treatment of advanced colorectal cancer

Chair: Claus-Henning Koehne, Oldenburg, Germany

Co-Chair: Thierry André, Paris, France

- 11.00** What can the molecular pathologist offer for optimal decision-making?  
Philip Quirke, Leeds, UK
- 11.30** Chemotherapy: Which drugs and when?  
Alberto Sobrero, Genoa, Italy
- 12.00** How to integrate molecular targeted agents in the continuum of care  
Claus-Henning Koehne, Oldenburg, Germany

**11.00–12.30 Pink Hall**

### Educational session

#### Prevention and treatment of side effects of systemic treatment

Chair: Mario Dicato, Luxembourg

Co-Chair: Jørn Herrstedt, Odense, Denmark

- 11.00** Anemia  
Mario Dicato, Luxembourg
- 11.30** Cardiotoxicity  
Josep Tabernero, Barcelona, Spain
- 12.00** Bone loss  
Jean-Jacques Body, Brussels, Belgium

**11.00–12.30 Blue Hall**

### Educational session

#### Updates in B-cell malignancies

Chair: Michele Ghilmini, Bellinzona, Switzerland

Co-Chair: Håkan Mellstedt, Stockholm, Sweden

- 11.00** Multiple myeloma  
Meletios Dimopoulos, Athens, Greece
- 11.30** Follicular lymphoma  
Michele Ghilmini, Bellinzona, Switzerland
- 12.00** Chronic lymphocytic leukemia  
Michael Hallek, Cologne, Germany



11.00–12.30 **Silver Hall****Proffered Paper session****Chest tumors I**

Chair: Luis Paz-Ares, Seville, Spain

Co-Chair: Rolf A. Stahel, Zurich, Switzerland

**11.00 LBA13** – Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations  
Caicun Zhou, Shanghai, China

**11.15 LBA14** – First biomarker analyses from a phase III, randomised, open-label, first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL, CTONG 0802)  
Yi-long Wu, Guangzhou, China

**11.30** Invited Discussant, LBA13 and LBA14  
Federico Cappuzzo, Livorno, Italy

**11.45 3630** – Final results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)  
Lecia Sequist, Boston, MA, USA

**12.00 LBA15** – Randomized multicenter double-blind placebo-controlled phase II study evaluating MetMab, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer  
David Spigel, Nashville, TN, USA

**12.15** Invited Discussant, Abstract 3630 and LBA15  
Luis Paz-Ares, Seville, Spain

11.00–12.30 **Red Hall****Special Symposium**

**ESMO/ESTRO/ESSO Joint Symposium. Surgery, radiotherapy and ablation of metastatic disease and chemotherapy for localized disease: Changing roles in multidisciplinary management of colorectal cancer**

Co-Chairs: Jean Bourhis, Villejuif, France and  
David J. Kerr, Oxford, UK

**11.00** Image guided therapy of metastases from colorectal cancer

Thierry de Baere, Villejuif, France

**11.20** It's resectable, but is it curable?

Graeme Poston, Liverpool, UK

**11.40** Radiotherapy: From palliation to cure and prophylaxis?

Guy Storme, Brussels, Belgium

**12.00** Locoregional delivery of chemotherapy for metastatic CRC – what's the evidence?

Rachel Midgley, Oxford, UK

**12.20** Conclusions

Peter Naredi, Umeå, Sweden

12.45–13.35 **Violet Hall****Keynote Lecture**

**Polymorphisms in drug metabolising enzymes and drug transporters: Influence on drug pharmacokinetics and patient response to treatment**

Chair: Marco A. Pierotti, Milan, Italy

Speaker: Jos Beijnen, Amsterdam, Netherlands

13.00–14.00 **Green Halls 1+2****Poster Symposium (Discussion session)****Breast cancer, early**

Co-Chairs: Bryan Hennessy, Dublin, Ireland and

Xavier Pivot, Besançon, France

**216PD** – ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy ± capecitabine (C) in triple-negative early breast cancer (TNBC)

Guenther Steger, Vienna, Austria

**217PD** – Adjuvant endocrine therapy, alone or in combination with zoledronic acid (ZOL), in premenopausal patients (pts) with endocrine-responsive early breast cancer (EBC): Subgroup analyses of ABCSG-12  
Guenther Steger, Vienna, Austria

**218PD** – The development of a formulation of trastuzumab for subcutaneous administration

Vernon Harvey, Auckland, New Zealand

**219PD** – Neo-adjuvant chemotherapy treatment and response in different breast cancer subtypes:

pooled multi-layer analysis of the German trials

Michael Untch, Berlin, Germany

**220PD** – A presurgical trial of lapatinib versus placebo in Her-2 positive breast cancer

Andrea De Censi, Genoa, Italy

**13.00** Invited Discussant, Abstracts 216PD-220PD

Xavier Pivot, Besançon, France

**221PD** – Validation of PRO\_10, a multigene prognostic signature, in patients (pts) with early, estrogen receptor positive (ER+) postmenopausal breast cancer (BC)

Andreas Moor, Berne, Switzerland

**222PD** – Prospective transGEICAM study of Oncotype DX® in clinical decision making in estrogen receptor-positive node-negative breast cancer women

Joan Albanell, Barcelona, Spain

- 223PD** – Economic impact of Oncotype DX assay in axillary node negative breast cancer, (AxN-BC) with positive hormone receptor (rec+) and normal HER-2 (HER2-) Elaine Wilson, Dublin, Ireland
- 13.15** Invited Discussant, Abstracts 221PD-223PD Bryan Hennessy, Dublin, Ireland
- 13.30** General Discussion

13.00–14.00 **Orange Halls 2+3**

### Poster Symposium (Discussion session)

#### Colorectal cancer

Co-Chairs: Fortunato Ciardiello, Naples, Italy, Gunnar Folprecht, Dresden, Germany and Graeme Poston, Liverpool, UK

- 581PD** – Trial participation in a multicentre phase III trial (CAIRO) in advanced colorectal cancer (ACC) patients (pts) in the Netherlands, and a comparison of outcome between trial and non-trial pts Cornelis Punt, Nijmegen, Netherlands
- 582PD** – Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). Analysis of the randomized trial of the German AIO CRC study group: KRK-0204 Sebastian Stintzing, Munich, Germany
- 583PD** – Efficacy and safety of second-line treatment with panitumumab plus irinotecan, both given every three weeks (Q3W), in patients (pts) with wild-type (WT) K-RAS metastatic colorectal cancer (mCRC): A study from the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) Auxiladora Gomez, Cordoba, Spain
- 13.00** Invited Discussant, Abstracts 581PD-583PD Gunnar Folprecht, Dresden, Germany
- 584PD** – Impact of KRAS status on survival in patients (pts.) with metastatic colorectal cancer (mCRC) undergoing bevacizumab (bev) containing chemotherapy regimen – Analysis of the AIO Colorectal Cancer Study Group Anke Claudia Reinacher-Schick, Bochum, Germany
- 585PD** – The multi-targeted kinase inhibitor AEE788 exerts anti-proliferative effects in BRAF mutated colorectal cancer cells Araceli Valverde, Cordoba, Spain
- 586PD** – High throughput somatic profiling of the Ras-Raf-MAP and PI3K-PTEN-Akt pathways in advanced colorectal cancer and correlations with response to cetuximab Christopher Smith, Cardiff, UK

- 13.12** Invited Discussant, Abstracts 584PD-586PD Fortunato Ciardiello, Naples, Italy
- 587PD** – Oncologic and functional outcomes after preoperative chemoradiotherapy followed by intersphincteric resection for very low rectal cancer Masaaki Ito, Kashiwa, Japan
- 588PD** – Trans-arterial chemoembolization of metastatic colorectal carcinoma (MCRC) to the liver adopting polyvinyl alcohol microspheres (PAM) loaded with irinotecan compared with FOLFIRI (CT): Evaluation at two years of a phase III clinical trial Giammaria Fiorentini, Empoli, Italy
- 13.24** Invited Discussant, Abstracts 587PD-588PD Graeme Poston, Liverpool, UK
- 13.36** General Discussion

13.00–14.00 **Yellow Hall 1**

### Poster Symposium (Discussion session)

#### Gynecological cancer

Co-Chairs: James Brenton, Cambridge, UK and Ate van der Zee, Groningen, Netherlands

- 973PD** – The ENDORAD trial: RAD001 (everolimus) monotherapy as second-line or third line treatment of advanced endometrial carcinoma: a phase II trial of GINECO group Isabelle Ray-coquard, Paris, France
- 974PD** – Single-agent activity and safety of the investigational Aurora A kinase inhibitor MLN8237 in patients with platinum-treated epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Ursula Matulonis, Boston, MA, USA
- 975PD** – A randomized, double-blind, placebo-controlled phase II study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer Ignace Vergote, Leuven, Belgium
- 976PD** – Tolerability of trabectedin (Tr) plus pegylated liposomal doxorubicin (PLD) in platinum sensitive (P-S) vs. platinum resistant (P-R) patients (pts) with relapsed ovarian cancer Karin Boman, Umeå, Sweden
- 13.00** Invited Discussant, Abstracts 973PD-976PD James Brenton, Cambridge, UK
- 977PD** – Prognostic value of early complete metabolic response by FDG-PET during neo-adjuvant chemotherapy in advanced ovarian cancer patients Marta Rosati, Bologna, Italy
- 978PD** – Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the

primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study  
Robert Burger, Philadelphia, PA, USA

**979PD** – Expression of DNA repair genes as biomarkers of outcome in epithelial ovarian cancer: A GEICO study  
Andres M Poveda, Valencia, Spain

**13.15** Invited Discussant, Abstracts 977PD-979PD  
Ate van der Zee, Groningen, Netherlands

**13.30** General Discussion

13.00–14.00 **Yellow Hall 2**

### Poster Symposium (Discussion session)

#### Biomarkers I

Co-Chairs: Giampaolo Tortora, Naples, Italy and  
Johan Vansteenkiste, Leuven, Belgium

**160PD** – Smoking-induced p16 methylation in young women

Yuk Ting Ma, Birmingham, UK

**161PD** – Diagnostic markers in bronchial fluid of lung cancer patients; immunoassay development and validation  
Sergio Carrera, Barakaldo, Spain

**162PD** – ProGRP levels in patients with lung cancer  
Rita Passerini, Milan, Italy

**163PD** – Long term follow-up for EBUS-TBNA negative mediastinal lesions

Matthew N. Wong, Hong Kong, China

**164PD** – Detection of tumor angiogenesis in solid tumours via the expression of  $\alpha$ 3 integrin using an RGD peptide, [<sup>18</sup>F]fluciclatide, and positron emission tomography (PET) imaging

Rohini Sharma, London, UK

**13.00** Invited Discussants, Abstract 160PD-164PD  
Johan Vansteenkiste, Leuven, Belgium

**165PD** – An EZH2 polymorphism predicts progression-free survival (PFS) in metastatic colorectal cancer (CRC) patients treated with first-line FOLFIRI plus bevacizumab (BV)  
Francesco Crea, Pisa, Italy

**166PD** – The single nucleotide polymorphism C>G rs420549 in TGFBR1 and microRNA 511 (miR-511) as a new biomarkers in advanced colorectal cancer  
José Carlos Villa Guzmán, Ciudad Real, Spain

**167PD** – Predictive value of the simultaneous detection of somatic quantitative molecular alterations using the quantitative multiplex PCR of short fluorescent fragments method (QMPSF) in stage II-III colon cancer: A prospective study

Laura Debeir, Rouen, France

**168PD** – Baseline levels of circulating angiogenic factors in metastatic colorectal cancer pts (mCRC) treated with bevacizumab (BEV)

Antonia Martinetti, Milan, Italy

**169PD** – Clinical significance of incidental focal colorectal uptake detected in <sup>18</sup>F-FDG PET-CT studies  
Jordi Fuertes, Barcelona, Spain

**13.15** Invited Discussants, Abstracts 165PD-169PD  
Giampaolo Tortora, Naples, Italy

**13.30** General Discussion

13.00–14.00 **Yellow Hall 3**

### Poster Symposium (Discussion session)

#### Supportive and palliative care

Co-Chairs: Dorothy M. K. Keefe, Adelaide, Australia and  
Lukas Radbruch, Bonn, Germany

**1199PD** – Cognitive symptoms in cancer patients attending medical oncology clinics

Victoria Bray, Sydney, Australia

**1200PD** – What Greek women with breast cancer want to know about their illness and how much do they want to participate in treatment decision making?

Aygoustina Almyroudi, Ioannina, Greece

**1182PD** – Attitude and knowledge about end-of-life support: A Bavarian survey

Wolfgang Sandtner, Landshut, Germany

**1237PD** – Effect of low-molecular-weight heparin (LMWH) nadroparin on hemostatic variables in ambulatory cancer patients enrolled in the PROTECHT trial

Anna Falanga, Bergamo, Italy

**13.00** Invited Discussant, Abstracts 1199PD-1200PD-1182PD-1237PD

Lukas Radbruch, Bonn, Germany

**1238PD** – Granulocyte colony stimulating factor (G-CSF) prophylaxis and febrile neutropenia (FN) incidence in patients with solid tumours receiving myelotoxic chemotherapy who are assessed as high risk for FN: IMPACT SOLID study  
Johanna Maenpää, Tampere, Finland

**1239PD** – Successful titration of fentanyl pectin nasal spray in a broad range of patient types for the treatment of breakthrough cancer pain

Luis Torres, Cadiz, Spain

**1183PD** – Randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed dose of oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed dose of pregabalin for the treatment of oncological neuropathic pain (NEUROPAIN-01)  
Marina Garassino, Milan, Italy

- 13.15** Invited Discussant, Abstracts 1238PD-1239PD-1183PD  
Dorothy M. K. Keefe, Adelaide, Australia
- 13.30** General Discussion

**14.00–15.30** **Blue Hall**

**Special Symposium**

**ESMO/JSMO Joint Symposium. Biomarkers and selected therapeutics in lung and gastrointestinal cancer**

Co-Chairs: David J. Kerr, Oxford, UK and Kazuo Tamura, Fukuoka, Japan

- 14.00** Recent progress in JSMO and society activities  
Kazuo Tamura, Fukuoka, Japan
- 14.05** EGFR-TKI for EGFR mutated NSCLC: New evidence  
Isamu Okamoto, Osaka, Japan
- 14.25** Anti-HER2 and angiogenesis inhibitors for gastric cancer: Updated results  
Atsushi Ohtsu, Kashiwa, Japan
- 14.45** Predictive biomarkers in the treatment of advanced colorectal cancer  
Josep Tabernero, Barcelona, Spain
- 15.05** The immediate future of customized treatment in lung cancer  
Rafael Rosell, Badalona, Barcelona, Spain
- 15.25** Conclusions  
David J. Kerr, Oxford, UK

**14.15–15.45** **Gold Hall**

**Educational session**

**Early-stage NSCLC: Challenges in staging and adjuvant treatment**

Chair: Thierry Le Chevalier, Villejuif, France

Co-Chair: Paul Baas, Amsterdam, Netherlands

- 14.15** Evidence-based staging  
Johan Vansteenkiste, Leuven, Belgium
- 14.45** Adjuvant chemotherapy: Where is it going?  
Thierry Le Chevalier, Villejuif, France
- 15.15** Do we have markers to select patients for adjuvant therapies?  
Krzysztof Konopa, Gdansk, Poland

**14.15–15.45** **Silver Hall**

**Educational session**

**Challenging issues in ovarian cancer**

Chair: Jonathan Ledermann, London, UK

Co-Chair: Cristiana Sessa, Bellinzona, Switzerland

- 14.15** How can proteomic profiling guide us in selecting therapy?  
Elise Kohn, Bethesda, MD, USA

- 14.45** The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer  
Michael Bookman, Tucson, AZ, USA
- 15.15** Optimal treatment for relapsing ovarian cancer  
Jonathan Ledermann, London, UK

**14.15–15.45** **Violet Hall**

**Educational session (Repetition)**

**Diagnostic and management issues in metastatic breast cancer**

Chairs: Fabrice André, Villejuif, France and

José Baselga, Boston, MA, USA

- 14.15** What can the pathologist offer for optimal treatment choice?  
Giuseppe Viale, Milan, Italy
- 14.45** Treatment of triple negative breast cancer  
Fabrice André, Villejuif, France
- 15.15** Treatment of Her2-overexpressing breast cancer  
José Baselga, Boston, MA, USA

**14.15–15.45** **Pink Hall**

**Educational session (Repetition)**

**Advances in neuroendocrine tumors**

Chair: William Travis, New York, NY, USA

Co-Chair: George Pentheroudakis, Kardamitsia, Greece

- 14.15** Lung neuroendocrine  
William Travis, New York, NY, USA
- 14.45** Gastrointestinal neuroendocrine tumors  
Kjell Oberg, Uppsala, Sweden
- 15.15** Merkel tumors  
Jürgen Becker, Würzburg, Germany

**16.00–17.30** **Gold Hall**

**Educational session (Repetition)**

**Advances in the treatment of advanced colorectal cancer**

Chair: Claus-Henning Koehne, Oldenburg, Germany

Co-Chair: Thierry André, Paris, France

- 16.00** What can the molecular pathologist offer for optimal decision-making?  
Philip Quirke, Leeds, UK
- 16.30** Chemotherapy: Which drugs and when?  
Alberto Sobrero, Genoa, Italy
- 17.00** How to integrate molecular targeted agents in the continuum of care  
Claus-Henning Koehne, Oldenburg, Germany



16.00–17.30 **Silver Hall**

**Educational session (Repetition)**

**New therapeutic opportunities in urological cancer**

Chair: Joaquim Bellmunt, Barcelona, Spain

Co-Chair: Vesa Kataja, Kuopio, Finland

**16.00** New hormonal agents in the treatment of advanced prostate cancer  
Johann de Bono, Sutton, UK

**16.30** New agents for bladder cancer  
Joaquim Bellmunt, Barcelona, Spain

**17.00** How to select targeted therapy in renal cancer  
Bernard Escudier, Villejuif, France

16.00–17.30 **Violet Hall**

**Educational session (Repetition)**

**Treatment of PT1N0 breast cancer**

Chair: Angelo Di Leo, Prato, Italy

Co-Chair: Fatima Cardoso, Lisbon, Portugal

**16.00** Multigene predictors to assess risk of relapse  
Christos Sotiriou, Brussels, Belgium

**16.30** Benefits and adverse effects of endocrine therapy  
Marco Colleoni, Milan, Italy

**17.00** Chemotherapy with or without trastuzumab  
Angelo Di Leo, Prato, Italy

16.00–17.30 **Pink Hall**

**Educational session (Repetition)**

**How much do we know about cancer cells?**

Chair: Carlos Cordon-Cardo, New York, NY, USA

Co-Chair: Marco A. Pierotti, Milan, Italy

**16.00** The epithelial-mesenchymal transition (EMT) phenomenon  
Pierre Savagner, Montpellier, France

**16.30** Cancer stem cells  
Carlos Cordon-Cardo, New York, NY, USA

**17.00** Circulating cancer cells  
Dimitrios Mavroudis, Heraklion, Greece

16.00–17.30 **Green Halls 1+2**

**Special Session**

**Chronic Disease Alliance: A time to work across specialties**

Chair: Hans-Jörg Senn, St. Gallen, Switzerland

**16.00** Introduction  
Hans-Jörg Senn, St. Gallen, Switzerland

**16.05** Reducing mortality — prevention and treatment  
Richard Peto, Oxford, UK

**16.25** Cardioncology — An alliance for prevention and treatment  
Roberto Ferrari, Ferrara, Italy

**16.45** Diabetes and cancers  
Ulf Smith, Gothenburg, Sweden

**17.05** The burden of chronic respiratory diseases in Europe  
Nikolaos Siafakas, Heraklion-Crete, Greece

**17.25** Conclusions  
David J. Kerr, Oxford, UK

17.30–19.30 **Blue Hall**

**ESMO Examination 2010**



# WELEDA

## Since the beginning Weleda has been supporting patient care

It all started with an empathetic bedside manner caring for the whole person and was followed by the development of natural organic cosmetics. Nowadays it includes the support of clinical research. Therefore our support of ESMO is a logical consequence of all our efforts

### to improve the patient's quality of life.

In harmony with nature and the human being  
Since 1921




Photo by J. Buess

[www.weleda.it](http://www.weleda.it)

## 8<sup>th</sup> ESMO Patient Seminar

15.00–15.10 **Red Hall**

### Introduction

15.00 Lorenz Jost, Bruderholz, Switzerland

15.05 Francesco De Lorenzo, Rome, Italy

15.10–16.40 **Red Hall**

### Cancer: We all care and share

Co-Chairs: Francesco De Lorenzo, Rome, Italy and TBC

15.10 The status of cancer in Europe now  
Andrea Micheli, Milan, Italy

15.25 What the European Union can do for patients  
Alojz Peterle, Brussels, Belgium

15.40 What cancer advocacy groups can do for patients  
Jan Geissler, Riemerling, Germany

15.55 General Discussion

16.40–17.10

### Coffee break

17.10–18.40 **Red Hall**

### Understanding new methods and new treatments of cancer

Co-Chairs: Roberto Labianca, Bergamo, Italy and  
Elisabetta Iannelli, Rome, Italy

17.10 Targeted therapy: A general overview  
Manfred Kaufmann, Witten, Germany

17.30 My life with targeted therapy  
Elisabetta Iannelli, Rome, Italy

17.40 Targeted therapy: Hope or hype  
Jean-Charles Soria, Villejuif, France

18.00 Participation in phase I studies  
Silvia Marsoni, Milan, Italy

18.20 General Discussion

# Poster Plan

13.00–14.00 **Hall 3**

## Poster Presentation (Display)

### Breast cancer, advanced

Chair: Fatima Cardoso, Lisbon, Portugal

**287P** – The impact of educational material (EM) on compliance and persistence rates with adjuvant aromatase inhibitor (AI) treatment: First year data, presented on behalf of the CARIATIDE study investigators  
Christos Markopoulos, Athens, Greece

**288P** – Phase I study of S-1 plus trastuzumab combination therapy in human epidermal-growth receptor 2-positive metastatic breast cancer  
Tsutomu Takashima, Osaka, Japan

**289P** – Trastuzumab-based therapy after disease progression following lapatinib and capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC)  
Giulio Metro, Rome, Italy

**290P** – Level of HER2/neu gene (HER2) amplification in primary and metastatic sites in HER2-positive metastatic breast cancer and response to trastuzumab(T)-based therapy  
Giuseppe Gullo, Dublin, Ireland

**291P** – Lapatinib (L) plus capecitabine (C) in HER2-positive metastatic breast cancer (MBC): An exploratory analysis of overall survival (OS) based on poststudy therapy  
Eleni Stergiou, Thessaloniki, Greece

**292P** – Evaluation of neratinib (HKI-272) and paclitaxel pharmacokinetics (PK) in Asian and caucasian patients with ErbB2+ breast cancer: A Phase I/II study of neratinib in combination with paclitaxel  
Richat Abbas, Collegeville, PA, USA


**293P** – HER-2 status correlation between primary breast cancer and corresponding distant metastatic sites  
Isabel Frahm, Buenos Aires, Argentina

**294P** – Australian breast cancer patients enrolled in the lapatinib expanded access program (LEAP)  
Jodi Lynch, Kogarah, Australia

**295P** – Trastuzumab (T) tolerability and activity in HER2+ metastatic breast cancer (MBC) patients (pts) aged ≥65 years  
Alessandra Bernardi, Bologna, Italy

**296P** – Neoadjuvant chemotherapy (NAC) with docetaxel and liposome-encapsulated doxorubicin in locally advanced HER2-breast cancer (LABC)  
Marco Merlano, Cuneo, Italy

**297P** – Taxane-based treatment options for patients with HER2-positive advanced breast cancer: Results of an observational study  
Mahmut Gümüş, Istanbul, Turkey



Breast cancer, advanced  
Gastrointestinal tumors  
Gastrointestinal tumors (upper)  
Genitourinary tumors  
Geriatric oncology

GI and neuroendocrine tumors  
Health services and public health  
Melanoma  
Prevention and screening  
Sarcoma

SATURDAY

SATURDAY

**298P** – A phase 1 study of neratinib (HKI-272) in combination with paclitaxel in Japanese patients with solid tumors  
Yoshinori Ito, Tokyo, Japan

**299P** – Ixabepilone (Ixa) and capecitabine (C) in patients (pts) with triple-negative breast cancer (TNBC): A retrospective analysis of phase II and phase III clinical studies  
Henri Roché, Toulouse, France

**300P** – Sorafenib (SOR) plus capecitabine (CAP) in patients (pts) with triple-negative (TN) advanced breast cancer (BC): Subgroup analysis of SOLTI-0701, a double-blind, randomised, placebo (PL)-controlled phase IIb study  
Henri Roché, Toulouse, France

**301P** – Paclitaxel (P) and bevacizumab (Bev), as first-line chemotherapy, in patients with HER2-negative metastatic breast cancer (MBC). The Hellenic Cooperative Oncology Group experience with biomarker evaluation  
Helen Kourea, Patras, Greece

**302P** – Updated results from a large, multicentre study of 1<sup>st</sup>-line bevacizumab (Bev) combined with paclitaxel (Pac) for HER2-negative metastatic breast cancer (mBC) in routine oncology practice  
Frank Förster, Chemnitz, Germany

**303P** – High prevalence and poor prognosis of triple negative tumors in Hispanic patients with breast cancer  
Monika Blake, Mexico City, Mexico

**304P** – Safety and efficacy of maintenance bevacizumab in HER2-negative metastatic breast cancer  
Michelangelo Russillo, Rome, Italy

**305P** – Sequential vinorelbine (VNR)/capecitabine (CAP) combination followed by metronomic CAP as first-line treatment in HER2-negative metastatic breast cancer (MBC): Prospective evaluation of activity, safety and quality of life  
Raffaella Palumbo, Pavia, Italy

**306P** – Meta-analysis of randomized clinical trials (RCTs) exploring single agent chemotherapy (SACH) versus multi-agent chemotherapy (MACH) in addition to trastuzumab (T) for HER-2-overexpressing advanced breast cancer (ABC): What is the most appropriate comparator?  
Isabella Sperduti, Rome, Italy

**307P** – Neo-adjuvant chemotherapy (NACT) in hormonal receptor positive (HR+) or triple negative (TN) operable breast cancer (BC): A randomized study comparing standard to response-adapted sequence  
Herve Cure, Reims, France

**308P** – Capecitabine (X) in advanced breast cancer in the real life setting – First 12-month results from the ELIXIR cohort  
Phillipe Dalivoust, Marseille, France

**309P** – Factors affecting survival in patients given multiple lines of chemotherapy (CT) for metastatic breast cancer (MBC): What do we gain beyond the third-line?  
Giovanni Bernardo, Pavia, Italy

**310P** – A qualitative systematic review of the evidence base for non cross-resistance between steroidal and non-steroidal aromatase inhibitors (AIs) in metastatic breast cancer  
Jayeta Chakrabarti, Surrey, UK

**311P** – Male breast cancer: About 127 cases collected at the National Institute of Oncology from 1985 to 2007  
Mouna Bourhafour, Rabat, Morocco

**312P** – Oral chemotherapy to optimize care of metastatic breast cancer (MBC) patients: Considering women's preference and quality of life (QoL)  
Maria Strada, Pavia, Italy

**313P** – Indirect comparison and UK cost-effectiveness analysis of paclitaxel albumin vs docetaxel for pretreated metastatic breast cancer  
Francois Prunieras, Paris, France

**314P** – Interim analysis of the German non-interventional post marketing surveillance study (NIS) on Quality of Life (QoL) of capecitabine in patients with metastatic breast cancer (MBC)  
Matthias Zaiss, Freiburg, Germany

**315P** – A retrospective survey of systemic anticancer therapy in women with metastatic breast cancer (MBC) in Belgium  
Christel Fontaine, Brussels, Belgium

**316P** – Implication of breast cancer phenotype in patients with leptomeningeal carcinomatosis  
Davis Torrejon, Barcelona, Spain

**317P** – To detect the expression of cytokeratin 19 in peripheral blood of patients with breast cancer and its clinical significance  
Xiu Dong, Dalian, China

**318P** – Serum IL-8 as a prognostic marker for triple negative advanced breast cancer  
Gouri Shankar Bhattacharyya, Kolkata, India

**319P** – A clinico-pathological analysis of breast cancer patients with a family history  
Yukie Yoda, Chuo-ku, Tokyo, Japan

**320P** – Ixabepilone (Ixa)-associated peripheral neuropathy (PN): Retrospective review of data from phase II and III clinical trials  
Linda Vahdat, New York, NY, USA

**321P** – Vinflunine after failure of a first-line vinorelbine based chemotherapy in advanced breast cancer: Results of a phase II multicentre study  
P. Bougnoux, Tours, France

**322P** – A phase I-II study of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC)

Monica Fornier, New York, NY, USA

**323P** – Population pharmacokinetic-pharmacodynamic (PK/PD) analysis of safety and efficacy of eribulin in metastatic or locally advanced breast cancer patients

Ziad Hussein, Hatfield, UK

**324P** – Effectiveness of taxane monotherapy (TM) and taxane combination (TC) treatment in patients with advanced breast cancer

Mutlu Demiray, Osmangazi-Bursa, Turkey

**325P** – Increasing role of metastasectomy in metastatic breast cancer patients: Who benefits more?

Fatih Selcukbiricik, Istanbul, Turkey

**327P** – Neoadjuvant chemotherapy with GM- or G-CSF:

Differential effects on dendritic cell subsets in patients with locally advanced breast cancer

Hester van Cruisen, Amsterdam, Netherlands

**328P** – Intrathecal chemotherapy (ITCT) improves prognosis in leptomeningeal carcinomatosis (LC) from breast cancer (BC): A single institution experience

Mafalda Oliveira, Lisboa, Portugal

**329P** – Does obesity hamper response to trastuzumab (T) in post-menopausal patients (pts) with metastatic breast cancer (MBC)?

I. Nuñez, Barcelona, Spain

**717P** – An Interim analysis of a phase II, open-label, multi-center, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance as first-line treatment in advanced gastric cancer

Xiaotian Zhang, Beijing, China

**718P** – Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TFOX) for advanced gastric and oesophageal adenocarcinoma (AGEC). Tolerance and response in 38 patients: Preliminary report

Simon Pernot, Malakoff, France

**719P** – Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil (PCF) for advanced gastric cancer

Kazuhiro Nishikawa, Osaka, Japan

**720P** – Retrospective study regarding the efficacy of 2nd or higher line chemotherapy of patients in advanced or recurrent gastric cancer (ARGC) after the failure of S-1 or S-1 combination chemotherapy (S+ )

Kazuma Kobayashi, Kochi City, Japan

**721P** – Triplet combination of capecitabine plus oxaliplatin and irinotecan in the treatment of patients with previously untreated advanced gastric cancer (AGC)

Elena Franceschelli, Milan, Italy

**722P** – Survival benefit associated with fluoropyrimidines, platinum agents, taxanes, and irinotecan during all lines of treatment in patients with advanced gastric cancer

Kohei Shitara, Nagoya, Japan

**723P** – Phase 2 study of telatinib in combination with capecitabine and cisplatin as first-line treatment in patients with advanced cancer of the stomach or gastro-esophageal junction (GEJ)

Maria Alsina, Barcelona, Spain

**724P** – Prognostic significance of free peritoneal tumor cells (FPTCs) in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing a potentially curative resection

Sylvie Lorenzen, Heidelberg, Germany

**725P** – Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Dok Hyun Yoon, Seoul, South Korea

**726P** – Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection

Seok Yun Kang, Suwon, South Korea

**727P** – Expression of BAX predicts outcome in advanced gastric cancer patients treated with 5-fluorouracil and platinum palliative chemotherapy

Seong Hyun Jeong, Suwon, South Korea

## Gastrointestinal tumors

Chair: TBC

**713P** – Randomized, double-blind, placebo-controlled, multicentre phase III study of capecitabine / cisplatin + bevacizumab (bev) or placebo (pl) as 1st-line therapy in patients (pts) with advanced gastric cancer (AGC) (AVAGAST update)

Eric Van Cutsem, Leuven, Belgium

**714P** – Novel chemotherapy combinations in advanced gastric cancer: An updated meta-analysis

Anna Dorothea Wagner, Lausanne, Switzerland

**715P** – Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion (C.I.) as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomised phase II trial of the Gruppo Oncologico dell'Italia Meridionale

Nicola Silvestris, Bari, Italy

**716P** – mFOLFOX-4 followed by mFOLFIRI or the reverse sequence in metastatic gastric cancer

Suee Lee, Busan, South Korea



**728P** – microRNA-196b and microRNA-363 were identified as gastric cancer specific microRNAs in human gastric cancer tissue using microarray experiment

Jae Yong Cho, Seoul, South Korea

**729P** – mRNA expression of BRCA1, RAP80 and SUMO ligases (PIAS1 and PIAS4) and survival in gastric cancer patients (p) receiving second-line docetaxel (doc)

Jia Wei, Nanjing, China

**730P** – SUVmax of F-18 FDG-PET/CT in advanced gastric cancer with tubular adenocarcinoma: Correlation with pathologic findings including immunohistochemical staining

Hong-Suk Song, Daegu, South Korea

**731P** – Predictive factors for adjuvant therapy in patients with localized gastric & gastro-esophageal junction (G/GEJ) cancer: A population based study

Shahid Ahmed, Saskatoon, SK, Canada

**732P** – Prognostic impact of immunohistochemical expression of Ki-67 in patient with advanced gastric cancer who underwent curative resection

Uhm Doyung, Incheon, South Korea

**733P** – Predictive significance of preoperative peripheral blood values for stage T4 gastric cancer

Masaki Aizawa, Kashiwa, Japan

**734P** – Survival benefit of gastrectomy  $\pm$  metastasectomy in metastatic gastric cancer patients receiving chemotherapy

Ki Hwan Kim, Seoul, South Korea

**735P** – 10-year follow-up of gastric submucosal tumors

Akira Sawaki, Nagoya, Japan

**736P** – Development of a comprehensive registry of gastrointestinal stromal tumor (GIST) patients (pts) in Eastern Ontario

Esmeralda Marginean, Ottawa, ON, Canada

**737P** – Cost-effectiveness of adjuvant imatinib in patients with surgically resected localized gastrointestinal stromal tumors (GIST): Canadian societal perspective

Vivek Pawar, Medford, OR, USA

**738P** – Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST): A conjoint analysis study

Juan Marcos Gonzalez, Research Triangle Park, NC, USA

**739P** – Randomized cross-over AIO phase III trial comparing gemcitabine plus erlotinib followed by capecitabine vs. capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer

Stefan Boeck, Munich, Germany

**740P** – 5-fluorouracil/leucovorin (5FU/LV) combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma

Elias Assaf, Cr teil, France

**741P** – Conatumumab (CON) or AMG 479 or placebo (pbo) + gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (mPC): A placebo-controlled, randomized, phase II study

Hedy Kindler, Chicago, IL, USA

**742P** – A prospective, randomized, double-blind, placebo controlled, group sequential trial of Polyclonal Antibody Stimulator (PAS) for the treatment of advanced pancreatic cancer

J. Oortgiesen, Research Triangle Park, NC, USA

**743P** – Results of a phase I/II study of nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer with SPARC and CA19-9 correlatives

Ramesh Ramanathan, Scottsdale, AZ, USA

**744P** – Efficacy of continuous infused 5-fluorouracil, doxorubicin, and mitomycin (iFAM) in the treatment of gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in salvage setting

Kyu-Hyoung Lim, Seoul, South Korea

**745P** – Gemcitabine (G) fixed rate dose infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC)

Alberto Mu oz, Baracaldo, Spain

**746P** – A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy

Seung Taek Kim, Cheonan, South Korea

**747P** – Evaluation of progression-free survival (PFS) by blinded independent central review (BICR) in patients (pts) with progressive, well-differentiated pancreatic neuroendocrine tumours (NET) treated with sunitinib (SU) or placebo

Eric Van Cutsem, Leuven, Belgium

**748P** – Therapeutic synergism of lapatinib and NVP-AEW541 against human pancreatic tumour cells

Adela Mazo, Barcelona, Spain

**749P** – Potentiation of gemcitabine effects with a cetuximab and trastuzumab combination in a novel human pancreatic orthotopic model

Anna Vidal-Pla, Barcelona, Spain

**750P** – Efficacy and safety of sorafenib (Sor) in patients (pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP and Asia-Pacific (AP) trials by baseline (BL) transaminase (ALT/AST)/alpha-fetoprotein (AFP) and bilirubin (Bil) levels

Jean-Luuc Raoul, Rennes, France

**751P** – Quality of life assessment with combined EORTC QLQ-C30 and EORTC-HCC18 as a prognostic factor for patients with hepatocellular carcinoma: A prospective study

Leung Li, Shatin, Hong Kong, China

**752P** – Preliminary pharmacokinetics (PK) and safety comparison of Child-Pugh A (CPA) vs. Child-Pugh B (CPB) patients (pts) enrolled in a phase II study in hepatocellular carcinoma (HCC)

Justin Ricker, Abbott Park, IL, USA

**753P** – Efficacy and tolerability of bevacizumab (B) and erlotinib (E) as first-line therapy in Asian patients (pts) with advanced hepatocellular carcinoma (HCC): A phase II trial

Chih-Hung Hsu, Taipei, Taiwan

**754P** – Management and cancer outcomes of secondary malignancies following liver transplantation

Hilary Martin, Bedford Park, Australia

**755P** – Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: A multicenter AGEO study

Thomas Aparicio, Bobigny, France

**756P** – Alcohol, tobacco, and risk of gastrointestinal (GI) cancers

Arthur Klatsky, Oakland, CA, USA

**883P** – Baseline cardiovascular risk factors predict cardiovascular (CV) events during androgen deprivation therapy (ADT) with degarelix

Laurence Klotz, Toronto, ON, Canada

**884P** – Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100

Mohammad Hirmand, San Francisco, CA, USA

**885P** – First results of high-intensity focused ultrasound for localized and locally advanced hormone-resistant prostate cancer

Vyacheslav Solovov, Samara, Russian Federation

**886P** – Immune vs. clinical response monitoring in patients with metastatic hormone-refractory prostate cancer receiving combined Prostate GVAX and anti-CTLA4 immunotherapy

Winald Gerritsen, Amsterdam, Netherlands

**887P** – Radium-223 chloride, a novel, highly targeted alpha-pharmaceutical for treatment of bone metastases from castration-resistant prostate cancer (CRPC): Hematologic and safety profile with repeated dosing

Christopher Parker, Surrey, UK

**888P** – A phase II prospective study of ketoconazole in castration-resistant prostate cancer patients (CRPC)

Elena Verzoni, Milan, Italy

**889P** – Hot flushes (HF) during androgen deprivation therapy: Direct comparison of monthly degarelix and leuprolide in a phase 3 trial

Peter Iversen, Copenhagen, Denmark

**890P** – Neutral endopeptidase (NEP) and endothelin 1 (ET-1) are inversely expressed in hormone-naïve prostate cancer and are predictors of biochemical failure from radical prostatectomy

Panagiotis Vlachostergios, Larissa, Greece

**891P** – Incidence of cancer treatment-induced bone loss (CTIBL) in non-osteoporotic men with prostate cancer (PC) receiving androgen deprivation therapy (ADT) and efficacy of treatment with zoledronic acid (ZOL): Results from the ROBUST bone mineral density (BMD) sub-study

Tim van den Wyngaert, Edegem, Belgium

**892P** – The influence of family history of breast and prostate cancer on prostate cancer diagnoses in the REDuction by DUTasteride of prostate Cancer Events (REDUCE) study

Ramiro Castro, Raleigh-Durham, NC, USA

**893P** – Effects of switching from leuprolide to degarelix on long-term prostate-specific antigen (PSA) and serum alkaline phosphatase (S-ALP) control

Bo-Eric Persson, St. Prex, Switzerland

## Genitourinary tumors

Co-Chairs: Maria De Santis, Vienna, Austria and

Thomas Powles, London, UK

**879P** – Reduction in surgical and non-surgical interventions for prostate cancer with Dutasteride Treatment in the REDuction by DUTasteride of prostate Cancer Events (REDUCE) study

Roger Rittmaster, Raleigh-Durham, NC, USA

**880P** – Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T

Mark Frohlich, Seattle, WA, USA

**881P** – An open-label phase II study of treatment with sunitinib in patients suffering from metastatic castrated refractory prostate cancer (CRPC) after progression with docetaxel-based regimen

Stephane Oudard, Paris, France

**882P** – Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: Final analysis of the multicenter phase II trial SAKK 08/07

Richard Cathomas, Chur, Switzerland

**894P** – Pharmacogenomic profile of castration-resistant prostate cancer: The influence of AR +1733 G>A and SHBG +5790 G>A polymorphisms

Marta Sousa, Porto, Portugal

**895P** – Adjuvant effect of IV clodronate on delay of bone metastasis in high-risk prostate cancer patients: A prospective study

Paulo Rodrigues, São Paulo, Brazil

**896P** – A multi-institutional phase II study of single agent ABI-007 in platinum refractory urothelial carcinoma

Yoo-Joung Ko, Toronto, ON, Canada

**897P** – Carboplatin and gemcitabine in elderly and/or frail patients (pts) with advanced transitional cell carcinoma (TCC): A phase II study

Abdelbari Baitar, Antwerp, Belgium

**898P** – Accelerated MVAC chemotherapy in patients with advanced bladder cancer pretreated with platinum-gemcitabine regimens

Julien Edeline, Rennes, France

**899P** – The combination of DNA repair gene polymorphisms significantly affect the risk of bladder cancer in population of Southwest China

Zhiwen Chen, Chongqing, China

**900P** – Multicenter Phase II study of sunitinib in patients with transitional cell carcinoma of the urothelium (TCCU) who failed or progressed after first-line chemotherapy (CT) for locally advanced or metastatic disease.

Preliminary results

Christine Theodore, Saint-Cloud, France

**901P** – A phase II study of paclitaxel, ifosfamide and nedaplatin as a second-line treatment in patients with cisplatin-refractory metastatic urothelial cancer

Hiroshi Kitamura, Sapporo, Japan

**902P** – Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A Japanese phase II study in patients with cytokine-refractory metastatic renal cell cancer (mRCC)

Yoshihiko Tomita, Yamagata, Japan

**903P** – Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma

Georg Bjarnason, Toronto, Canada

**904P** – Incidence and management of hepatic toxicity in pazopanib-treated patients

Vicki Goodman, Collegeville, PA, USA

**905P** – Sorafenib safety over time in >4600 patients with renal cell carcinoma (RCC): Insights from an integrated database of 8 company-sponsored trials

Timothy Eisen, Cambridge, UK

**906P** – Sorafenib in older patients with advanced renal cell carcinoma: Subanalysis by age of an integrated database of 8 company-sponsored clinical trials

Giuseppe Procopio, Milan, Italy

**907P** – Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma (RCC) patients

Mayer Fishman, Tampa, FL, USA

**908P** – Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial

Aurore Blesius, Villejuif, France

**909P** – Serum thrombospondin-1 (TSP-1), basic-fibroblast growth factor (B-FGF), vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) as predictive factors for sorafenib plus interferon-2a (IFN) in metastatic renal cell carcinoma (mRCC): Biologic results from the “RAPSODY” randomized phase II trial

Sergio Bracarda, Arezzo, Italy

**910P** – Second-line treatment with pazopanib following first-line sunitinib or bevacizumab in advanced renal cell carcinoma: Preliminary results of a phase II trial

John Hainsworth, Nashville, TN, USA

**911P** – Phase 3 RECORD-1 study of everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies

Emiliano Calvo, Madrid, Spain

**912P** – Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): Results and evaluation of circulating T-regulatory cells (TREG) and other cytokines. A GOIRC study

Rodolfo Passalacqua, Cremona, Italy

**913P** – Clinical outcome of Asian vs. non-Asian patients with metastatic renal cell carcinoma (mRCC) with continuous once-daily dosing of sunitinib as first-line therapy

Carlos Barrios, Porto Alegre, Brazil

**914P** – Comparative outpatient resource utilization study of metastatic renal cell carcinoma patients receiving oral vs. intravenous mTOR inhibitors

Zhimei Liu, East Hanover, NJ, USA

**915P** – Trough PK concentration, age of patient, and baseline ALT are important factors in predicting ALT elevations in pazopanib treated mRCC patients

Lini Pandite, Research Triangle Park, NC, USA

**916P** – Sorafenib (Sor) dosage patterns in >4600 patients (pts) with renal cell carcinoma (RCC), including the elderly and pts treated for >12 months (mo): Results from an integrated database of 8 company-sponsored trials  
Carsten Bokemeyer, Hamburg, Germany

**917P** – Zoledronic acid (ZOL) reduces the incidence of skeletal-related event (SREs) and may improve survival in patients with bone metastases (mets) from renal cell carcinoma (RCC): A retrospective integrated analysis  
Dror Michaelson, Boston, MA, USA

**918P** – Sequential therapy in metastatic renal cell carcinoma – simulation and comparison of progression-free-survival outcomes

Gerald Mickisch, Bremen, Germany

**919P** – Targeted therapy in first-line therapy of metastatic renal cell cancer (mRCC): Systematic review with meta-analysis (SRMA)

Flavio Carcano, Sao Paulo, Brazil

**920P** – mTOR Inhibition and renal cell carcinoma; a comparison between sirolimus and temsirolimus  
Jim Barber, Cardiff, UK

**921P** – Bone metastasis in clear cell renal cell carcinoma: a predictive factor for outcome on sunitinib in retrospective analysis

Benoit Beuselinck, Paris, France

**922P** – An Italian multicentre retrospective analysis of 189 advanced renal-cell carcinoma patients treated sequentially, either with sorafenib followed by sunitinib, or vice versa  
Camillo Porta, Pavia, Italy

**923P** – Thyroid-stimulating hormone (TSH) levels in patients with metastatic renal cell cancer treated with sunitinib  
Theofanis Vassileiadis, Thessaloniki, Greece

**924P** – Baseline quality of life as a prognostic tool of median survival in patients receiving sunitinib for metastatic renal cell carcinoma

David Cella, Chicago, IL, USA

**925P** – An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients using a robust matching technique

Giuseppe Di Lorenzo, Naples, Italy

**926P** – A phase II study of safety and efficacy of temsirolimus (CCI-779) administered as a single agent in East Asian patients with advanced renal cell carcinoma  
Yan Sun, Beijing, China

**927P** – Cost-effectiveness of treating metastatic renal cell carcinoma (mRCC) patients whose disease failed on VEGF-TKI therapies with everolimus compared to treating with best supportive care (BSC) alone: A Canadian societal perspective  
Khalid El Ouagari, Dorval, QC, Canada

**928P** – PREDICT global non-interventional study: baseline characteristics of RCC patients treated with sorafenib  
Dirk Jäger, Heidelberg, Germany

**929P** – Randomized, placebo-controlled, phase III study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy

Sergio Bracarda, Arezzo, Italy

**930P** – Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit risk conjoint study

Ateesha Mohamed, Research Triangle Park, NC, USA

**931P** – The outcome of patients who fail sunitinib and do not have access to sunitinib therapy

Emilio Poffiri, Birmingham, UK

**932P** – Incidence, time and mode of detection of testis cancer (TC) relapses: Retrospective analysis of a single-institution cohort on a uniform follow-up program

Mark Bachner, Vienna, Austria

**933P** – Teratoma with malignant differentiation in male germ-cell tumors (GCT): Updated results from a single institution series and future perspectives

Andrea Necchi, Milan, Italy

**934P** – Salvage chemotherapy (CT) of patients (pts) with late-relapse metastatic germ cell tumor (mGCT): Single institute experience

Mikhail Fedyanin, Moscow, Russian Federation

**935P** – Increased age is associated with thromboembolic events in patients with germ cell tumors treated with chemotherapy

Maria Luengo, Murcia, Spain

**936P** – Updated results of adjuvant carboplatin (carbo AUC 7 and 7.7) in stage I seminoma (sem) of the testis from the BOC Oncology Centre

Marios Decatris, Nicosia, Cyprus

**937P** – Salvage chemotherapy with high dose chemotherapy and peripheral blood stem cell transplant in patients with germ cell tumors

Ignacio Garcia-Escobar, Madrid, Spain

**938P** – Updated results of the combination of paclitaxel, cisplatin and gemcitabine (TPG) followed by surgery as third-line therapy for male germ cell tumors

Andrea Necchi, Milan, Italy

**939P** – A combination of cisplatin and 5-fluorouracil plus a taxane for advanced squamous-cell carcinoma (SCC) of the penis. A single institution series

Andrea Necchi, Milan, Italy

## Geriatric oncology

Chair: Riccardo Audisio, Liverpool, UK

**576P** – Treatment of lymphoma in the elderly – toxicities and outcomes

Louise Fullam, Dublin, Ireland

**577P** – Multiple tumors in elderly patients: Epidemiology and survival in a single center experience

Antonella Brunello, Padova, Italy

**578P** – 2-year tolerance of adjuvant trastuzumab for early breast cancer occurring in elderly: A companion study of the GERICO-06 phase II trial

Marc Debled, Bordeaux, France

**579P** – Cancer in an Italian nursing home

Claudia D'Alessandro, Milan, Italy

## Health services and public health

Chair: TBC

**1094P** – Rare cancers in Europe

Gemma Gatta, Milan, Italy

**1095P** – Cancer registry integration in the Umbria Regional Cancer Network: Breast cancer as a model to build a supportive information system

Fabrizio Stracci, Perugia, Italy

**1096P** – A review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies

Henrik Finnnern, Ingelheim, Germany

**1097P** – Development of a multi-centric assessment tool for measuring and improving standardised organisation and provision of care in cancer structures

Mahasti Saghatchian, Villejuif, France

**1098P** – Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts): A multidisciplinary quality improvement project

Simona Rizzato, Udine, Italy

**1099P** – Patient (pt) reported symptoms of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer (MCRC) in a US community-based oncology practice network

Elaine Yu, South San Francisco, CA, USA

**1100P** – What have we accomplished with targeted chemotherapy for incurable solid cancers?

Henry Conter, Edmonton, AB, Canada

**1101P** – Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients (pts) with bone metastases (BM) – US interim analysis (IA) results from a multinational observational study

Peter Suenaert, Uxbridge, UK

**1102P** – The Italian cross-sectional survey on the management of bone health in oncology: The ZETA study

Francesco Bertoldo, Verona, Italy

**1103P** – Long-term economic burden of cancer patients

Nobuo Koinuma, Sendai, Japan

**1104P** – Environmental contamination with cytotoxic drugs in the home setting in outpatients on cancer chemotherapy

Michiko Yuki, Fukushima, Japan

**1105P** – Reducing mortality rates related to capecitabine induced diarrhoea: Importance of clinical audit

Sindu Vivekanandan, Colchester, UK

**1106P** – Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX)

Yeonmi Yim, South San Francisco, CA, USA

**1107P** – Testing and treatment patterns in HER2+ breast cancer patients in the adjuvant setting

Deepa Lalla, South San Francisco, CA, USA

**1108P** – A new organizational model in the city of Milan has improved the best setting of care for terminal patients

Shela Piva, Milan, Italy

**1109P** – A survey on ethics committees reviewing cancer clinical trials in India

Mohandas K. Mallath, Mumbai, India

**1110P** – An awareness and screening programme of cervical cancer in rural West Bengal

Jayasri Basak, Kolkata, India

**1111P** – Darbepoetin alfa versus epoetin alfa for treatment of chemotherapy-induced anemia: A health economic evaluation

Jindrich Finek, Plzen, Czech Republic

**1112P** – Interactions with anticancer agents in clinical practice: More frequent than we imagine

Ariane Mouzon, Yvoir, Belgium

**1113P** – Clinical outcome of patients with cancer submitted to hemodialysis (HD) at the Brazilian National Cancer Institute (INCA)

Daniel Herchenhorn, Rio de Janeiro, Brazil

**1114P** – Cancer research is leading the way – A study of cancer publications in pivotal medical journals over the last two decades

Paul Barnfield, Toronto, ON, Canada



## Melanoma

Chair: TBC

- 1326P** – Ipilimumab produces durable objective responses in patients with previously treated, advanced melanoma: Results from a phase III trial  
Christian Ottensmeier, Southampton, UK
- 1327P** – Ipilimumab improves overall survival in patients with previously treated, advanced melanoma: Long-term survival results from a phase III trial  
John Haanen, Amsterdam, Netherlands
- 1328P** – Health related quality of life (HRQL) outcomes of ipilimumab treatment in patients with previously treated unresectable stage III or IV melanoma (USIII/IV Mel)  
Dennis Revicki, Bethesda, MD, USA
- 1329P** – Assessment of pharmacokinetic interaction between ipilimumab and chemotherapy in a randomized study  
Jeffrey Weber, Tampa, FL, USA
- 1330P** – Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both in a phase III study of previously-treated patients with advanced melanoma: Update of clinical characteristics of patients  
Caroline Robert, Villejuif, France
- 1331P** – Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs)  
Paul Lorigan, Manchester, UK
- 1332P** – Long term survival of high risk melanoma patients immunized with an allogeneic whole cell genetically modified vaccine (AGI-101) after complete resection  
Andrzej Mackiewicz, Poznan, Poland
- 1333P** – Toward the characterization of a genetic profile with prognostic value at CDKN2A locus in melanoma patients  
Giuseppe Palmieri, Sassari, Italy
- 1334P** – Use of subcutaneous NGcGM3/VSSP vaccine in the treatment of advanced melanoma patients. A phase II clinical trial  
Elias Gracia, Ciudad de la Habana, Cuba
- 1335P** – CTC biomarker assessment to aid dosing selection of E6201, a potential MEK1 inhibitor, for treatment of BRAF-mutated melanoma  
Andrew Eisen, Woodcliff Lake, NJ, USA
- 1336P** – Cyclin dependent kinase 4 as a therapeutic target for metastatic melanoma  
Thamir Mahgoub, Dublin, Ireland

**1337P** – The effects of patient and tumor characteristics and treatment modalities on prognosis of patients with uveal melanoma

Deniz Tural, Istanbul, Turkey

**1338P** – Histology and outcomes of newly detected lung lesions in malignant melanoma (MM) patients  
Elizabeth Smyth, New York, NY, USA

**1339P** – Socio-economic status and education level influence Breslow thickness, disease free and overall survival in clinical stage I-II AJCC skin melanoma  
Mario Mandalà, Bergamo, Italy

---

## Neuroendocrine tumors and CUP

Chair: TBC

- 846P** – Phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET): Impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS)  
Juan Valle, Manchester, UK
- 847P** – Sunitinib efficacy and tolerability in patients with neuroendocrine tumors out of a trial: A Spanish multicenter cohort  
Jorge Barriuso, Madrid, Spain
- 848P** – mTOR activation in advanced neuroendocrine tumors in treatment with somatostatin analogues – a single center study  
Isabel Fernandes, Lisboa, Portugal
- 849P** – mTOR expression analysis in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)  
Laura Catena, Milan, Italy
- 850P** – Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of Spanish Neuroendocrine Tumor Group (GETNE-0801)  
Daniel Castellano, Madrid, Spain
- 851P** – Utility of progression-free survival (PFS) as a primary endpoint in clinical studies of advanced neuroendocrine tumors (NET)  
Simron Singh, Toronto, ON, Canada
- 852P** – Characteristics associated with health-related quality of life of patients with neuroendocrine tumor (NET)  
James Yao, Houston, TX, USA
- 853P** – Prognostic and predictive value of chromogranin A and neuron-specific enolase in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) treated with everolimus  
Kjell Öberg, Uppsala, Sweden

**854P** – Carcinoid & neuroendocrine tumor society of Singapore (CNETS) survey on delay in diagnosis of neuroendocrine tumors (NET)

W. Claxton, Singapore

**855P** – Neuroendocrine tumors: 20-years rare hormonal tumors group experience

Fernando Cirillo, Cremona, Italy

**856P** – A cost-consequence model for octreotide LAR as treatment for metastatic midgut NET

Sonia Pulgar, Florham Park, NJ, USA

**857P** – Diagnosis and management of metastatic malignant disease of unknown primary origin (MUP) –

Large cancer centre experience

Syed Zubair, Leeds, UK

**858P** – Molecular profiling as a strategy to prospectively identify primary solid tumours in metastatic cancer patients

Evandro De Azambuja, Brussels, Belgium

## Prevention and screening

Chair: TBC

**1125P** – Early detection program focusing on primary and secondary health care providers achieved major and sustainable reduction of late stage diagnosis of breast cancer  
C. R. Beena Devi, Sarawak, Malaysia

**1126P** – An assessment of annual lung cancer screening in Yokohama: The 27 years' cumulative data

Yuki Misumi, Yokohama, Japan

**1127P** – A large, multicenter, retrospective epidemiological survey: The incidence and treatment of bone metastatic disease in Chinese cancer patients

Li Zhang, Guangzhou, China

**1128P** – Genetic testing of cancer predisposition and progression: Analysis of gene variations in tumor is required

Evgeny Denisov, Tomsk, Russian Federation

**1129P** – School health program to prevent tobacco use  
Natia Jokhadze, Tbilisi, Georgia

## Sarcoma

Chair: Paolo G. Casali, Milan, Italy

**1348P** – First-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) with nilotinib

Peter Reichardt, Bad Saarow, Germany

**1349P** – Early evaluation of efficacy in molecularly targeted therapy of gastrointestinal stromal tumor

Toshirou Nishida, Osaka, Japan

**1350P** – Correlation of microRNA profile with kinase genotype in gastrointestinal stromal tumours (GISTs)

Maria Pantaleo, Bologna, Italy

**1351P** – Value of educational campaign to raise awareness of gastrointestinal stromal tumours (GIST) and its impact on the referral patterns in a tertiary referral cancer centre

Marios Decatris, Nicosia, Cyprus

**1352P** – Phase I dose-escalation study of imatinib mesylate (IM) associated with fixed dose of oral metronomic cyclophosphamide (MC) in selected tumors which may benefit from IM

Antoine Adenis, Lille, France

**1353P** – Neo-adjuvant chemotherapy with regional hyperthermia (RHT) for localized high-risk soft-tissue sarcoma (HR-STs) with abdominal/retroperitoneal location  
Lars Lindner, Munich, Germany

**1354P** – No improvement of outcome with reduced vs. conventional high intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients  
Uwe Thiel, Munich, Germany

**1355P** – A retrospective analysis of trabectedin activity in pre-treated advanced Ewing sarcoma (ES): Experience in 31 patients  
Palma Dileo, Milan, Italy

**1356P** – Clinical activity of gemcitabine-based chemotherapy in frail and/or heavily pre-treated patients with bone sarcomas  
Olivier Mir, Paris, France

**1357P** – Does the mutation of Wnt occur in osteosarcomas?  
Kanji Sasaki, Niigata-city, Japan

**1358P** – RNA expression of XPG, ERCC1 and BRCA1 in myxoid liposarcoma patients treated with neoadjuvant trabectedin

Alessandro Gronchi, Milan, Italy

**1359P** – Nonpegylated liposomal doxorubicin plus ifosfamide versus conventional doxorubicin plus ifosfamide in locally advanced or metastatic soft tissue sarcoma: Interim analysis of a randomized phase II trial

Maren Knoedler, Berlin, Germany

**1360P** – Gemcitabine in angiosarcoma  
Silvia Stacchiotti, Milan, Italy

**1361P** – Activity of sunitinib in advanced soft tissue sarcoma and its correlation with potential predictive biomarkers  
Lore Decoster, Brussels, Belgium

**1362P** – Treatment and outcomes in primary cardiac sarcoma: The IGR experience  
Meryem Glaoui, Rabat, Morocco

- 1363P** – Increased Dicer expression levels are associated with higher grades of leiomyosarcomas  
Dionysios Papachristou, Rion Patras, Greece
- 1365P** – Pulmonary artery sarcomas presenting as pulmonary hypertension: A review and discussion of further treatment  
Ioannis Gounaris, Cambridge, UK

## Upper gastrointestinal tumors

Chair: TBC

- 803P** – Phase II study of induction treatment (IT) of cetuximab (Cet) with chemotherapy (docetaxel, cisplatin, 5FU –DCF-) followed by Cet with concurrent chemoradiotherapy (cisplatin) in patients (p) with locoregional oesophageal cancer (LROC). The TTD-06-02/ GICOR Spanish Cooperative Groups trial  
Fernando Rivera, Santander, Spain
- 804P** – Results of neoadjuvant chemoradiotherapy with docetaxel and 5-FU followed by esophagectomy for locally advanced esophageal cancer  
Yoichi Hamai, Hiroshima, Japan
- 805P** – Neoadjuvant therapy in esophageal carcinoma followed by a long interval until resection: A high incidence of complete pathological response  
Rachel Blom, Heerlen, Netherlands
- 806P** – Docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy in gastro-oesophageal adenocarcinoma. A phase II study of the Arbeitsgemeinschaft Internistische Onkologie AIO  
Dmitry Bichev, Berlin, Germany
- 807P** – Predictive factors in locally advanced squamous cell carcinoma (SCC) of the oesophagus treated with preoperative radiochemotherapy (RCT) and surgery  
Michael Stahl, Essen, Germany
- 808P** – Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer  
Ajay Kakkar, London, UK
- 809P** – Does external ultrasonography of the neck add diagnostic value to integrated PET-CT scanning in the diagnosis of cervical metastases in patients with esophageal carcinoma?  
Meindert Sosef, Heerlen, Netherlands
- 810P** – Response and survival in oesophageal cancer patients following neoadjuvant chemotherapy assessed by FDG-PETCT imaging and correlation to pathologic response

- Yogesh Manikyam, Belfast, UK
- 811P** – FDG-PET/CT evaluation of early metabolic response after neoadjuvant chemotherapy in patients with esophageal and GEJ cancer – a pilot study  
Milada Zemanová, Prague, Czech Republic
- 812P** – What direct costs are associated with evaluation of upper gastrointestinal cancers? Results of a 32 month audit  
Aiza Jamil, Ashford, UK
- 813P** – Comparison of a sequential treatment versus a 5-FU/LV regimen as adjuvant therapy for resected gastric cancer. Tolerability and feasibility analysis of ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) trial  
Emilio Bajetta, Milan, Italy
- 814P** – Patterns of gastric cancer recurrence after adjuvant chemoradiation  
Steven Maclellan, Toronto, ON, Canada
- 815P** – Sunitinib (SU) with cisplatin (P) and capecitabine (X) or oxaliplatin (O) and X (XELOX) in advanced gastric cancer (GC) – a phase I, dose-finding study  
Jennifer Tursi, Milan, Italy
- 816P** – Phase I study of sunitinib (SU) plus S-1 and cisplatin (P) in patients (pts) with advanced or metastatic gastric cancer (GC)  
Kei Muro, Aichi, Japan
- 817P** – Lapatinib + capecitabine in advanced gastric cancer: an open-label phase II study of non-ErbB2-targeted disease  
Heinz-Josef Lenz, Los Angeles, CA, USA
- 818P** – A phase I, dose-finding study of sunitinib (SU) in combination with cisplatin (P) and 5-fluorouracil (5-FU) in patients (pts) with advanced gastric cancer (GC)  
Carlos Gómez-Martín, Madrid, Spain
- 819P** – Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)  
Kazumasa Fujitani, Osaka, Japan
- 820P** – Although the AJCC new 7th edition's number-based N-category improves over the 6th, Lymph Node Ratios are still a better prognostic indicator for overall survival  
Iain Tan, Singapore
- 821P** – Clinical outcome of advanced gastric cancer (GC) patients (pts) by human epidermal growth factor receptor 2 (HER2) status when treated before the trastuzumab era  
Roberto Pazo Cid, Zaragoza, Spain
- 822P** – Her2 over-expression and gene amplification in gastric cancer  
Young Soo Park, Seoul, South Korea

**823P** – HER2 status in primary and paired distant metastatic sites of gastric carcinoma

Francesca Negri, Parma, Italy

**824P** – SOCS-1,-3 gene delivery in gastric cancer cells induces a potent anti-proliferative effect via the suppression of JAK/STAT and P38 MAPK signaling pathways

Satoshi Serada, Ibaraki City (Osaka), Japan

**825P** – Long term survival post curative intent gastrectomy in gastric cancer patients with positive peritoneal cytology (an independent indicator of poor prognosis)

Hwee Yong Lim, Singapore

**826P** – Oxaliplatin + 5-fluorouracil/leucovorin (FOLFOX4) in advanced HCC: Updated efficacy results of the EACH trial

Shukui Qin, Nanjing, China

**827P** – First interim results of the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNIB (GIDEON) study

Riccardo Lencioni, Pisa, Italy

**828P** – Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective comparison with previously known prognostic models

Kyung Kee Baek, Seoul, South Korea

**829P** – Novel KRAS mutation detected amongst gallbladder cancer patients from Eastern India  
Rakesh Roy, Kolkata, West Bengal, India

## Sunday, 10 October 2010

08.00–08.45 **Turquoise 2**

### Young Oncologist Breakfast

**How to conduct effective public speaking and slide presentations**

Jan Vermorken, Edegem, Belgium

08.00–09.00 **Yellow Hall 1**

### Challenge Your Expert session (Repetition)

**Cancer of unknown primary site (CUP): 20 questions to be answered**

Nicholas Pavlidis, Ioannina, Greece

08.00–09.00 **Yellow Hall 2**

### Challenge Your Expert session (Repetition)

**Mesothelioma**

Walter Weder, Zurich, Switzerland

08.00–09.00 **Yellow Hall 3**

### Challenge Your Expert session (Repetition)

**Genetic counselling for hereditary predisposition to ovarian and breast cancer**

James Mackay, London, UK

08.00–09.00 **Green Hall 3**

### Challenge Your Expert session (Repetition)

**Osteosarcoma**

Stefan Bielack, Stuttgart, Germany

08.00–09.00 **Green Halls 1+2**

### Patient Cases

**Challenging cases in testicular cancer**

Co-Chairs: Carsten Bokemeyer, Hamburg, Germany and Christian Kollmannsberger, Vancouver, BC, Canada

**08.00** Treatment options in early stage seminoma  
Christian Kollmannsberger, Vancouver, BC, Canada

**08.10** Relapsed and/or refractory non-seminoma  
Carsten Bokemeyer, Hamburg, Germany

**08.20** Discussion

08.00–09.00 **Orange Halls 2+3**

### Patient Cases

**How to improve curability of locally advanced head and neck cancer**

Co-Chairs: Johannes A. Langendijk, Groningen, Netherlands and Dirk Schrijvers, Antwerp, Belgium

**08.00** Site-related co-morbidities in decision making  
Johannes Langendijk, Groningen, Netherlands

- 08.10 Supportive care measures to improve patient outcome  
Dirk Schrijvers, Antwerp, Belgium
- 08.20 Discussion

---

08.00–09.00 **Orange Hall 1**

**Special Session**

**European Union Translational Research Program**

Coordination of cancer research through the  
FP7 HEALTH programme

Jan-Willem van de Loo, Brussels, Belgium

---

09.00–10.30 **Silver Hall**

**Educational session (Repetition)**

**Early-stage NSCLC: Challenges in staging and  
adjuvant treatment**

Chair: Thierry Le Chevalier, Villejuif, France

Co-Chair: Paul Baas, Amsterdam, Netherlands

- 09.00 Evidence-based staging  
Johan Vansteenkiste, Leuven, Belgium
- 09.30 Adjuvant chemotherapy: Where is it going?  
Thierry Le Chevalier, Villejuif, France
- 10.00 Do we have markers to select patients for  
adjuvant therapies?  
Krzysztof Konopa, Gdansk, Poland

---

09.00–10.30 **Blue Hall**

**Educational session (Repetition)**

**Updates in B-cell malignancies**

Chair: Michele Ghielmini, Bellinzona, Switzerland

Co-Chair: Håkan Mellstedt, Stockholm, Sweden

- 09.00 Multiple myeloma  
Meletios Dimopoulos, Athens, Greece
- 09.30 Follicular lymphoma  
Michele Ghielmini, Bellinzona, Switzerland
- 10.00 Chronic lymphocytic leukemia  
Michael Hallek, Cologne, Germany

---

09.00–10.30 **Violet Hall**

**Proffered Paper session**

**Upper gastrointestinal tumors**

Chair: Arnaud Roth, Geneva, Switzerland

Co-Chair: Claus-Henning Koehne, Oldenburg, Germany

- 09.00 8000 – Impact of neoadjuvant chemoradiation in  
localised oesophageal cancer: results of a randomised  
controlled phase III trial FFCD 9901  
Christophe Mariette, Lille, France

- 09.15 8010 – Final results of the intergroup FFCD-GERCOR-  
FNCLCC 03-07 phase III study comparing two sequences of  
chemotherapy in advanced gastric cancers  
Rosine Guimbaud, Toulouse, France
- 09.30 Invited Discussant, Abstracts 8000 and 8010  
Michael Stahl, Essen, Germany
- 09.45 8020 – Photostent-02; Porfimer Sodium photodynamic therapy  
plus stenting versus stenting alone in patients (pts) with  
advanced or metastatic cholangiocarcinomas and other biliary  
tract tumours (BTC): A multicentre, randomised phase III trial  
Stephen Pereira, London, UK
- 10.00 730 – Final results of a randomized phase III trial  
comparing folfinirix (F: 5FU/leucovorin [LV], irinotecan [I]  
and oxaliplatin [O]) vs gemcitabine (G) as first-line  
treatment for metastatic pancreatic adenocarcinoma  
(MPA). The Prodigé 4 / ACCORD 11 trial  
Françoise Desseigne, Lyon, France
- 10.00 Invited Discussant, Abstract 8020 and 730  
TBC

---

09.00–10.45 **Pink Hall**

**Proffered Paper session**

**Sarcoma**

Chair: Axel Le Cesne, Villejuif, France

Co-Chair: Paolo G. Casali, Milan, Italy

- 09.00 13430 – Bone angiosarcoma: A retrospective analysis of  
73 patients from two referral centres  
Emanuela Palmerini, Bologna, Italy
- 09.15 13440 – Safety and efficacy results from a phase 1/2  
study of the anti-IGF-IR antibody figitumumab in patients  
with refractory Ewing's and othersarcomas  
Heribert Juergens, Muenster, Germany
- 09.30 Invited Discussant, Abstracts 13430 and 13440  
Hans Gelderblom, Leiden, Netherlands
- 09.40 13450 – A pooled analysis of the final results of the two  
randomized phase II studies comparing gemcitabine (G)  
vs gemcitabine + docetaxel (G+D) in patients (pts) with  
metastatic/relapsed leiomyosarcoma (LMS)  
Florence Duffaud, Marseille, France
- 09.55 13460 – A retrospective analysis of 41 primary localized  
rectal/pararectal gastrointestinal stromal tumors (GISTs)  
from the French Sarcoma Group (FSG).  
Thanh K. Huynh, Marseille, France
- 10.10 13470 – Antitumor activity of sunitinib malate (SM) in  
solitary fibrous tumors (SFT)  
Silvia Stacchiotti, Milan, Italy
- 10.25 Invited Discussant, Abstracts 13450, 13460 and 13470  
Serge Leyvraz, Lausanne, Switzerland



09.15–10.15 **Gold Hall**

### Controversy session

#### Over-diagnosis of breast cancer by screening is a peril

Moderator: Ian Smith, London, UK

- 09.15 Introduction and vote  
Ian Smith, London, UK
- 09.25 Benefit  
Harry De Koning, Rotterdam, Netherlands
- 09.45 Peril  
Karsten J. Jørgensen, Copenhagen, Denmark
- 10.05 Vote and conclusions  
Ian Smith, London, UK

09.15–10.15 **Orange Hall 1**

### Multidisciplinary Interactive session (MIS)

#### Locally advanced rectal cancer

Co-Chairs: Andrés Cervantes, Valencia, Spain and  
Cornelis van de Velde, Leiden, Netherlands

- 09.15 Surgery  
Cornelis van de Velde, Leiden, Netherlands
- 09.30 Medical Oncology  
Andrés Cervantes, Valencia, Spain
- 09.45 Discussion

09.30–11.00 **Yellow Hall 2**

### Special Session

#### Communication skills training (CST)

Chair: Alexander Kiss, Basel, Switzerland

Co-Chair: Friedrich Stiefel, Lausanne, Switzerland

- 09.30 Introduction  
Alexander Kiss, Basel, Switzerland
- 09.35 CST in oncology: Results from a consensus meeting  
among European experts in 2009  
Friedrich Stiefel, Lausanne, Switzerland
- 09.55 A reaction to the proposition of the European consensus  
on CST in oncology  
Darius Razavi, Brussels, Belgium
- 10.15 Mandatory training, minimal requirements an  
implementation of CST in oncology:  
The European perspective  
Wolf Langewitz, Basel, Switzerland
- 10.35 The future of CST in oncology  
Lesley Fallowfield, Brighton, UK
- 10.55 Conclusions  
Alexander Kiss, Basel, Switzerland

10.30–12.00 **Orange Hall 1**

### Special Symposium

#### The more (we are), the better (we serve)!

#### ESMO and OECl: towards high-quality cancer care

Co-Chairs: David J. Kerr, Oxford, UK and

Mahasti Saghatchian, Villejuif, France

- 10.30 Introduction: Quality fatality, necessity or opportunity?  
Mahasti Saghatchian, Villejuif, France and  
Richard Sullivan, London, UK
- 10.40 The OECl accreditation programme  
Mahasti Saghatchian, Villejuif, France
- 10.55 ESMO designated Centres of Integrated Oncology and  
Palliative Care  
Nathan Cherny, Jerusalem, Israel
- 11.10 Developing a designation system for cancer centres  
Wim van Harten, Amsterdam, Netherlands
- 11.25 Assessment frameworks for cancer centres: novel methodologies  
Richard Sullivan, London, UK
- 11.40 Q&A and Conclusions  
David J. Kerr, Oxford, UK and  
Mahasti Saghatchian, Villejuif, France

10.45–12.45 **Gold Hall**

### ESMO Clinical Practice Guidelines

Chair: Nicholas Pavlidis, Ioannina, Greece

Co-Chair: Andrés Cervantes, Valencia, Spain

- 10.45 Introduction  
Nicholas Pavlidis, Ioannina, Greece
- 10.50 ESMO CPG Questionnaire  
Andrés Cervantes, Valencia, Spain  
Breast cancer (triple negative)
- 10.55 Speaker  
Helen Gogas, Athens, Greece
- 11.15 Discussant  
Andrew Tutt, London, UK  
GIST
- 11.30 Speaker  
Laura Kairevice, Kaunas, Lithuania
- 11.50 Discussant  
Alessandro Gronchi, Milan, Italy  
Pancreatic cancer
- 12.05 Speaker  
Stefan Boeck, Munich, Germany
- 12.25 Discussant  
Stefano Cascinu, Ancona, Italy
- 12.40 Conclusions  
Andrés Cervantes, Valencia, Spain

10.45–12.15 **Silver Hall**

**Educational session (Repetition)**

**Challenging issues in ovarian cancer**

Chair: Jonathan Ledermann, London, UK

Co-Chair: Cristiana Sessa, Bellinzona, Switzerland

**10.45** How can proteomic profiling guide us in selecting therapy?

Elise Kohn, Bethesda, MD, USA

**11.15** The addition of new drugs to standard therapy in the

first-line treatment of ovarian cancer

Michael Bookman, Tucson, AZ, USA

**11.45** Optimal treatment for relapsing ovarian cancer

Jonathan Ledermann, London, UK

---

10.45–12.15 **Green Halls 1+2**

**Educational session (Repetition)**

**Prevention and treatment of side effects  
of systemic treatment**

Chair: Mario Dicato, Luxembourg

Co-Chair: Jørn Herrstedt, Odense, Denmark

**10.45** Anemia

Mario Dicato, Luxembourg

**11.15** Cardiotoxicity

Josep Taberero, Barcelona, Spain

**11.45** Bone loss

Jean-Jacques Body, Brussels, Belgium

---

10.45–12.15 **Violet Hall**

**Special Symposium**

**Targeted therapies in NSCLC: State-of-the-art and  
new developments**

Chair: Luis Paz-Ares, Seville, Spain

Co-Chair: Rolf A. Stahel, Zurich, Switzerland

**10.45** Introduction

Luis Paz-Ares, Seville, Spain

**10.50** Gefitinib – the resurrection

Luis Paz-Ares, Seville, Spain

**11.05** Erlotinib – the adult

Rafael Rosell, Badalona, Barcelona, Spain

**11.20** Bevacizumab – the adolescent

Jean-Charles Soria, Villejuif, France

**11.35** Cetuximab – the newborn

Ken O'Byrne, Dublin, Ireland

**11.50** New molecular targets – the next generation of drugs

Cesare Gridelli, Avellino, Italy

**12.05** Conclusions

Rolf A. Stahel, Zurich, Switzerland

11.00–12.15 **Pink Hall**

**Proffered Paper session**

**Melanoma**

Chair: Patrick Schöffski, Leuven, Belgium

Co-Chair: Alexander M. M. Eggermont, Rotterdam, Netherlands

**11.00** **13240** – Ipilimumab improves survival in previously  
treated, advanced melanoma patients with poor  
prognostic factors: Subgroup analyses from a phase III trial  
Céleste Lebbé, Paris, France

**11.15** Invited Discussant, Abstract 13240 plus 1 expected LBA  
Cornelis J.A. Punt, Nijmegen, Netherlands

**11.30** **13250** – Retrospective analysis of 470 metastatic uveal  
melanoma (MUM) patients managed at Institut Curie  
between 2000 and 2008

Sophie Piperno-Neumann, Paris, France

**11.45** **LBA27** – Phase 1/2 study of GSK2118436, a selective  
inhibitor of V600 Mutant (Mut) BRAF kinase: Evidence of  
activity in melanoma brain metastases (Mets)

Georgina Long, Westmead, Australia

**12.00** Invited Discussant, Abstract 13250 and LBA27

Caroline Robert, Paris, France

---

11.00–12.30 **Blue Hall**

**Special Symposium**

**Targeting molecular pathways in the jungle of  
soft tissue sarcoma histology**

Chair: Eva Wardelmann, Bonn, Germany

Co-Chair: Michael Montemurro, Lausanne, Switzerland

**11.00** Introduction

Michael Montemurro, Lausanne, Switzerland

**11.05** Angiogenesis inhibitors: Are they useful for all sarcomas?  
Stefan Sleijfer, Rotterdam, Netherlands

**11.25** mTOR inhibitors: From lymphangioleiomyomatosis to where?  
Paolo Casali, Milan, Italy

**11.45** Is the indication of IGFR antibodies in advanced refractory  
sarcomas expanding?

Jean-Yves Blay, Lyon, France

**12.05** At the crossroads of molecular pathways and sarcoma  
subtypes

Jean-Michel Coindre, Bordeaux, France

**12.25** Conclusions

Eva Wardelmann, Bonn, Germany

12.30–13.20 **Violet Hall**

### Keynote Lecture

#### A historical view and perspectives on angiogenesis inhibition and in particular anti-VEGF therapy in cancer

Chair: Marco A. Pierotti, Milan, Italy

Speaker: Peter Carmeliet, Leuven, Belgium

12.30–13.30 **Green Halls 1+2**

### Poster Symposium (Discussion session)

#### Chest tumors

Co-Chairs: Lucio Crinò, Perugia, Italy,

Filippo de Marinis, Rome, Italy and Robert Pirker, Vienna, Austria

**364PD** – QOL Analysis from NEJ 002 study comparing gefitinib to chemotherapy for non-small cell lung cancer with mutated EGFR

Hirohisa Yoshizawa, Niigata, Japan

**365PD** – Randomized phase II study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: Quantitative and qualitative benefits

Suresh Ramalingam, Atlanta, GA, USA

**366PD** – Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC)

David Ross Camidge, Aurora, CO, USA

**367PD** – A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2)

Wu-Chou, Tainan, Taiwan

**12.30** Invited Discussant, Abstracts 364PD–367PD

Filippo de Marinis, Rome, Italy

**368PD** – A double-blind, randomized, placebo-controlled phase III study of gefitinib (G) versus placebo (P) in patients (Pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021- ILCP)

Veerle Surmont, Ghent, Belgium

**369PD** – Erlotinib maintenance therapy in patients with stable disease after first-line platinum-doublet chemotherapy for advanced NSCLC

Frederico Cappuzzo, Livorno, Italy

**370PD** – Final results from the IFCT-GFPC 0502 phase III study: Maintenance therapy in advanced NSCLC with either gemcitabine (G) or erlotinib (E) versus observation (O) after cisplatin-gemcitabine induction chemotherapy (CT), with a predefined second-line treatment

Maurice Pérol, Lyon, France

**12.42** Invited Discussant, Abstracts 368PD–370PD

Lucio Crinò, Perugia, Italy

**371PD** – A phase II study of Tumor Treating Fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer (NSCLC)

Miklos Pless, Winterthur, Switzerland

**372PD** – Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation therapy with NVBo and P plus best supportive care (BSC) or BSC alone in stage (st) III non small cell lung cancer (NSCLC): Preliminary results of a phase III study

Michael Flentje, Würzburg, Germany

**373PD** – Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small-cell lung cancer (NSCLC) patients (p)

Sara Simonetti, Barcelona, Spain

**374PD** – S-1 plus carboplatin has become one of the standard regimens for advanced non-small-cell lung cancer: Results of a randomized phase III study conducted by the West Japan Oncology Group (WJTOG 3605)

Takashi Seto, Fukuoka, Japan

**375PD** – Overall survival (OS) and progression free survival (PFS) results for a randomized phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIB/IV non-small cell lung cancer (NSCLC)

Thomas Lynch, Jr, New Haven, CT, USA

**12.54** Invited Discussant, Abstracts 371PD–375PD

Robert Pirker, Vienna, Austria

**13.06** General Discussion

12.30–13.30 **Green Hall 3**

### Poster Symposium (Discussion session)

#### Health services and public health

Co-Chairs: Christos Chouaid, Paris, France and

Heinz Ludwig, Vienna, Austria

**1085PD** – Maintenance chemotherapy in advanced non-small cell lung cancer: Cost utility of pemetrexed and gemcitabine

Tiago Takahashi, Sao Paulo, Brazil

**1086PD** – Improving the quality of abstracts for cost-effectiveness analyses (CEA) in oncology

Winson Cheung, Vancouver, BC, Canada

**12.30** Invited Discussant, Abstracts 1085PD–1086PD

Christos Chouaid, Paris, France

**1087PD** – Oral prevalence and clearance of high-risk human papilloma virus (HR-HPV) in healthy people in San Patrignano, a rehabilitation community for substance abusers

Davide Pugliese, Coriano, Italy

**1088PD** – Breast cancer is a more aggressive disease in Palestinian Arab women than in Jewish women in Israel  
Jamal Zidan, Safed, Israel

**1089PD** – Breast cancer survival in Brazil related with the disparities in health services access  
Roberta Wolp Diniz, Villejuif, France

**1090PD** – Patterns of adjuvant endocrine therapy for early breast cancer in Ontario: A population-based study  
Yolanda Madarnas, Kingston, ON, Canada

**1091PD** – Computerized physician order entry systems and chemotherapy (CT) prescription errors  
Marianna Aita, Udine, Italy

**1092PD** – How are departments of cancer medicine organized in Europe? Results from a survey conducted in 7 countries

Karim Fizazi, Villejuif, France

**1093PD** – What do German office-based community oncologists expect from ESMO? Results from a 2010 survey among members of the Professional Association of Haematologists and Oncologists in Germany (BNHO)  
Robert Eckert, Wendlingen, Germany

**12.45** Invited Discussant, Abstracts 1087PD-1093PD  
Heinz Ludwig, Vienna, Austria

**13.00** General Discussion

**12.30–13.30** **Orange Halls 2+3**

#### Poster Symposium (Discussion session)

#### Biomarkers II – Circulating tumor cells and molecular markers

Co-Chairs: Maria Grazia Daidone, Milan, Italy and  
Klaus Pantel, Hamburg, Germany

**170PD** – Circulating tumor cells in breast cancer: are currently available detection methods enough?

Cristina Raimondi, Rome, Italy

**171PD** – Relationship between lymphopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer

Ugo De Giorgi, Lecce, Italy

**172PD** – Baseline circulating tumour cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) prognostic score to optimise patient selection for phase 1 clinical trials

Christophe Massard, Sutton, UK

**173PD** – Enumeration circulating tumor cells (CTCs) is a prognostic and predictive factor for progression-free survival (PFS) and overall survival (OS) in colon cancer patients receiving first-line chemotherapy plus bevacizumab. A TTD Spanish Group Cooperative Study

Javier Sastre, Madrid, Spain

**12.30** Invited Discussant, Abstracts 170PD-173PD

Klaus Pantel, Hamburg, Germany

**174PD** – Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab + capecitabine/cisplatin in patients with advanced gastric cancer

Manish Shah, New York, NY, USA

**175PD** – Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (mCRC) patients (pts)

Chiara Cremolini, Livorno, Italy

**176PD** – SPARC microenvironment signature (SMS) as a prognostic biomarker when combined with LDH and plasma SPARC

Neil Desai, Los Angeles, CA, USA

**177PD** – Circulating SPARC levels negatively impact chemotherapies in cancer models

Neil Desai, Los Angeles, CA, USA

**12.45** Invited Discussant, Abstracts 174PD-177PD

Maria Grazia Daidone, Milan, Italy

**13.00** General Discussion

**12.30–13.30** **Yellow Hall 1**

#### Poster Symposium (Discussion session)

#### Developmental therapeutics

Co-Chairs: Johann de Bono, Sutton, UK and  
Anthony Tolcher, San Antonio, TX, USA

**498PD** – Dynamic tumor growth evaluation could predict overall survival for patients included in phase I clinical trials  
Bertrand Billemonet, Paris, France

**499PD** – Current phase I trials: Dose-levels and first signs of efficacy

Jacques Bonnetterre, Lille, France

**500PD** – Phase I study of the tumor-targeting human L19TNF monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors

Gianluca Spitaleri, Milan, Italy

**12.30** Invited Discussant, Abstracts 498PD-500PD

Anthony Tolcher, San Antonio, TX, USA

**501PD** – A phase 1 study of IPI-926, an inhibitor of the hedgehog pathway, in patients (pts) with advanced or metastatic solid tumors

Antonio Jimeno, Aurora, CO, USA

**502PD** – LDE225, a smoothened (Smo) antagonist: Phase I safety and pharmacologic results in patients with advanced tumors

Jordi Rodon Ahnert, Barcelona, Spain

**503PD** – Treatment of castration refractory prostate cancer patients with 2 different immunotherapeutic approaches against EGFR

Tania Crombet, Havana, Cuba

**12.45** Invited Discussant, Abstracts 501PD-503PD

Johann de Bono, Sutton, UK

**13.00** General Discussion

**12.30–13.30** **Yellow Hall 2**

### Poster Symposium (Discussion session)

#### Basic science and translational research

Co-Chairs: Cristiana Sessa, Bellinzona, Switzerland and TBC

**77PD** – P3H collagen prolyl hydroxylases are tissue selective tumour suppressors

Cristiana Lo Nigro, Cuneo, Italy

**78PD** – Expression of matrix metalloproteinase 1 (MMP1), Dickkopf-1 (Dkk1) and colony-stimulating factor receptor 1 (CSF1R) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors

Luis Costa, Lisbon, Portugal

**79PD** – mRNA expression of VEGF family members has prognostic significance in high-risk early breast cancer patients participating in a prospective randomized study of the Hellenic Cooperative Oncology Group (HeCOG)

Helena Linardou, Athens, Greece

**12.30** Invited Discussant, Abstracts 77PD-79PD

TBC

**80PD** – Antitumor activity of nab-paclitaxel and bevacizumab against a new triple negative breast cancer model

Vuong Trieu, Los Angeles, CA, USA

**81PD** – The mTOR signaling pathway as potential therapeutic target in meningiomas

Christian Mawrin, Magdeburg, Germany

**82PD** – Novel insights for therapeutic strategies in pancreatic neuroendocrine tumors (pNET)

Aldo Scarpa, Verona, Italy

**83PD** – Considerations in the development and validation of genomic tests for cancer recurrence and treatment benefit

David J. Kerr, Oxford, UK

**12.45** Invited Discussant, Abstracts 80PD-83PD

Cristiana Sessa, Bellinzona, Switzerland

**13.00** General Discussion

**12.30–13.30** **Yellow Hall 3**

### Poster Symposium (Discussion session)

#### Hematological malignancies

Co-Chairs: Lena Specht, Copenhagen, Denmark and TBC

**1136PD** – Melphalan, prednisone, lenalidomide (MPR) versus melphalan (200 mg/m<sup>2</sup>) and autologous transplantation (MEL200) in newly diagnosed myeloma patients: A phase III trial

Federica Cavallo, Turin, Italy

**1137PD** – Long term follow up of new cases of acute promyelocytic leukemia treated by arsenic trioxide as sole treatment without ATRA and/or chemotherapy

Ardeshtir Ghavamzadeh, Tehran, Iran

**1138PD** – Results of a randomized, phase II study of bevacizumab and bortezomib vs. bortezomib in patients with relapsed/refractory multiple myeloma: AMBER study

Darrell White, Halifax, NS, Canada

**12.30** Invited Discussant, Abstracts 1136PD-1138PD

TBC

**1139PD** – The role of del(13q14.3) in diffuse large B-cell lymphomas

Ekaterina Chigrinova, Bellinzona, Switzerland

**1140PD** – Bone marrow involvement and 7q gain in diffuse large B-cell lymphoma: A combination of clinical and molecular data

Ekaterina Chigrinova, Bellinzona, Switzerland

**1141PD** – Activity and safety of dose-adjusted infusional CHOP chemotherapy with rituximab (DA-POCH-R) in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin's lymphoma

Daniela Boggiani, Parma, Italy

**12.40** Invited Discussant, Abstracts 1139PD-1141PD

TBC

**1142PD** – Non-Hodgkin lymphoma: Increased survival in case of adherence to quality indicators

L. Wennekes, Nijmegen, Netherlands

**1143PD** – Evaluation of 18F-Fluorodeoxyglucose PET/CT compared to contrast-enhanced full-dose PET/CT in the management of patients with lymphoma

David Fuster, Barcelona, Spain

**1144PD** – Phase II study of intrathecal long acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in HIV-related non-Hodgkin's lymphoma

Michele Spina, Aviano, Italy

**12.50** Invited Discussant, Abstracts 1142PD-1144PD

Lena Specht, Copenhagen, Denmark

**13.00** General Discussion



13.30–15.00 **Gold Hall**

### Proffered Paper session

#### Colorectal cancer

Chair: Jean-Yves Douillard, St. Herblain, France

Co-Chair: Alberto Sobrero, Genoa, Italy

**13.30 LBA19** – Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, phase III STUDY (HORIZON II)  
Paulo Hoff, São Paulo, Brasil

**13.45 5800** – mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, Phase II/III study (HORIZON III)  
Hans-Joachim Schmoll, Halle, Germany

**14.00** Invited Discussant, LBA19 and Abstract 5800  
Claus-Henning Koehne, Oldenburg, Germany

**14.15 LBA20** – Randomized phase III study of 5-fluorouracil/folate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group  
Kjell Magne Tveit, Oslo, Norway

**14.30 LBA21** – A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC)  
Jordan Berlin, Nashville, TN, USA

**14.45** Invited Discussant, LBA20 and LBA21  
Alberto Sobrero, Genoa, Italy

13.45–15.15 **Silver Hall**

### Educational session

#### Diagnostic and management issues in gastroesophageal cancer

Chair: Florian Lordick, Hannover, Germany

Co-Chair: João Oliveira, Lisbon, Portugal

**13.45** Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?  
Michael Stahl, Essen, Germany

**14.15** Multimodality treatment for localized gastroesophageal cancer  
David Cunningham, Sutton, UK

**14.45** New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan  
Florian Lordick, Hannover, Germany

13.45–15.15 **Violet Hall**

### Special Symposium

#### ESMO/AIOM Joint Symposium: Young medical oncologists facing daily difficulties in clinical practice

Co-Chairs: Massimo Di Maio, Naples, Italy and

Michael V. Karamouzis, Papagou, Greece

**13.45** Introduction

Massimo Di Maio, Naples, Italy and  
Michael V. Karamouzis, Papagou, Greece

**13.50** Presenting bad news to the patient  
Francesco Atzori, Cagliari, Italy

**14.05** The risk of burn out: Are young oncologists at higher risk?  
Laurence Albiges, Villejuif, France

**14.20** Presenting a completed research project as an oral presentation  
Valentina Guarneri, Modena, Italy

**14.35** Presenting the data of a project in a manuscript  
Evandro De Azambuja, Brussels, Belgium

**14.50** Invited Discussant  
Valter Torri, Milan, Italy

**15.00** Q&A

13.45–15.15 **Pink Hall**

### Special Symposium

#### Bullseye: PARP

Chair: Johann de Bono, Sutton, UK

Co-Chair: Hilary Calvert, London, UK

**13.45** From platinum to PARP  
Hilary Calvert, London, UK

**13.50** Targeting the Achilles heel: Synthetic lethality  
Alan Ashworth, London, UK

**14.10** Encouraging first experiences with PARP inhibitors  
Ruth Plummer, London, UK

**14.30** Early tales: PARP and BRCA  
Jan H M Schellens, Amsterdam, Netherlands

**14.50** Later tales: Phase II and beyond  
Andrew Tutt, London, UK

**15.10** Conclusions  
Johann de Bono, Sutton, UK

13.45–15.15 **Blue Hall**

### Special Symposium

#### Toxicities of targeted therapies: Prevention and management

Chair: Fausto Roila, Terni, Italy

Co-Chair: Dorothy M. K. Keefe, Adelaide, Australia

**13.45** Introduction  
Dorothy M. K. Keefe, Adelaide, Australia

- 13.50** Skin toxicity  
Mario Lacouture, Chicago, IL, USA
- 14.15** Gastrointestinal toxicity  
Dorothy M. K. Keefe, Adelaide, Australia
- 14.40** Renovascular and cardiac toxicity  
Thomas Suter, Bern, Switzerland
- 15.05** Conclusions  
Fausto Roila, Terni, Italy

#### 15.15–16.15 **Gold Hall**

##### **Controversy session**

##### **Active surveillance in early prognosis prostate cancer should be standard of care**

Moderator: Sten Nilsson, Stockholm, Sweden

- 15.15** Introduction and vote  
Sten Nilsson, Stockholm, Sweden
- 15.25** Pro speaker  
Fritz Schröder, Rotterdam, Netherlands
- 15.45** Contra speaker  
Kurt Miller, Berlin, Germany
- 16.05** Vote and conclusions  
Sten Nilsson, Stockholm, Sweden

#### 15.30–17.30 **Violet Hall**

##### **Proffered Paper session**

##### **Breast cancer, advanced**

Chair: Fatima Cardoso, Lisbon, Portugal  
Co-Chair: PierFranco Conte, Modena, Italy

- 15.30** **LBA11** – Final Efficacy and Safety Results of a Randomized Phase II Study of the PARP Inhibitor Iniparib (BSI-201) in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC)  
Joyce O'Shaughnessy, Dallas, TX, USA
- 15.45** **LBA12** – Results of the first randomized phase II study of cationic liposomal paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)  
Ahmad Awada, Brussels, BE
- 16.00** Invited Discussant, LBA11 and LBA12  
Richard Bell, Milan, Italy
- 16.15** **2750** – Eribulin mesylate (E7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): Subgroup analyses from the EMBRACE study  
Chris Twelves, Leeds, UK
- 16.30** **2760** – Prolonging chemotherapy until disease progression improves progression free and overall survival in metastatic breast cancer: Results of a systematic review  
Alessandra Gennari, Genoa, Italy

- 16.45** Invited Discussant, Abstracts 2750, 2760  
Miguel Martin, Madrid, Spain
- 17.00** **2770** – A phase II study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy  
Ian Krop, Boston, MA, USA
- 17.15** Invited Discussant, Abstract 2770  
Fabio Puglisi, Udine, Italy

#### 15.30–17.00 **Silver Hall**

##### **Educational session**

##### **Towards an individualized approach of advanced non-small cell lung cancer**

Chair: Enriqueta Felip, Barcelona, Spain  
Co-Chair: Rafal Dziadziuszko, Gdansk, Poland

- 15.30** Should we continue to use the term non-small cell lung cancer?  
Adi F Gazdar, Dallas, TX, USA
- 16.00** How to integrate current knowledge in selecting first-line therapy  
Enriqueta Felip, Barcelona, Spain
- 16.30** Consequences of targeted treatments for second-line therapy  
Federico Cappuzzo, Livorno, Italy

#### 15.30–17.00 **Pink Hall**

##### **Educational session**

##### **Advances in head and neck cancer**

Chair: Jan Vermorken, Edegem, Belgium  
Co-Chair: Marshall Posner, New York, NY, USA

- 15.30** The role of papilloma virus infection  
Stina Syrjänen, Turku, Finland
- 16.00** Integrating systemic agents into multimodality treatment of locally advanced diseases  
Marshall Posner, New York, NY, USA
- 16.30** Optimal treatment for relapsing or metastatic disease  
Jan Vermorken, Edegem, Belgium

#### 15.30–17.00 **Blue Hall**

##### **Educational session**

##### **Soft tissue sarcoma: From molecular diagnosis to selection of treatment**

Chair: Ian Judson, Sutton, UK  
Co-Chair: Serge Leyvraz, Lausanne, Switzerland

- 15.30** Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies  
Eva Wardelmann, Bonn, Germany

- 16.00** Histology-driven chemotherapy of soft tissue sarcoma  
Mikael Eriksson, Lund, Sweden
- 16.30** Targeted therapies in soft tissue sarcoma  
Ian Judson, Sutton, UK

**16.30–17.30** **Gold Hall**

### Controversy session

#### Access to novel drugs improves survival

Moderator: Thomas Szucs, Basel, Switzerland

- 16.30** Introduction and vote  
Thomas Szucs, Basel, Switzerland
- 16.40** Pro Speaker  
Ivar S. Kristiansen, Oslo, Norway
- 17.00** Contra Speaker  
Franz Porzsolt, Ulm, Germany
- 17.20** Vote and conclusions  
Thomas Szucs, Basel, Switzerland

## 8<sup>th</sup> ESMO Patient Seminar

**09.30–10.30** **Red Hall**

### Living with cancer: Early rehabilitation

Co-Chairs: Paola Varese, Ovada, Italy and  
Stella Kyriakides, Nicosia, Cyprus

- 09.30** Early rehabilitation: where does it lead?  
Anita Margulies, Zurich, Switzerland
- 09.45** The importance of psycho-oncology  
Luigi Grassi, Ferrara, Italy
- 10.00** Common paths in the European Union  
Sanja Rozman, Ljubljana, Slovenia
- 10.15** General Discussion

**10.30–10.45**

### Break

**10.45–12.15** **Red Hall**

### Living with cancer: Long-term rehabilitation

Co-Chairs: Elisabetta Iannelli, Rome, Italy  
and Dorothy M. K. Keefe, Adelaide, Australia

- 10.45** The long term and late effects of cancer.  
Implications for research and public policy  
Kevin Stein, Atlanta, GA, USA
- 11.15** Psychological and social consequences  
Patrizia Pugliese, Formello, Rome, Italy
- 11.30** Poster discussion  
AIMaC (Associazione Italiana Malati di Cancro), Italy  
APOZ and Friends, Bulgaria  
ATTIVECOMEPRIMA, Italy  
WALCE (Women Against Lung Cancer in Europe), Italy

**12.15–13.15**

### Lunch

13.15–14.15 **Red Hall**

**Do we always need specific cancer treatment?**

Co-Chairs: Kevin Stein, Atlanta, GA, USA  
and Stella Kyriakides, Nicosia, Cyprus

- 13.15 General principles in treatment of frail and elderly patients  
Matti S. Aapro, Genolier, Switzerland
  - 13.30 What is co-morbidity and how is it evaluated?  
Dirk Schrijvers, Antwerp, Belgium
  - 13.45 When not to operate  
Alberto Costa, Milan, Italy
  - 14.00 General Discussion
- 

15.15–14.30

**Move to breakout sessions**

---

14.30–15.30 **Red Hall**

**Latest developments in breast cancer**

Co-Chairs: Rosalba Torrisi, Milan, Italy and  
Anna Mancuso, Milan, Italy

- 14.30 Short overview  
Rosalba Torrisi, Milan, Italy
  - 14.45 Revision and management of patients with skin problems for radiotherapy  
Marie Paule Gardes, Milan, Italy
  - 15.00 General discussion
- 

14.30–15.30 **Yellow Hall 1**

**Latest developments in gastrointestinal tumors**

Co-Chairs: Jim Cassidy, Glasgow, UK and TBC

- 14.30 Short overview  
Jim Cassidy, Glasgow, UK
  - 14.45 Management of alopecia problems for best QoL  
Alessandra Milani, Milan, Italy
  - 15.00 General discussion
- 

14.30–15.30 **Yellow Hall 2**

**Latest developments in haematological malignancies**

Co-Chairs Michael Hallek, Cologne, Germany and  
Davide Petruzzelli, Brughiero, Italy

- 14.30 Short overview  
Michael Hallek, Cologne, Germany
  - 14.45 Therapeutic relation with the patient  
Miriam Magri, Milan, Italy
  - 15.00 General discussion
- 

14.30–15.30 **Yellow Hall 3**

**Latest developments in prostate cancer**

Co-Chairs Francesco Montorsi, Milan, Italy IT and  
Riccardo Valdagni, Milan, Italy

- 14.30 Short overview  
Francesco Montorsi, Milan, Italy
  - 14.45 The rehabilitative nursing function for urinary incontinence. A challenge for best QoL  
Mara Marchetti, Milan, Italy
  - 15.00 General discussion
- 

15.30–15.40

**Move back to plenary**

---

15.40–16.40 **Red Hall**

**Review and general discussion**

Co-Chairs: Lorenz Jost, Bruderholz, Switzerland and TBC

- 15.40 Best Cancer Reporter Award Ceremony,  
presented by Kathy Redmond, Milan, Italy
  - 15.45 Short review of major points emerging from the breakout sessions  
TBC
  - 16.00 General Discussion
- 


16.40–17.15

**Farewell drink**

**Breast cancer, early**

Chair: Luca Gianni, Milan, Italy

- 224P** – Letrozole or anastrozole for the treatment of hormone positive breast cancer: A clinical comparison using indirect statistical techniques  
Satyin Kaura, Florham Park, NJ, USA
- 225P** – Effects of exemestane or tamoxifen on bone health within the tamoxifen exemestane adjuvant multinational (TEAM) trial: A meta-analysis  
Peyman Hadji, Marburg, Germany
- 226P** – Elevated serum levels of the HER2 extracellular domain (ECD) in primary breast cancer (PBC) with HER2 overexpression predict early failure of adjuvant trastuzumab  
Sebastien Thureau, Rouen, France
- 227P** – Her2 status and trastuzumab use among patients with early breast cancer receiving care within the US oncology network  
Justin Doan, South San Francisco, CA, USA
- 228P** – Triple-negative (TN) treatment approach in Italy: An update of NEMESI, a multicenter observational study on early breast cancer (EBC) management  
Vincenzo Adamo, Milan, Italy
- 229P** – Anthracycline and concurrent radiotherapy significantly reduced breast cancer relapse rate  
Nabil Ismaili, Rabat, Morocco
- 230P** – Timing of subsequent surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (Tx) in early breast cancer (EBC)  
Leticia de Mattos-Arruda, Barcelona, Spain
- 231P** – A multicenter study of image-guided radiofrequency ablation of small breast carcinomas  
Takayuki Kinoshita, Tokyo, Japan
- 232P** – Long term persistent alopecia and suboptimal hair regrowth after adjuvant chemotherapy for breast cancer, alert for an emerging side effect: French ALOPERS observatory  
Hugues Bourgeois, Le Mans, France
- 233P** – Adjuvant chemotherapy for early breast cancer in Italy: What has changed today versus the early 2000's. A comparison between two observational national studies – NORA and NEMESI  
Giorgio Mustacchi, Milan, Italy
- 234P** – High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in early stage and operable breast cancer: Retrospective long-term analysis of the European experience  
Carmelo Bengala, Modena, Italy



Breast cancer, early  
Colorectal cancer  
Gynecological cancer  
Head and neck cancer



Neuro-oncology  
Palliative care  
Supportive care



**235P** – Access of high-risk breast cancer patients to adjuvant clinical research programs in French comprehensive cancer centres: A survey by the REMAGUS group

Nawal Ahbeddou, Saint Cloud, France

**236P** – Early breast cancer: Prognosis related to Ki-67 expression

Raquel Gerson, Mexico City, Mexico

**237P** – The biological characteristics of early breast cancer (EBC) from NEMESI, an Italian retrospective observational study

Marco Venturini, Negrar, Italy

**238P** – Adjuvant breast cancer chemotherapy based on sequential anthracyclin and taxane: Retrospective analysis of hematological toxicity

Nuno Couto, Porto, Portugal

**239P** – NEMESI: A retrospective observational longitudinal study to investigate patient characteristics and treatment in the early breast cancer (EBC) in Italy

Matteo Clavarezza, Milan, Italy

**240P** – Abdominal obesity and weight gain as a consequence of taxane-based adjuvant chemotherapy for breast cancer

Dimitris Mavroudis, Heraklion, Greece

**241P** – Impact of Mammaprint on the routine treatment decision making process in an unselected early breast cancer patient population in Belgium

Pino Cusumano, Liège, Belgium

**242P** – The outcomes of the specialized genetic program provided for the carriers of the genetic alterations predisposing to the breast cancer

Martina Zimovjanova, Prague, Czech Republic

**243P** – Adjuvant chemotherapy prescription according to multidisciplinary team decision or the MINDACT protocol (Microarray in Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy) (EORTC10041 BIG 3-04)

Carine Mitine, Haine Saint Paul, Belgium

**244P** – Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy

Yu Hsuan Kuo, Taipei, Taiwan

**245P** – Impact of different prognostic factors on the development of brain metastasis in adjuvant breast cancer patients

Sara Amin, Giza, Egypt

**246P** – Are breast cancer (BC) prognostic factors different in young patients?

Zora Baretta, Padova, Italy

**247P** – Low expression level of nucleostemin (GNL3), stimulator of cancer stem cell feather, is a promising biomarker to predict pathologic complete response (pCR) in neoadjuvant treatment with breast cancer

Kenji Tamura, Tokyo, Chuo-ku, Japan

**248P** – Predictive factors for complete pathological response after neoadjuvant chemotherapy in breast cancer. Results from a single institution

Vanessa Pons, Valencia, Spain

**249P** – The 70-gene expression profile for breast cancer patients in Italian hospitals

Daniele Generali, Amsterdam, Netherlands

**250P** – Evaluation of completeness and quality of the information process during genetic counselling for cancer predisposition. Preliminary results of the genetic counselling service (GCS) of Southern Switzerland

Elena Scaffidi, Viganello, Switzerland

**251P** – Breastfeeding in breast cancer survivors: Pattern, behaviour and effect on breast cancer outcome

Hatem Azim Jr, Cairo, Egypt

---

## Colorectal cancer

Chair: Eduardo Diaz-Rubio, Madrid, Spain

**589P** – Integrative evaluation of EGFR downstream signalling functionality to predict response to anti-EGFR monoclonal antibodies in KRAS wild-type mCRC

Anne-Sophie Chretien, Vandoeuvre les Nancy, France

**590P** – Inter-observer reproducibility of evaluation of EGFR status in colorectal carcinoma

Catherine Julié, Boulogne-Billancourt, France

**591P** – European reglementation for cetuximab still required the EGFR positive status: Results of a French translational study OMIT of 330 patients to define if this criteria is relevant

Jean-Philippe Metges, Brest, France

**592P** – “Determina KRAS” Project: What’s new after twenty months?

Jesus Garcia-Foncillas, Pamplona, Spain

**593P** – Evaluation of KRAS mutation status in primary colorectal tumours and corresponding liver metastases

Nikki Knijn, Nijmegen, Netherlands

**594P** – Evaluation of KRAS, BRAF and PI3KCA in synchronous and metachronous metastatic colorectal cancer (mCRC)

Fabiola Rojas Llimpe, Bologna, Italy

**595P** – KRAS mutational status in Japanese patients with colorectal cancer: Results from a multicenter, cross-sectional, large observational study conducted by the Japan Study Group of KRAS mutation in colorectal cancer

Kentaro Yamazaki, Shizuoka, Japan



**596P** – Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (MCRC): Analysis from the CRYSTAL study  
Hubert Piessevaux, Brussels, Belgium

**597P** – Cetuximab and 1<sup>st</sup>-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): A pooled analysis of the CRYSTAL and OPUS studies  
Gunnar Folprecht, Dresden, Germany

**598P** – The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan-cetuximab  
Mario Scartozzi, Ancona, Italy

**599P** – Incidence and prognostic value of BRAF mutation in metastatic colorectal cancer (CRC) with mismatch repair deficiency (dMMR)  
Miriam Koopman, Nijmegen, Netherlands

**600P** – Multicenter phase II study of second-line FOLFIRI+cetuximab with KRAS wild type gene in metastatic CRC (FLIER)  
Takeshi Kato, Minoh, Japan

**601P** – Efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC)  
Christian Jehn, Berlin, Germany

**602P** – Safety, pharmacokinetics (PK), and efficacy of imprime PGG plus cetuximab (cetux) with and without irinotecan (irino) in advanced metastatic colorectal cancer (mCRC) patients  
Ma Tamayo, Manila, Philippines

**603P** – Early magnesium modifications as a surrogate markers of efficacy of cetuximab based anticancer treatment in advanced colorectal cancer patients  
Sara Galluzzo, Rome, Italy

**604P** – Hypomagnesemia related to anti-EGFR monoclonal antibody therapies: A pooled analysis of randomised trials  
Faustro Petrelli, TREVIGLIO, Italy

**605P** – Genetic polymorphisms of the Fc RIIa-Fc RIIIa are not predictive of clinical outcomes after cetuximab based chemotherapy in patients with metastatic colorectal cancer  
Seong Joon Park, Seougl, South Korea

**606P** – Chemotherapy with or without bevacizumab in advanced colorectal cancer: A phase III trial  
Georgios Stathopoulos, Athens, Greece

**607P** – Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab in patients with metastatic colorectal cancer  
Yoshito Komatsu, Sapporo, Japan

**608P** – Bevacizumab (BV) in combination with FOLFOXIRI compared with BV plus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO)  
Gianluca Masi, Pisa, Italy

**609P** – Efficacy and safety of second-line bevacizumab (BV) plus FOLFIRI / FOLFOX in patients with metastatic colorectal cancer (mCRC) who failed prior-combination chemotherapy without BV: Multicenter retrospective 2nd-BV study in Tsukuba Cancer Clinical Trial Group (TCTG)  
Toshikazu Moriaki, Tsukuba-Shi, Japan

**610P** – Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine (C) alone or in combination with bevacizumab (B) +/- mitomycin C (M) in advanced colorectal cancer (CRC)  
Timothy Price, Adelaide, Australia

**611P** – Current chemotherapy and monoclonal antibody use patterns in metastatic colorectal cancer in Western Europe  
Zhongyun Zhao, Newbury Park, CA, USA

**612P** – Clinical and economic burden of toxicities associated with monoclonal antibodies for metastatic colorectal cancer (mCRC)  
Chakkarin Burudpakdee, Philadelphia, PA, USA

**613P** – Perfusion computed tomography as prognostic and predictive factor in patients with colorectal cancer liver metastases treated with bevacizumab  
Rita De Sanctis, Rome, Italy

**614P** – A blinded placebo (P) controlled phase I/II dose escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild type (KWT) advanced or metastatic colorectal cancer (amCRC): Safety, tolerability and pharmacokinetics (PK) findings  
Young Suk Park, Seoul, South Korea

**615P** – A phase II study of cediranib in combination with mFOLFOX6 in Japanese patients (pts) with metastatic colorectal cancer (CRC)  
Kei Muro, Nagoya, Japan

**616P** – Phase II study of first-line sunitinib (SU) in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI) in Japanese patients (pts) with unresectable/metastatic colorectal cancer (mCRC)  
Akihito Tsuji, Kochi, Japan

**617P** – Sorafenib (S) with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): A phase I study  
Jean Maroun, Ottawa, ON, Canada

**618P** – A phase II study of two dose levels of vorinostat (V) in combination with fluorouracil (5-FU) and leucovorin (LV) in fluoropyrimidine-refractory colorectal cancer (CRC) patients (pts)

Marwan Fakih, Buffalo, NY, USA

**619P** – Analysis of plasma biomarkers, DCE-MRI, and KRAS mutations in patients (pts) with advanced colorectal carcinoma (CRC) treated with the multikinase inhibitor regorafenib

Olaf Christensen, Montville, CT, USA

**620P** – Identification of predictive biomarkers for individual response to mFOLFOX6 in colorectal cancer patients

Masahiko Nishiyama, Hidaka, Saitama, Japan

**621P** – Intermittent versus continuous erlotinib with concomitant modified 'XELOX' (q3W) in first-line treatment of metastatic colorectal cancer (mCRC)

Steven L. Chan, Hong Kong, China

**622P** – Cost comparison: Capecitabine + oxaliplatin (XELOX) vs 5-FU/LV + oxaliplatin (FOLFOX4) in the adjuvant treatment of patients with colon cancer (aCC)

Klaus Hieke, Binningen, Switzerland

**623P** – Meta-analysis of the validity of progression-free survival as a surrogate endpoint for overall survival in metastatic colorectal cancer trials

Chirila Costel, Research Triangle Park, NC, USA

**624P** – Analysis of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients (pts)

Kenichi Sugihara, Tokyo, Japan

**625P** – Significant Impact of Her2/neu, Bcl-2 and P53 overexpression on survival in colorectal cancer (using tissue microarray)

Ola Khorshid, Cairo, Egypt

**626P** – Thrombocytosis as a predictive and prognostic marker in advanced colorectal cancer (aCRC): Results of the MRC COIN trial explored

Tim Maughan, Cardiff, UK

**627P** – Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian "bone metastases" survey

Daniele Santini, Rome, Italy

**628P** – Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone

Giuseppe Tonini, Rome, Italy

**629P** – Preliminary results from the South Australian (SA) Clinical Registry for advanced colorectal cancer (CRC) assessing the impact of age and choice of chemotherapy on outcome

Amanda Townsend, Adelaide, Australia

**630P** – Patients not receiving systemic therapy for metastatic colorectal cancer – what are the drivers and what are the outcomes?

Mark Voskoboynik, Melbourne, Australia

**631P** – Should the primary tumor be resected in patients with unresectable synchronous metastasis of colorectal cancer? Prognostic retrospective multicentric study of 128 patients

Elise Desot, Reims, France

**632P** – Survival after surgical resection of hepatic metastases from colorectal cancer: A systematic review and meta-analysis

Aliki Taylor, Uxbridge, UK

**633P** – Analysis of overall survival among patients with metastatic colorectal cancer, with and without undergoing elective colectomy

Mariana Ferreira, Barretos, Brazil

**634P** – RIPK1 polymorphism as prognostic marker for survival in patients with colorectal cancer after complete resection

Won Sik Lee, Daegu, South Korea

**635P** – Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for 1st-line therapy: Results of the ETNA cohort study

Denis Smith, Bordeaux, France

**636P** – FUFIRI or mIROX for first-line treatment in metastatic colorectal cancer (mCRC) and secondary resection of liver metastasis: A post-hoc analysis of tumor response and overall survival in the FIRE-trial

Clemens Giessen, Munich, Germany

**637P** – The role of perioperative bevacizumab in the management of patients with colorectal cancer and liver metastases treated with liver metastasectomy

Anastasia Constantinidou, London, UK

**638P** – Liver resection plus local destruction of liver metastases for patients with metastatic colorectal cancer

Igor Sagaidak, Moscow, Russian Federation

**639P** – Treatment for recurrence after hepatectomy in patients with colorectal liver metastasis

Shinichi Miyagawa, Matsumoto, Japan

**640P** – A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study

Christos Papadimitriou, Athens, Greece

**641P** – Randomised phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS) or overall survival (OS)

Daniel Haller, Philadelphia, PA, USA

**642P** – Efficacy findings from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant therapy for patients with stage III colon cancer: No impact of age on disease-free survival or overall survival

Chris Twelves, Leeds, UK

**643P** – Stroma production within the primary tumor correlates with poor survival for stage I-II colon cancer patients

Wilma Mesker, Leiden, Netherlands

**644P** – Is mucinous carcinoma an independent histologic type in colon cancer? A significance of mucin in histologic classification

Yuji Maeda, Isehara, Japan

**645P** – CpG island methylator phenotype and microsatellite instability as a prognostic factor in colon cancer treated with adjuvant FOLFOX chemotherapy

Hyun Jung Lee, Seoul, South Korea

**646P** – CpG island methylation in MGMT, cadherin E and H promoters, K-ras and B-raf mutations: Determining progression and sequence in colorectal adenoma-carcinoma

Brigitte Metzger, Luxembourg

**647P** – Importance of perineural invasion in early stage colorectal cancer

Mehmet Ozturk, Istanbul, Turkey

**648P** – Perineural invasion is a strong independent prognostic factor following pre-operative chemo/radiotherapy for locally advanced rectal cancer

Amandeep Dhadda, Hull, UK

**649P** – Early detection of colorectal cancer using mass spectrometry based serum protein profiling

Anouck Huijbers, Leiden, Netherlands

**650P** – Development and measurement of guideline-based indicators for colorectal carcinoma

P. B. Ottevanger, Nijmegen, Netherlands

**651P** – MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy

Byung Woog Kang, Seoul, South Korea

**652P** – Prognostic impact of insulin-like growth factor gene polymorphisms on survival of patients with colorectal cancer

Jong Gwang Kim, Daegu, South Korea

**653P** – Is obesity changes the expression profile of genes coding IGF in the colorectal cancer patients?

Ewa Nowakowska Zajdel, Bytom, Poland

**654P** – Phase II study with panitumumab, oxaliplatin, 5-fluorouracil and concurrent radiotherapy in high-risk locally advanced rectal cancer patients (STARPAN/STAR-02 study)

Carmine Pinto, Bologna, Italy

**655P** – CRAB trial: Updated results from a prospective phase II study evaluating neoadjuvant capecitabine, radiotherapy (RT) and bevacizumab in locally advanced rectal cancer

Vaneja Velenik, Ljubljana, Slovenia

**656P** – Chemoradiotherapy with 5-FU versus capecitabine on rectal cancer downstaging

Lúcia Águas, Porto, Portugal

**657P** – Final safety and efficacy results of a phase II trial of Bevacizumab, Capecitabine, Oxaliplatin, Radiation Rectal Cancer Trial (A-CORRECT)

Hagen Kennecke, Vancouver, BC, Canada

**658P** – Critical role of bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early prediction

Antonio Avallone, Naples, Italy

**659P** – The location of lymphangiogenesis is an independent prognostic factor in rectal cancers with or without preoperative radiotherapy

Annica Holmqvist, Linköping, Sweden

**660P** – Biomarker profiles are not of predictive value for response and outcome in patients with locally advanced rectal cancer undergoing cetuximab-based preoperative chemoradiotherapy

Kathrin Dellas, Halle (Saale), Germany

**661P** – Circulating level of VEGF, E-selectin, TGF- $\beta$ , EGF and 18F-FDG PET uptake in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CRT) and panitumumab (StarPan/STAR-02 phase II study)

Sara Pini, Bologna, Italy

**662P** – Topoisomerase II  $\alpha$  in colorectal carcinoma: Expression and prognostic role

Antonio Juretic, Zagreb, Croatia

**663P** – A Let-7 microRNA complementary site polymorphism in the KRAS 3'-UTR region as a genetic regulator in advanced colorectal cancer

David Pérez, Barcelona, Spain

**664P** – Circulating tumor cells in colorectal cancer. A prospective study

Virginia Arrazubi, Pamplona, Spain

## Gynecological cancer

Chair: TBC

**980P** – Randomized phase II study of paclitaxel-carboplatin (PC) versus gemcitabine-carboplatin (GC) followed by paclitaxel-carboplatin (PC) in platinum-sensitive recurrent ovarian carcinoma (PSROC): A GEICO

(Spanish Group for Investigation in Ovarian Cancer) study  
Antonio Gonzalez Martin, Madrid, Spain

**981P** – Should CA 125 still be part of tumour evaluation criteria in ovarian cancer trials? Experience of the GCIG CALYPSO trial  
Jerome Alexandre, Paris, France

**982P** – NGR-hTNF in combination with doxorubicin in progressive or recurrent ovarian cancer  
Domenica Lorusso, Rome, Italy

**983P** – Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Facilitation of phase 3 dose selection by population pharmacokinetic/pharmacodynamic (PK/PD) modeling  
Jian-Feng Lu, Thousand Oaks, CA, USA

**984P** – Trabectedin has a low cardiac risk profile: A comprehensive safety analysis  
Claudia Lebedinsky, Madrid, Spain

**985P** – Paclitaxel/carboplatin versus single agent carboplatin in patients with epithelial ovarian cancer and correlation to serum marker VEGF  
Raafat Abdel Malek, Cairo, Egypt

**986P** – Evaluation of rebound ascites following discontinuation of bevacizumab in recurrent ovarian cancer  
Roisin O'Cearbhaill, New York, NY, USA

**987P** – Bowel obstruction in ovarian and peritoneal malignancy: The Christie Hospital experience  
Emma Dean, Manchester, UK

**988P** – Clinical features and outcomes in epithelial ovarian cancer (EOC) associated with BRCA1 and BRCA2 mutations in Polish population – an observational study  
Malgorzata Hutka, Katowice, Poland

**989P** – BRCA1 germline mutations are associated with gynecologic sarcomas  
Dorota Nowakowska, Warsaw, Poland

**990P** – CYP3A4\*1B (rs2740574) gene polymorphism has prognostic value in ovarian cancer  
Dania Santos, Porto, Portugal

**991P** – CARMA3: A novel target for cancer therapy  
Jiyuan Sun, Houston, TX, USA

**992P** – Long-term follow-up of a phase II feasibility study of regional hyperthermia added to chemoradiotherapy in advanced cervical cancer  
Anneke Westermann, Amsterdam, Netherlands

**993P** – Phase II study of neoadjuvant chemotherapy with CPT-11 and nedaplatin (CPT-11/NDP) for stage IB2/II carcinoma of the cervix (Japanese Gynecologic Oncology Group 1065 study)  
Tadahiro Shoji, Morioka Iwate, Japan

**994P** – Intraarterial chemotherapy in treatment of advanced primary cervix cancer  
Nargiza Yuldasheva, Tashkent, Uzbekistan

**995P** – Weekly paclitaxel and paraplatin as first-line treatment in patients with recurrent or metastatic cervical carcinoma  
Wael El-Sadda, Mansoura, Dakahlia, Egypt

**996P** – Chemotherapy using gemcitabine (G) & cisplatin (C) in recurrent and metastatic squamous cell carcinoma of the cervix  
Hassen Mahfouf, Algiers, Algeria

**997P** – EGFR mutation status and the efficacy of gefitinib in combination with paclitaxel and carboplatin as neoadjuvant treatment in locally advanced cancer of cervix: A study from Eastern India  
Ritwik Pandey, Kolkata, India

**998P** – A phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial cancer: A Japan Endometrial Cancer Study Group trial  
Seisuke Kumagai, Iwate, Japan

**999P** – Expression of annexin A4 in endometrial cancer and relation to carboplatin sensitivity  
Shinya Matsuzaki, Suita Osaka, Japan

**1000P** – Incidence of second malignancies (SM) in the treatment field following pelvic radiotherapy (RT): A case-control study from South East Wales (SEW)  
Ayman Madi, Newcastle upon Tyne, UK

### Head and neck cancer

Chair: Lisa Licitra, Milan, Italy

**1012P** – The expression of Toll-like receptor pathway molecules in peripheral blood mononuclear cells and its use as a potential biomarker for tumor behavior in laryngeal carcinoma  
Katarzyna Starska, Lodz, Poland

**1013P** – Heat shock proteins 27, 105 expressions in oral tongue squamous cell carcinoma and their correlations with clinicopathological characteristics by immunohistochemistry  
Kazem Anvari, Mashhad, Iran

**1014P** – Expression of survivin in adenoid cystic carcinoma of the head and neck and its clinicopathological relationship  
Yoon Ho Ko, Seoul, South Korea

**1015P** – Tumor stage, humanpapilloma virus (HPV) and smoking status affect the survival of patients with oropharyngeal cancer: An Italian validation study  
Roberta Granata, Milan, Italy

**1016P** – Is concurrent chemoradiotherapy with altered fractionation (C-AFRT) better than standard concurrent chemoradiotherapy (C-RT) in head and neck cancer? An exploratory network meta-analysis using individual patient data  
Pierre Blanchard, Villejuif, France

**1017P** – Larynx preservation (LP) in selected stage III and IV patients (pts) with squamous cell carcinoma (LC) using concurrent chemotherapy (CT) and hyperfractionated radiotherapy (RT)

Raul Giglio, Buenos Aires, Argentina

**1018P** – Efficacy and safety of induction chemotherapy with cisplatin plus paclitaxel followed by chemoradiotherapy for locally advanced head and neck cancer – An interim analysis of safety and response rate

Alexandre Jácome, Barretos, Brazil

**1019P** – Is there a role for induction chemotherapy (iCT) in locally advanced head and neck squamous cell carcinoma (LAHNSCC)? A single institution experience

Isabel Sargento, Lisboa, Portugal

**1020P** – Comparison of two modalities of induction chemotherapy in head and neck cancer with unresectable bulky nodal disease; an intent-to-treat analysis

Svetislav Jelic, Belgrade, Serbia

**1021P** – Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma

Hye Ryun Kim, Seoul, South Korea

**1022P** – Impact of age on prognosis of locally advanced head and neck cancer (LAHNC) treated with chemoradiation (CRT). A single institutional experience

Nerina Denaro, Messina, Italy

**1023P** – A multicenter phase II trial to evaluate the combination of cetuximab (C) plus TPF (docetaxel, cisplatin and fluorouracil) as induction chemotherapy (IC) followed by cetuximab plus accelerated radiotherapy (RT) with concomitant boost in patients (pts) with unresectable locally advanced squamous cell carcinoma of head and neck (SCCHN)

Ricard Mesia, Barcelona, Spain

**1024P** – Single-centre experience of quality assurance (QA) measures in a phase II trial of radiotherapy (RT) + panitumumab vs chemo-RT (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Andreas Meister, Aarau, Switzerland

**1025P** – Phase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Lisa Licitra, Milan, Italy

**1026P** – Impact of salivary composition changes on saliva quality & quality of life after radiotherapy of head and neck cancer: A prospective longitudinal study

Manpreet Tiwana, Dehradun, India

**1027P** – Oropharyngeal mucositis prophylaxis in combined radioimmunotherapy

Wolf Jordan, Lehrte, Germany

**1028P** – Hypomagnesaemia after induction TPF chemotherapy followed by concomitant cisplatin/cetuximab/radiotherapy (ccRT) in locally advanced head and neck cancer (LAHNC)

Cvetka Grasic Kuhar, Ljubljana, Slovenia

**1029P** – Clinical outcome and incidence of renal failure (RF) after concurrent chemo-radiation with 3-weekly (3WC) versus weekly (1WC) cisplatin for locally advanced squamocellular head and neck cancer (SCHNC)

Vittoria Espeli, Geneva, Switzerland

**1030P** – Body mass index (BMI) in prognosis of locoregionally advanced and metastatic squamocellular head and neck carcinomas (SCHNC)

Miroslav Kreacic, Belgrade, Serbia

**1031P** – Trends in the treatment of locally advanced squamous cell carcinoma of the head and neck (LASCCHN) in Europe between 2006 and 2009

Volker Budach, Berlin, Germany

**1032P** – Ability of FDG-PET/CT to detect residual disease on posttreatment follow-up of patients with head and neck squamous cell carcinoma treated with chemoradiotherapy compared with CT

Pilar De La Morena, Murcia, Spain

**1033P** – Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Changes in 1st-line treatment patterns in Europe 2008–2009

Hansjochen Wilke, Essen, Germany

**1035P** – Weekly regimen of paclitaxel-carboplatin-cetuximab as first-line chemotherapy in patients with platinum-resistant recurrent or metastatic squamous cell carcinoma of head and neck (SSCHN): Results of a phase II study

Antonio Rozzi, Grottaferrata (Rome), Italy

**1034P** – Cetuximab in combination with bendamustine as an alternative therapeutic option for recurrent head and neck cancer

Hayssam Zakaria, Lehrte, Germany

**1036P** – Panitumumab (PMAB) regimen in second-line monotherapy (PRISM) in patients (pts) with recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis

Danny Rischin, East Melbourne, Australia

**1037P** – Analysis of antibodies against Epstein-Barr virus and viral DNA quantification as early screening tools of nasopharyngeal carcinoma

Susanna Hutajulu, Yogyakarta, Indonesia



**1038P** – The continuing role of platinum-based chemotherapy in the era of targeted drugs in advanced nasopharyngeal carcinoma (NPC): A systematic review  
Quan-Sing Ng, Singapore

**1039P** – Phase II trial of first-line capecitabine plus oxaliplatin in patients with metastatic nasopharyngeal carcinoma

Daniel Chua, Happy Valley, Hong Kong, China

**1040P** – Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC)

Esma Kerboua, Algiers, Algeria

**1041P** – A phase II trial of induction chemotherapy with cisplatin, docetaxel and capecitabine followed by concurrent cisplatin- radiotherapy in advanced nasopharyngeal carcinoma

Mohamed Yamouni, Oran, Algeria

**1042P** – Introduction chemotherapy with docetaxel, cisplatin and S-1(TPS) followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma

Tomoko Yamazaki, Kashiwa, Japan

**1043P** – A dendritic cell vaccine transduced with Ad5-f35-dLMP1-I-LMP2 for patients with metastatic nasopharyngeal carcinoma – A phase II clinical trial  
John Chia, Singapore

**1044P** – Prognostic factors influencing outcome of patients with recurrent or metastatic carcinoma (R&M) of the head and neck: Results of an Italian monoinstitutional study  
Aurora Mirabile, Milan, Italy

**1045P** – Radiotherapy after hyperbaric oxygen concurrent with superselective intra-arterial carboplatin chemotherapy enhances survival of patients with oral cancer

Ryoichi Oya, Kitakyushu, Japan

**1046P** – Oral carcinoma after stem cell transplantation – a single centre experience

Ana Castro, Porto, Portugal

**1047P** – Local use of carboplatin in complex treatment of retinoblastoma

Rustam Usmanov, Tashkent, Uzbekistan

**1048P** – Gemcitabine plus oxaliplatin (GEMOX) regimen in radioactive iodine resistant metastatic thyroid cancer: Activity and safety study

Yann Vano, Paris, France

**1049P** – Olfactory neuroblastoma: Impact of induction chemotherapy and proton beam therapy

Makoto Tahara, Kashiwa, Chiba, Japan

## Neuro-oncology

Chair: Roger Stupp, Vevey and Lausanne, Switzerland

**1056P** – Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (GBM): A national retrospective cohort of the ANOCEF (Association des Neuro-oncologues d'Expression Française) group

Sophie Taillibert, Paris, France

**1057P** – Encouraging overall survival (OS) with bevacizumab (Bev) in patients with recurrent high-grade glioma (HGG) treated outside clinical trials

Silvia Hofer, Zurich, Switzerland

**1058P** – Bevacizumab and irinotecan in recurrent malignant glioma: Results of a French retrospective cohort study OMIT of 264 patients in real practice!  
Françoise Grudé, Angers, France

**1059P** – Efficacy, safety and pattern of relapse of bevacizumab (BEV) versus chemotherapy for recurrent glioblastoma multiforme (GBM):

A McGill University study

Solmaz Sahebjam, Montreal, QC, Canada

**1060P** – Clinical predictive factors of increased overall survival with bevacizumab/irinotecan for primary recurrent glioblastoma (GBM)

Jean Sebastien Frenel, Saint Herblain, Nantes, France

**1061P** – Experience with the monoclonal antibody bevacizumab (Bev) combined with chemotherapy in children with poorly differentiated glial CNS tumours  
Boris Kholodov, Moscow, Russian Federation

**1062P** – Sorafenib (So) in association with low-dose metronomic temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM): Preliminary results of a phase II study

Lorenza Landi, Livorno, Italy

**1063P** – TEMOCAR: Carboplatin in addition to radiotherapy and temozolomide in newly diagnosed unresectable glioblastoma

Nicolas Pecuchet, Paris, France

**1064P** – Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme

Seyit Zincircioglu, Diyarbakir, Turkey

**1065P** – Pre-treatment platelet count as a prognostic marker in patients with glioblastoma (GBM) treated with radiotherapy and concurrent and adjuvant temozolomide (RCAT)

Vasiliki Michalarea, London, UK

**1066P** – Maintenance temozolomide in glioblastoma – 6 versus 12 cycles

Matilde Salgado, Porto, Portugal

- 1067P** – Transition from 2D conventional to 3D conformal radiation therapy in patients with brain gliomas: Clinical outcome (Mansoura University experience)  
Ibrahim Awad, Mansoura, Dakhliya, Egypt
- 1068P** – MGMT promotor methylation status and Ki-67 in correlation to survival and response to treatment with temozolamide and radiotherapy in newly diagnosed glioblastoma patients  
Khaled Abdel Karim, Cairo, Egypt
- 1069P** – Correlation of epidermal growth factor receptor status with treatment outcome in postoperative glioblastoma multiforme patients treated with chemoradiotherapy  
Supriya Mallick, New Delhi, India
- 1070P** – Radiotherapy response of brain metastases in patients with non-small cell lung cancer (NSCLC) and methylation status of O6-methyl guanine methyl transferase (MGMT) promoter region  
Kenji Hashimoto, Tokyo, Japan
- 1071P** – Pemetrexed (P) plus carboplatin (Cb) as up-front treatment for patients with brain metastases of lung adenocarcinoma  
Kader Chouahnia, Bobigny, France
- 1072P** – Influence of cytostatic agents on pH-regulating transporter in glioma cells  
Nicole Basler, Greifswald, Germany
- 1073P** – Influence of ABCB1, ABCG2 and MGMT promoter methylation and gene polymorphisms on clinico-pathological characteristics of glioma patients  
Sandra Bien, Greifswald, Germany
- 1074P** – Histone deacetylase inhibitor vorinostat reduces expression of platelet-derived growth factor receptor A (PDGFRA) and matrix metalloproteinase-2 (MMP2) genes in glioblastoma cell lines  
Pavel Bezecny, London, UK
- 1075P** – The activity of MRP1 membrane transporter confers resistance to anticancer drugs in glioblastoma multiforme cells  
Claudia Quezada, Valdivia, Chile
- 1076P** – mRNAs overexpression in glioblastomas versus low-grade gliomas  
Juan Carlos Martinez, Madrid, Spain
- 1077P** – Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9  
Reza Ghasemi, Tehran, Iran
- 1078P** – The role of multislice CT-angiography to assess giant cranio-facial meningiomas vascular supply mode  
David Miminoshvili, Tbilisi, Georgia

## Palliative care

Chair: TBC

- 1184P** – Evaluation of the possibility of outpatient management of febrile neutropenia patients with an intermediary risk of complications and impact on cost  
Isabelle Borget, Villejuif, France
- 1185P** – Bone antiresorptive agents in patients with metastatic bone disease: Pharmacokinetic and pharmacodynamic effects  
Peyman Hadji, Marburg, Germany
- 1186P** – Cancer pain management in oncological settings. The role of oxycodone: A new option as starting strategy therapy?  
Olga Martelli, Rome, Italy
- 1187P** – Positive airway stenting for symptomatic tracheobronchial strictures in metastatic non-lung cancer patients  
Masahiro Endo, Shizuoka, Japan
- 1188P** – Increased patient medication safety in advanced palliative home care through the inclusion of dispensing pharmacists: A development project  
Barbro Norrstrom, Alvsjo, Sweden
- 1189P** – Description and prevalence of palliative care inpatients: A prospective study in 14 Belgian hospitals  
Marianne Desmedt, Brussels, Belgium
- 1190P** – Analysis of advance directives among terminal cancer patients admitted to a palliative care unit: A single center's experience  
So Yeon Oh, Seoul, South Korea
- 1191P** – Comparison of medical expenditure according to types of hospice care  
Bong Seog Kim, Seoul, South Korea
- 1192P** – Literature search on end-of-life aggressiveness of care studies with respect to anticancer treatments  
Lea Choung Wong, Singapore

## Supportive care

Chair: Jørn Herrstedt, Odense, Denmark

- 1240P** – The analgesic therapy of patients with hematologic or solid tumours: Results from Italian ECAD\_O survey  
Carla Ripamonti, Milan, Italy
- 1241P** – Pain management in critically ill patients: What is important? The results from Italian ECAD\_O survey  
Carla Ripamonti, Milan, Italy

**1242P** – Oxycodone/acetaminophen combination tablet in patients with metastatic bone pain: A randomized, double-blinded, placebo-controlled trial  
Lei Sima, Beijing, China

**1243P** – Study on the prevalence of post-treatment chronic pain in breast cancer patients and interference of pain with life functions

Ali Taghizadeh Kermani, Mashhad, Iran

**1244P** – Multicenter phase II study of an opioid-based pain control program for patients with head and neck cancer treated by chemoradiotherapy

Akihiro Homma, Sapporo, Japan

**1245P** – Supportive care in relapsed head and neck cancer: Transdermal buprenorphine formulation

Mario Airolidi, Turin, Italy

**1246P** – First baseline results of a Pan-European phase IV open-label multicentre study of the titration of fentanyl buccal tablets (FBT) in patients with breakthrough cancer pain (BTcP)

Jerzy Jarosz, Warsaw, Poland

**1247P** – Opioid-induced constipation prevalence and correlation with the therapy: An Italian prospective, multicentric analysis of 1210 oncologic patients

Furio Zucco, Garbagnate Milanese, Italy

**1248P** – Effects of denosumab vs zoledronic acid (ZA) on pain in patients (pts) with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials  
Charles Cleeland, Houston, TX, USA

**1249P** – Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials

Allan Lipton, Hershey, PA, USA

**1250P** – Medical ozone (O3) heals osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs). Preliminary results

Carla Ripamonti, Milan, Italy

**1251P** – Randomized pharmacokinetic evaluation of subcutaneous versus intravenous palonosetron in cancer patients treated with platinum-based chemotherapy  
Anabel Del Barrio, Pamplona, Spain

**1252P** – Aprepitant palonosetron and dexamethasone to prevent nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

Flavia Longo, Rome, Italy

**1253P** – Evaluation of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients

Hye-Suk Han, Cheongju, South Korea

**1254P** – Identification and ranking of side-effects in patients receiving radiotherapy and concomitant weekly cisplatin. A multinational collaborative survey  
Christina Ruhlmann, Odense, Denmark

**1255P** – Dexamethasone (DEX)-sparing regimen for prevention of emesis following moderately emetogenic chemotherapy (MEC): Analysis of prognostic factors affecting anti-emetic outcome. An I.T.M.O. study  
Luigi Celio, Milan, Italy

**1258P** – High-level resistance to antimicrobials in febrile neutropenia: Experience from a tertiary care cancer center in India

Indranil Ghosh, New Delhi, India

**1256P** – Administration of granulocyte-colony stimulating factors (G-CSF) in solid tumors. An Italian observational study by the OBSERVE Study Group  
Sandro Barni, Treviglio, Italy

**1257P** – Management of febrile neutropenia at an outpatient clinic: Risk self-assessment by a simplified scoring system

Toshiro Mizuno, Tsu City, Japan

**1259P** – A predictive model to estimate the true risk of severe neutropenia in cancer patients treated with chemotherapy

Eugeniu Banu, Cluj Napoca, Romania

**1260P** – A randomised trial comparing peripherally inserted central venous catheters (PICC) vs subcutaneously implanted port-chamber catheters (PORT) for delivery of chemotherapy to patients with non-haematological malignancies

Kunal Jain, Ludhiana, India

**1261P** – Thrombovascular events (TVEs) and predisposing TVE risk factors in cancer patients receiving chemotherapy and epoetin alfa QW or TIW for anemia  
Kris Deprince, Beerse, Belgium

**1262P** – Nadroparin for the prevention of thromboembolic events in ambulatory patients receiving chemotherapy with metastatic or locally advanced cancer: A post-hoc analysis of thromboembolic risk related to type chemotherapy in the PROTECT study

Giampietro Gasparini, Rome, Italy

**1263P** – Pulmonary embolism: Unsuspected finding in cancer patients

Ignacio García-Escobar, Madrid, Spain

**1264P** – Master oncology: A multicenter, case-control, observational study on the epidemiology and risk factors for thromboembolic events in cancer patients  
Roberto Labianca, Bergamo, Italy

**1265P** – Impact of epistaxis on the use of fentanyl pectin nasal spray to treat breakthrough cancer pain

David Brooks, Chesterfield, UK

**1266P** – A phase III, randomized double-blind placebo-controlled study of epoetin beta in lung and gynecological cancer receiving platinum-based chemotherapy: Japan Erythropoietin Study Group

Akira Yoshizaki, Morioka, Iwate, Japan

**1267P** – Darbepoetin alfa dosing weekly and every three weeks in cancer patients with chemotherapy-induced anaemia – efficacy data from the CHOICE study

Simon Van Belle, Ghent, Belgium

**1268P** – Darbepoetin alfa in the treatment of chemotherapy-induced anaemia; effects of target haemoglobin label change: Data from the APRIORI study

Veronika Sárosi, Pécs, Hungary

**1269P** – A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

Daniell Mitchell, Glattbrugg, Switzerland

**1270P** – Anemia and darbepoetin alfa administration in patients treated with CHOP+/-R chemotherapy: Results from an observational study of patients with non-Hodgkin lymphoma

Beatrix Pujol, Zug, Switzerland

**1271P** – Cardioprotective effect of telmisartan in cancer patients treated with epirubicin

Giovanni Mantovani, Cagliari, Italy

**1272P** – High incidence of severe sorafenib-induced diarrhea in patients with hyperbilirubinemia and/or hypoalbuminemia

Judith Michels, Paris, France

**1273P** – Sulphasalazine in the prevention of radiation-induced acute proctitis in patients with prostate cancer

Simin Hemati, Isfahan, Iran

**1274P** – Duration of paclitaxel (PTX)-induced peripheral neuropathy (PN)

Yuko Tanabe, Tsukiji, Chuo-ku, Tokyo, Japan

**1275P** – Topical silver sulfadiazine for prevention of acute dermatitis during irradiation for breast cancer

Simin Hemati, Isfahan, Iran

**1278P** – Cutaneous infections in the emergency unit of a cancer research centre

Emna Elleuche, Sfax, Tunisia

**1276P** – Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and limeclicline. A phase II study

Roberta Grande, Frosinone, Italy

**1277P** – Assessment of supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin

Takeo Otsuki, Sendai, Japan

**1279P** – Palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD): An observational study

Maria Luisa Gonzalez, Murcia, Spain

**1280P** – Management of oral mucositis (OM) with a muco-adhesive oral rinse: European clinical experience

Andreas Duckert, Frankfurt/Oder, Germany

**1281P** – Functional magnetic resonance imaging with food stimuli in lung cancer patients with and without anorexia

Karla Sanchez Lara, Mexico City, Mexico

**1282P** – Improvement of physical activity as an alternative objective variable to measure treatment effects of anti cachexia therapy in cancer patients

Giovanni Mantovani, Cagliari, Italy

**1283P** – Relationship between performance status, nutritional status and chemotherapy dose-intensity in patients with solid tumors

Anatole Cessot, Paris, France

**1284P** – Evaluation of a hospital-home medical program (HHMP) for the management of chemotherapy-related toxicities in the outpatient setting

Romein Coriat, Paris, France

**1285P** – Attitudes of health professionals to patients who receive chemotherapy information from the internet and their discussion of internet information with patients

Elaine Davies, Northampton, UK

**1286P** – Internet usage by patients receiving chemotherapy information – is the Internet beneficial or deleterious to patients?

Elaine Davies, Northampton, UK

**1287P** – Importance of religion and spirituality in cancer patients cared for in oncological, supportive care, psychological and rehabilitation ambulatory settings

Carla Ripamonti, Milan, Italy

**1288P** – Sexual dysfunctions and cancer, or cancer and sexual dysfunctions?

Silvia Bonicatto, Gonnet, Argentina

**1289P** – Pharmacological interventions for fertility preservation during chemotherapy – a systematic review and meta-analysis

Irit Ben-Aharon, Petach-Tikva, Israel

**1290P** – Feasibility of removal of Huber needle by patients or their family members during chemotherapy for colorectal cancer

Kaoru Shibamoto, Shizuoka, Japan

**1291P** – A randomized, pilot, stratified trial regarding the perception and satisfaction of patients with complementary therapies in a dedicated room

Daniela Grosso, Padova, Italy

**1292P** – Changes in daily activities of cancer patients after diagnosis: How do Canadian and Iranian patients perceive the change?

Ali Taghizadeh Kermani, Mashhad, Iran

**1293P** – N-terminal pro-brain natriuretic peptide (NT-proBNP) as a marker of outcome in elderly cancer patients receiving chemotherapy

Camille Chenevier-Gobeaux, Paris, France

**1294P** – Patients' ratings of the effect of toxicities on likely adherence to gastrointestinal stromal tumor (GIST) treatments

Brett Hauber, Research Triangle Park, NC, USA

## Monday, 11 October 2010

08.00–08.45 **Turquoise Hall 2**

### YO Breakfast

#### Medical information. Where to find it, what to trust

Medical information: Where to find it, what to trust  
Lewis Rowett, Oxford, UK

08.00–09.00 **Yellow Hall 1**

### Challenge Your Expert session

#### Nasopharyngeal cancer

Anthony Chan, Hong Kong, China

08.00–09.00 **Yellow Hall 2**

### Challenge Your Expert session

#### Multiple myeloma

Joan Bladé, Barcelona, Spain

08.00–09.00 **Yellow Hall 3**

### Challenge Your Expert session

#### Advances of systemic treatment in metastatic melanoma

Alexander M. M. Eggermont, Rotterdam, Netherlands

08.00–09.00 **Green Hall 3**

### Challenge Your Expert session

#### Advances in the treatment of metastatic or unresectable biliary tract cancer

Juan W. Valle, Manchester, UK

08.00–09.00 **Green Halls 1+2**

### Patient Cases

#### Early endometrial cancer

Co-Chairs: Carien L. Creuzberg, Leiden, Netherlands and  
Thomas Högberg, Lund, Sweden

**08.00** Chemotherapy

Thomas Högberg, Lund, Sweden

**08.10** Radiotherapy

Carien L. Creuzberg, Leiden, Netherlands

**08.20** Discussion

08.00–09.00 **Orange Halls 2+3**

### Patient Cases

#### Genotyping GIST for clinical decision-making

Co-Chairs: Alessandro Gronchi, Milan, Italy and  
Peter Reichardt, Bad Saarow, Germany

**08.00** Tailoring the drug

Peter Reichardt, Bad Saarow, Germany



- 08.10** Tailoring the scalpel  
Alessandro Gronchi, Milan, Italy
- 08.20** Discussion

---

**09.00–10.30** **Violet Hall**

**Proffered Paper session**

**Breast cancer, early**

Chair: Martine Piccart, Brussels, Belgium

Co-Chair: Luca Gianni, Milan, Italy

- 09.00** 2130 – Distant recurrences at median of 5-years among 9.779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy  
Hans Nortier, Leiden, Netherlands
- 09.15** 2140 – Final results of the Hellenic Cooperative Oncology Group phase III trial (HE10/00) exploring the efficacy of postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in high risk breast cancer patients  
Helen Gogas, Athens, Greece
- 09.30** Invited Discussant, Abstracts 2130 and 2140  
Heikki Joensuu, Helsinki, Finland
- 09.45** LBA10 – Optimal treatment of the axilla after positive sentinel lymph node biopsy in primary invasive breast cancer patients (surgery versus radiotherapy). Early results of a randomized clinical trial  
Gábor Péley, Norwich, UK
- 10.00** 2150 – HER2 status as predictor of mammographic screening detection: Comparison of interval- and screen-detected breast cancers  
Antonino Musolino, Parma, Italy
- 10.15** Invited Discussant, LBA10 and Abstract 2150  
Richard Bell, Milan, Italy

---

**09.00–10.30** **Pink Hall**

**Proffered Paper session**

**Developmental therapeutics**

Chair: James Spicer, London, UK

Co-Chair: Christian Ditttrich, Vienna, Austria

- 09.00** 4940 – A European multi-institutional study of prognostic factors in cancer patients (pts) treated within phase-I (Ph I) oncology trials  
David Olmos, Sutton, UK
- 09.15** 4950 – The oral MEK 1/2 inhibitor GSK1120212 demonstrates early efficacy signals  
Gerald Falchook, Houston, TX, USA
- 09.30** Invited Discussant, Abstracts 4940 and 4950  
Francesco Cognetti, Rome, Italy

- 09.45** 4960 – A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL)  
Johanna Bendell, Nashville, TN, USA
- 10.00** 4970 – A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors  
Andrew Wagner, Boston, MA, USA
- 10.15** Invited Discussant, Abstracts 4960 and 4970  
Christian Ditttrich, Vienna, Austria

---

**09.00–10.30** **Red Hall**

**Proffered Paper session**

**Biomarkers**

Chair: Carlos Caldas, Cambridge, UK

Co-Chair: Rafal Dziadziuszko, Gdansk, Poland

- 09.00** 1560 – LACE-bio pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non-small cell lung cancer (NSCLC)  
Ming Tsao, Toronto, ON, Canada
- 09.15** 1570 – Prognostic and predictive role of PIK3CA mutations in non small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors (TKIs)  
Vienna Ludovini, Perugia, Italy
- 09.30** Invited Discussant, Abstracts 1560 and 1570  
Rafal Dziadziuszko, Gdansk, Poland
- 09.45** 1580 – Prognostic value of a cell cycle expression profile score among men with conservatively treated localized prostate cancer  
Jack Cuzick, London, UK
- 10.00** 1590 – A RNA gene signature for screening of colorectal cancer from whole blood with high sensitivity and a specificity close to that of colonoscopy  
André Rosenthal, Potsdam, Germany
- 10.15** Invited Discussant, Abstracts 1580 and 1590  
Carlos Caldas, Cambridge, UK

---

**09.00–10.30** **Silver Hall**

**Special Symposium**

**Targeted agents in prostate cancer: Changing the paradigms**

Chair: Thomas Powles, London, UK

Co-Chair: Karim Fizazi, Villejuif, France

- 09.00** Introduction  
Karim Fizazi, Villejuif, France
- 09.05** Improved inhibition of the androgen receptor  
Gerhardt Attard, Sutton, UK
- 09.25** Angiogenesis in prostate cancer  
William K. Kelly, New Haven, CT, USA

- 09.45** Bone targeting in prostate cancer  
Karim Fizazi, Villejuif, France
- 10.05** Results from molecular biology that translate to treatment  
Jack Schalken, Nijmegen, Netherlands
- 10.25** Conclusions  
Thomas Powles, London, UK

---

**09.00–10.30** **Blue Hall**

**Young Oncologist Forum**

**Supportive care of cancer patients**

Chair: Michael V. Karamouzis, Papagou, Greece  
 Co-Chair: Serena Di Cosimo, Barcelona, Spain  
 Session Shooters: Gilberto de Castro Junior, São Paulo, Brazil;  
 Eduardo De Azambuja, Brussels, Belgium; Margaret Hutka,  
 Gliwice, Poland and Pia Osterlund, Helsinki, Finland

- 09.00** Introduction  
Michael V. Karamouzis, Papagou, Greece
- 09.05** Management of cancer pain  
Julia Riley, London, UK
- 09.25** Systemic therapeutic options for bone metastases  
Tiina Saarto, Helsinki, Finland
- 09.45** Management of fatigue / cachexia  
Stein Kaasa, Trondheim, Norway
- 10.05** Palliative chemotherapy versus best palliative care –  
evidence based decision  
Jean-Philippe Durand, Paris, France
- 10.25** Conclusions  
Serena Di Cosimo, Barcelona, Spain

---

**09.15–10.15** **Gold Hall**

**Controversy session**

**Maintenance treatment of advanced NSCLC:**

**Utopia or necessity?**

Moderator: Robert Pirker, Vienna, Austria

- 09.15** Introduction and vote  
Robert Pirker, Vienna, Austria
- 09.25** Necessity  
Maurice Pérol, Lyon, France
- 09.45** Utopia  
Giorgio Scagliotti, Orbassano, Italy
- 10.05** Vote and conclusions  
Robert Pirker, Vienna, Austria

---

**09.15–10.15** **Orange Hall 1**

**Multidisciplinary Interactive session (MIS)**

**Localised prostate cancer**

Co-Chairs: Alan Horwich, Sutton, UK and  
 Robert A. Huddart, Sutton, UK

- 09.15** Medical Oncology  
Alan Horwich, Sutton, UK
- 09.30** Radiotherapy  
Robert Huddart, Sutton, UK
- 09.45** Discussion

---

**10.30–12.15** **Gold Hall**

**Proffered Paper session**

**Late-Breaking Abstract Session**

Chair: Rolf A. Stahel, Zurich, Switzerland  
 Co-Chair: Josep Tabernero, Barcelona, Spain

- 10.30** **LBA6** – Sunitinib (SU) in combination with erlotinib (E) for  
the treatment of advanced/metastatic non-small cell lung  
cancer (NSCLC): a phase III study  
Giorgio Scagliotti, Orbassano, Italy
- 10.45** Invited Discussant, LBA6  
Cesare Gridelli, Avellino, Italy
- 11.00** **LBA7** – A Phase III randomized study comparing the efficacy  
of cediranib as monotherapy, and in combination with  
lomustine, with lomustine alone in recurrent glioblastoma  
patients  
Tracy Batchelor, Boston, MA, USA
- 11.15** Invited Discussant, LBA7  
Roger Stupp, Vevey and Lausanne, Switzerland
- 11.30** **LBA8** – A randomized, double-blind, placebo-controlled,  
multicenter phase III trial of everolimus + octreotide LAR  
vs placebo + octreotide LAR in patients with advanced  
neuroendocrine tumors (NET) (RADIANT-2)  
Marianne Pavel, Berlin, Germany
- 11.45** **LBA9** – A randomized, double-blind, placebo-controlled,  
multicenter phase III trial of everolimus in patients with  
advanced pancreatic neuroendocrine tumors (pNET)  
(RADIANT-3)  
James Yao, Houston, TX, USA
- 12.00** Invited Discussant, LBA8 and LBA9  
Michel Ducreux, Villejuif, France

10.45–12.15 **Silver Hall**

### Special Symposium

#### Breast cancer challenges in the setting of curable disease

Chair: Wolfgang Eiermann, Munich, Germany

Co-Chair: Sabino De Placido, Naples, Italy

- 10.45 Introduction  
Sabino De Placido, Naples, Italy
- 10.50 Preservation of fertility in young patients  
Kutluk Oktay, New York, NY, USA
- 11.10 Optimizing endocrine treatment of pre-menopausal women  
Mitchell Dowsett, London, UK
- 11.30 Should bone-targeted treatment be used in the adjuvant setting?  
Robert Coleman, Sheffield, UK
- 11.50 Evolving issues in inflammatory breast cancer  
Luca Gianni, Milan, Italy
- 12.10 Conclusions  
Wolfgang Eiermann, Munich, Germany

10.45–12.15 **Violet Hall**

### Special Symposium

#### ESMO/ASCO Joint Symposium:

#### The future of antiangiogenesis therapy

Co-Chairs: David J. Kerr, Oxford, UK and

George Sledge, Indianapolis, IN, USA

- 10.45 Introduction  
George Sledge, Indianapolis, IN, USA
- 10.55 The biology of antiangiogenic therapy in the adjuvant setting  
Peter Carmeliet, Leuven, Belgium
- 11.15 Re-appraising the biological basis of antiangiogenic drugs for adjuvant therapy  
Robert Kerbel, Toronto, ON, Canada
- 11.35 An analysis of currently available adjuvant colorectal data  
Lee M. Ellis, Houston, TX, USA
- 11.55 COX-2 inhibition in the adjuvant setting for colorectal cancer  
David J. Kerr, Oxford, UK

10.45–12.15 **Blue Hall**

### Special Symposium

#### Overcoming disparities in cancer control in Europe

Chair: Lars Holmberg, London, UK

Co-Chair: Hans-Jörg Senn, St. Gallen, Switzerland

- 10.45 Introduction  
Hans-Jörg Senn, St. Gallen, Switzerland

- 10.50 Differences in cancer survival in Europe  
Franco Berrino, Milan, Italy
- 11.10 Social inequalities and cancer  
Anton Kunst, Amsterdam, Netherlands
- 11.30 Cancer control plans in Europe  
Andreas Ullrich, Geneva, Switzerland
- 11.50 Moving forward with cancer control  
Nick Fahy, Luxembourg
- 12.10 Conclusions  
Lars Holmberg, London, UK

10.45–12.30 **Pink Hall**

### Proffered Paper session

#### Gynecological cancer

Chair: Antonio Gonzalez Martin, Madrid, Spain

Co-Chair: Michael Bookman, Tucson, AZ, USA

- 10.45 9700 – Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) randomized phase III trial  
Sandro Pignata, Naples, Italy
- 10.55 Invited Discussant, Abstract 9700  
Antonio Gonzalez Martin, Madrid, Spain
- 11.10 LBA24 – Results of a randomized, open-label, phase III trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian, or peritoneal cancer  
Nicoletta Colombo, Milan, Italy
- 11.25 9710 – Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations  
Stan Kaye, Sutton, UK
- 11.40 9720 – A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C+P) versus C+P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC)  
Christopher Poole, Coventry, UK
- 11.55 LBA25 – A phase 2, randomized, placebo-controlled study of Hedgehog (Hh) Pathway Inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2<sup>nd</sup> or 3<sup>rd</sup> complete remission (CR)  
Stan Kaye, Sutton, UK
- 12.10 Invited Discussant, 9710, 9720 and 2 expected LBAs  
Elise Kohn, Bethesda, MA, USA

10.45–11.45 **Red Hall**

### Proffered Paper session

#### Basic science and translational research

Chair: TBC

Co-Chair: Eric Van Cutsem, Leuven, Belgium

- 10.45 740** – Clinicopathologic correlation of cancer susceptibility loci from genome-wide association (GWAS) studies of colorectal cancer (CRC)  
Derek Power, New York, NY, USA
- 11.00 750** – Differences in clinicopathological features, DNA copy number profiles and outcome of metastatic colorectal cancer (CRC) patients with hepatic versus extrahepatic disease  
Leonie Mekenkamp, Nijmegen, Netherlands
- 11.15 760** – A novel colorectal cancer susceptibility SNP in the EIF3H promoter influences patient survival and response to treatment  
Christopher Smith, Cardiff, UK
- 11.30** Invited Discussant, Abstracts 740, 750 and 760  
Eric Van Cutsem, Leuven, Belgium

10.45–12.15 **Yellow Hall 2**

### Special Session

#### Oncology mentors Forum

Chair: Heine H. Hansen, Copenhagen, Denmark

Co-Chair: Martin Gore, London, UK

- 10.45** Introduction  
Heine H. Hansen, Copenhagen, Denmark
- 10.50** Global recognition of Medical Oncology  
Eduardo Cazap, Buenos Aires, Argentina
- 11.00** ESMO/ASCO updated Global Core Curriculum for training in medical oncology and log book opportunities  
Heine H. Hansen, Copenhagen, Denmark
- 11.20** How you and your institution can benefit from being a home or host mentor within the ESMO fellowship program  
Martin Gore, London, UK
- 11.35** How to check the status of your trainees knowledge and readiness for the license exam: ESMO examination opportunities  
Carsten Bokemeyer, Hamburg, Germany
- 11.50** Teaching medical oncology to medical students  
Nicholas Pavlidis, Ioannina, Greece
- 12.05** Q&A

12.30–13.20 **Violet Hall**

### Keynote Lecture

#### Detection, clinical relevance and specific biological properties of disseminated cancer cells

Chair: Carlos Caldas, Cambridge, UK

Speaker: Klaus Pantel, Hamburg, Germany

12.30–13.30 **Green Halls 1+2**

### Poster Symposium (Discussion session)

#### Breast cancer, advanced

Co-Chairs: John Crown, Dublin, Ireland and  
Dimitros Tryfonopoulos, Athens, Greece

- 278PD** – Meta-analysis of patients (pts)  $\geq 65$  years from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC)  
David Miles, London, UK
- 279PD** – Meta-analysis of patients (pts) previously treated with taxanes from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC)  
David Miles, London, UK
- 280PD** – Outcomes for metastatic breast cancer patients continuing on bevacizumab alone in study E2100  
See-Chun Phan, South San Francisco, CA, USA
- 281PD** – Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC)  
Istvan Lang, Budapest, Hungary
- 282PD** – Evolution of chemotherapy options in HER2-negative metastatic breast cancer (MBC)  
Sunil Verma, Toronto, Canada
- 12.30** Invited Discussant, Abstracts 278PD–282PD  
John Crown, Dublin, Ireland
- 283PD** – Beyond CHAT: Overall survival (OS) update from the CHAT study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC)  
Richard Bell, Geelong, Australia
- 284PD** – Results from two phase I trials of Her2/Neu-directed active cellular immunotherapy in patients with advanced malignancies  
Robert Sims, Seattle, WA, USA
- 285PD** – Duration of trastuzumab therapy may improve survival in HER2(+) metastatic breast carcinoma patients in the absence of adjuvant trastuzumab  
Ibrahim Türker, Ankara, Turkey

**286PD** – Evaluation of the predictive value of PIK3CA mutations and PTEN loss in the efficacy of trastuzumab therapy  
Evangelia Razis, Athens, Greece

**12.45** Invited Discussant, Abstracts 283PD-286PD  
Dimitrios Tryfonopoulos, Athens, Greece

**13.00** General Discussion

---

**12.30–13.30** **Orange Halls 2+3**

**Poster Symposium (Discussion session)**

**Genitourinary tumors**

Co-Chairs: Vesa Kataja, Kuopio, Finland and  
Thomas Powles, London, UK

**870PD** – Survival results of the IMPACT trial of sipuleucel-T for advanced prostate cancer

Daniel George, Durham, NC, USA

**871PD** – Cabazitaxel plus prednisone /prednisolone significantly increases overall survival compared to mitoxantrone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results with updated overall survival of a multinational phase III trial (TROPIC)

Stephane Oudard, Paris, France

**872PD** – PSA doubling time is the strongest predictor for metastases, castration resistance, and death in patients with prostate cancer treated with intermittent androgen deprivation for isolated biochemical relapse

Laurence Albiges, Villejuif, France

**873PD** – A Phase II pharmacodynamic study of pre-operative figitumumab (F) in patients (pts) with localized prostate cancer (PCa)

Kim Chi, Vancouver, BC, Canada

**874PD** – MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer

Lotta von Boehmer, Zurich, Switzerland

**12.30** Invited Discussant, Abstracts 870PD-874PD

Vesa Kataja, Kuopio, Finland

**875PD** – Survival update of a randomized phase 2 study (IMA901-202) investigating therapeutic vaccination with multiple tumor-associated peptides (TUMAP) in renal cell carcinoma (RCC) patients after failure of previous therapy with cytokines or kinase inhibitors

Wolfram Brugger, Villingen-Schwenningen, Germany

**876PD** – Combined chemo-radiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma (TCC) of the urinary bladder and/or in patients ineligible for surgery: Results of a phase I trial

Maria De Santis, Vienna, Austria

**877PD** – An international expanded access program (EAP) of everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy

Viktor Grunwald, Hannover, Germany

**878PD** – The mTOR inhibitor everolimus cooperates with the TLR9 agonist IMO in renal cell carcinoma by interfering with both tumor cells and microenvironment

Giampaolo Tortora, Naples, Italy

**12.45** Invited Discussant, Abstracts 875PD-878PD  
Thomas Powles, London, UK

**13.00** General Discussant

---

**12.30–13.30** **Yellow Hall 1**

**Poster Symposium (Discussion session)**

**Upper gastrointestinal tumors**

Co-Chairs: David Cunningham, Sutton, UK and TBC

**709PD** – Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study)

Mitsuru Sasako, Nishinomiya, Japan

**710PD** – Sorafenib does not improve the results of chemotherapy in advanced pancreatic cancer: A GISCAD randomised phase II trial

Rossana Berardi, Ancona, Italy

**12.30** Invited Discussant, Abstracts 709PD-710PD

David Cunningham, Sutton, UK

**711PD** – Impact of circumferential margin (CRM) size on overall survival (OS) in oesophageal cancer (OC)

David Landau, London, UK

**712PD** – Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced non-metastatic pancreatic cancer

Volker Heinemann, Munich, Germany

**12.40** Invited Discussant, Abstracts 711PD-712PD

TBC

**12.50** General Discussion

12.30–13.30 **Yellow Hall 2**

### Poster Symposium (Discussion session)

#### Head and neck cancer

Co-Chairs: Ezra Cohen, Chicago, IL, USA and  
Amanda Psyrris, Athens, Greece

- 1006PD – Randomized phase II/III trial of a tumor vascular disrupting agent, fosbretabulin tromethamine (CA4P), with carboplatin (C), and paclitaxel (P) in anaplastic thyroid cancer (ATC): Interim safety and efficacy results of the FACT trial  
Rossella Elisei, Pisa, Italy
- 1007PD – Vandetanib in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA)  
Eric Baudin, Villejuif, France
- 1008PD – Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): A randomized, double-blind phase II trial  
Sophie Leboulleux, Villejuif, France
- 12.30 Invited Discussant, Abstracts 1006PD-1008PD  
Ezra Cohen, Chicago, IL, USA
- 1009PD – Identification and validation of gene expression models that predict outcome in patients with early stage laryngeal cancer  
Elena Fountzilas, Boston, MA, USA
- 1010PD – Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN)  
Tanguy Seiwert, Chicago, IL, USA
- 1011PD – Influence of AKT1, AKT2 and FRAP1 polymorphisms on response and survival in head and neck cancer (SCCHN) patients treated with docetaxel and cetuximab  
Katharina Pfisterer, Berlin, Germany
- 12.45 Invited Discussant, Abstracts 1009PD-1011PD  
Amanda Psyrris, Athens, Greece
- 13.00 General Discussion

12.30–13.30 **Yellow Hall 3**

### Poster Symposium (Discussion session)

#### Geriatric oncology

Co-Chairs: Riccardo Audisio, Liverpool, UK and  
Pierre Soubeyran, Bordeaux, France

- 567PD – Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (> 70 years) with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): Final results and long term follow-up  
Michele Spina, Aviano, Italy

569PD – Digestive cancers in an elderly population: Which treatment for the intermediate Balducci group?

Olivier Dubreuil, Paris, France

570PD – Influence of age on the pharmacokinetic of i.v. vinflunine: Results of a phase I trial in elderly cancer patients  
Jean-Marie Tourani, Poitiers, France

574PD – Safety of gemcitabine in elderly patients  
Hanene Djedi, Annaba, Algeria

575PD – Treatment of advanced non-small cell lung cancer (NSCLC) in patients (p) older than 70  
Eduardo Richardet, Cordoba, Argentina

12.30 Invited Discussant, Abstracts 567PD, 569PD, 570PD, 574PD and 575PD

Pierre Soubeyran, Bordeaux, France

566PD – Evaluation of the Groningen Frailty Index (GFI) as a screening tool in elderly patients (pts): An interim analysis  
Dirk Schrijvers, Antwerp, Belgium

568PD – Prediction of chemotherapy toxicity by the Groningen Frailty Index (GFI) and the Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (pts): An interim analysis

Frank van Fraeyenhove, Antwerp, Belgium

571PD – Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy

Harukaze Yamamoto, Tokyo, Japan

572PD – Screening success and inclusion failure rates in a prospective trial of adjuvant chemotherapy for breast cancer in elderly women by the French Geriatric Oncology Group GERICO  
Etienne Brain, Saint Cloud, France

573PD – Assessment and treatment of osteopenia/osteoporosis in elderly women receiving anastrozole for early breast cancer

Cristina Falci, Padova, Italy

12.45 Invited Discussant, Abstracts 566PD, 568PD, 571PD, 572PD and 573PD  
Riccardo Audisio, Liverpool, UK

13.15–14.30 **Gold Hall**

### Proffered Paper session

#### Chest tumors II

Chair: Thierry Le Chevalier, Villejuif, France

Co-Chair: Filippo de Marinis, Rome, Italy

- 13.15 LBA16 – Sorafenib (S) + gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): Phase III NSCLC research Experience Utilizing Sorafenib (NExUS) trial  
Ulrich Gatzemeier, Hamburg, Germany



- 13.30** Invited Discussant, LBA16  
Benjamin Besse, Villejuif, France
- 13.45** **LBA17** – Randomized phase 2b study of pralatrexate vs erlotinib in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of prior platinum-based therapy  
Karen Kelly, Kansas City, KS, USA
- 14.00** **LBA18** – Efficacy and safety of PF299804 as first-line treatment (tx) of patients (pts) with advanced (adv) NSCLC selected for activating mutation (mu) of epidermal growth factor receptor (EGFR)  
Tony S. K. Mok, Hong Kong, China
- 14.15** Invited Discussant, LBA17 and LBA18  
Giuseppe Giaccone, Bethesda, MD, USA

#### 13.15–14.45 **Red Hall**

##### **Special Symposium**

##### **Ovarian cancer: New biology, new targets**

Chair: Stan Kaye, Sutton, UK

Co-Chair: David Huntsman, Vancouver, BC, Canada

- 13.15** Introduction  
Stan Kaye, Sutton, UK
- 13.20** Molecular subtypes of ovarian cancer: Insights into the drivers of high-grade ovarian serous and clear cell tumours  
David Bowtell, Melbourne, Australia
- 13.40** The molecular classification of ovarian carcinoma: implications for treatment  
David Huntsman, Vancouver, BC, Canada
- 14.00** Pathway driven treatments of ovarian cancer: Beyond chemotherapy  
Cristiana Sessa, Bellinzona, Switzerland
- 14.20** Functional imaging of ovarian cancer  
Elisabeth De Vries, Groningen, Netherlands
- 14.40** Conclusions  
Stan Kaye, Sutton, UK

#### 13.30–15.15 **Silver Hall**

##### **Awards session**

Co-Chairs: David J. Kerr, Oxford, UK and  
Josep Tabernero, Barcelona, Spain

- 13.30** Hamilton Fairley Award to Bengt Glimelius  
presented by David J. Kerr
- 13.35** Hamilton Fairley Award Lecture “Colorectal Cancer: A multidisciplinary disease revealing significant progress”  
Bengt Glimelius, Uppsala and Stockholm, Sweden
- 13.50** ESMO 2009 Best Exam Award to Juerger Wehmeyer,  
Münster, Germany
- 13.50** Fellowship Awards 2010, presented by David J. Kerr and  
Josep Tabernero
- 14.00** Fellowship Program – new Institutes, presented by  
Josep Tabernero
- Karolinska Institutet, Stockholm, Sweden
  - Vall d’Hebron Hospital, Barcelona, Spain
- 14.05** Palliative Care Designated Centre accreditation  
presented by Nathan Cherny, Jerusalem, Israel
- 14.15** ESMO Lifetime Achievement Award  
supported by an unrestricted grant from GSK  
to Alan Hilary Calvert, presented by David J. Kerr
- 14.20** ESMO Lifetime Achievement Award lecture  
Alan Hilary Calvert
- 14.35** ESMO Flower of Hope to José Baselga, ESMO Honorary  
Member, presented by David J. Kerr

#### 13.30–15.15 **Violet Hall**

##### **Proffered Paper session**

##### **Genitourinary tumors**

Co-Chairs: Carsten Bokemeyer, Hamburg, Germany and  
Maria De Santis, Vienna, Austria

- 13.30** **LBA22**– Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): final overall survival (OS) results  
Cora N. Sternberg, Rome, Italy
- 13.45** **8670** – Evaluation of different polymorphisms as markers of sunitinib efficacy and toxicity in first line treatment of renal clear cell carcinoma: a prospective study of the Spanish Oncologic GenitoUrinary Group  
Jesus Garcia-Donas, Alcorcon, Spain
- 14.00** **8680** – Phase 2 Randomized Discontinuation Trial (RDT) of Tivozanib in Patients With Renal Cell Carcinoma (RCC): Results in Patients Randomized to Tivozanib vs. Placebo  
Dmitry Nosov, Moscow, Russian Federation
- 14.15** Invited Discussant, LBA22 and Abstracts 8670 and 8680  
Tim Eisen, Cambridge, UK

- 14.35 LBA23** – Phase II study of Pazopanib monotherapy for patients with relapsed/refractory urothelial cancer (INT70/09, NCT01031875)  
Andrea Necchi, Milan, Italy
- 14.50 8690** – A prospective multicenter GETUG phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed metastatic germ-cell tumors (GCT)  
Karim Fizazi, Villejuif, France
- 15.05** Invited Discussant, LBA23 and Abstract 8690  
Jörg Beyer, Berlin, Germany

#### 13.30–14.45 **Blue Hall**

#### **Proffered Paper session**

#### **Head and neck cancer**

Chair: Lisa Licitra, Milan, IT

Co-Chair: Francesco Cognetti, Rome, Italy

- 13.30 LBA26** – Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (pmab)  
Jan Vermorken, Edegem, Belgium
- 13.45 10030** – Phase III study of pemetrexed in combination with cisplatin (PEM/CIS) versus placebo plus cisplatin (CIS) in patients with recurrent or metastatic squamous cell head and neck cancer (HNC)  
Susan Urba, Ann Arbor, MI, USA
- 14.00** Invited Discussant, LBA26 and Abstract 10030  
Marshall Posner, New York, NY, USA
- 14.15 10040** – Five-year survival (OS) and patterns of failure for human papillomavirus (HPV) positive and negative oropharynx cancer (OPC) in the TAX 324 clinical trial: Results of sequential therapy  
Marshall Posner, New York, NY, USA
- 14.30** Invited Discussant, Abstract 10040  
Lisa Licitra, Milan, Italy

#### 15.00–17.30 **Gold Hall**

#### **Presidential Symposium**

Chair: David J. Kerr, Oxford, UK

Co-Chair: Rolf A. Stahel, Zurich, Switzerland

- 15.00 LBA1** – Phase IIb/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1)  
Vincent Miller, New York, NY, USA
- 15.15 LBA2** – Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)  
Chi-Hsin Yang, Taipei, Taiwan
- 15.30** Invited Discussant, LBA1 and LBA2  
Jean-Charles Soria, Villejuif, France
- 15.45 2740** – The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1)  
José Baselga, Boston, MA, USA
- 16.00 LBA3** – Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g)  
Edith Perez, Jacksonville, FL, USA
- 16.15** Invited Discussant, Abstract 2740 and LBA3  
Eric Winer, Boston, MA, USA
- 16.30 LBA4** – ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC)  
Tim Perren, Leeds, UK
- 16.45** Invited Discussant, LBA4  
Michael Bookman, Tucson, AZ, USA
- 17.00 LBA5** – Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study  
Johann de Bono, Sutton, UK
- 17.15** Invited Discussant, LBA5  
Cora Sternberg, Rome, Italy

15.30–17.00 **Pink Hall**

### Special Symposium

#### Tailoring treatment of metastatic colorectal cancer

Chair: Jean-Yves Douillard, St. Herblain, France

Co-Chair: Eduardo Diaz-Rubio, Madrid, Spain

- 15.30** Introduction  
Eduardo Diaz-Rubio, Madrid, Spain
- 15.35** Aggressive versus non-aggressive initial treatment  
Tim Maughan, Cardiff, UK
- 15.55** Intermittent or continuous therapy  
Cornelis Punt, Nijmegen, Netherlands
- 16.15** **21IN** – Personalizing treatment based on biomarkers  
Sabine Tejpar, Leuven, Belgium
- 16.35** **22IN** – The combination of targeted agents: A look to the future  
Arnaud Roth, Geneva, Switzerland
- 16.55** Conclusions  
Jean-Yves Douillard, St-Herblain, France

---

15.30–17.00 **Red Hall**

### Special Symposium

#### MicroRNA's: The new genes involved in cancer

Chair: Carlo Croce, Columbus, OH, USA

Co-Chair: Ruggero De Maria, Rome, Italy

- 15.30** Introduction  
Ruggero De Maria, Rome, Italy
- 15.35** MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases  
George Calin, Houston, TX, USA
- 15.55** Micromanagers of malignancy: The role of microRNAs in regulating metastasis  
Carlo Croce, Columbus, OH, USA
- 16.15** miRNA in lymphomas, profile expression/prognosis  
Charles Lawrie, Oxford, UK
- 16.35** Cancerous microRNAs and regulatory RNA binding proteins  
Reuven Agami, Amsterdam, Netherlands
- 16.55** Conclusions  
Ruggero De Maria, Rome, Italy

15.30–17.00 **Blue Hall**

### Proffered Paper session

#### Hematological malignancies

Chair: Lena Specht, Copenhagen, Denmark

Co-Chair: TBC

- 15.30** **11320** – Zoledronic acid (ZOL) significantly reduces skeletal-related events (SREs) versus clodronate (CLO) in patients (pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study  
Gareth Morgan, London, UK
- 15.45** **11330** – Bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance for initial therapy of multiple myeloma: A prospective randomized trial  
Sara Bringhen, Turin, Italy
- 16.00** **11340** – Cytokine interleukin-16 is an important growth-promoting factor for multiple myeloma  
Djordje Atanackovic, Hamburg, Germany
- 16.15** Invited Discussant, Abstracts 11320, 11330 and 11340  
Joan Bladé, Barcelona, Spain
- 16.35** **11350** – Long-term follow-up of rituximab and infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkin's lymphomas (NHL)  
Michele Spina, Aviano, Italy
- 16.50** Invited Discussant, Abstract 11350  
TBC


# Poster Plan

12.30–13.30 Hall 3

## Poster Presentation (Display)

### Basic science and translational research

Chair: Maria Grazia Daidone, Milan, Italy



Basic science and translational research  
Biomarkers  
Chest tumors

Developmental therapeutics  
Hematological malignancies  
Psycho-oncology



**84P** – Novel gold speckled silica nanoparticles as mediators of tumor imaging and photothermal ablation therapy for breast cancer

Nobutaka Iwakuma, Fukuoka, Japan

**85P** – Cytotoxicity of curcumin combined with docetaxel in MCF7 breast tumor cells implicates the glutathione cycle and an antioxidant response: A metabolomics investigation

Mathilde Bayet-Robert, Clermont-Ferrand, France

**86P** – S-nitrosothiol homeostasis and nitrosative stress modulate proliferation of breast cancer cells

Amanda Cañas, Cordoba, Spain

**87P** – Molecular mechanisms involved in the response to combined antiangiogenic-antihormonal therapy in breast cancer

Miguel Angel Berciano Guerrero, Cordoba, Spain

**88P** – Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells

Nicola Normanno, Naples, Italy

**89P** – Breast cancer stem cells involvement in bone marrow metastasis

Tsuyoshi Shirakawa, Fukuoka, Japan

**90P** – Epigenetics silencing of the tumor suppressor protein 14-3-3 sigma by methylation in sporadic breast cancer

Joaquina Martinez-Galan, Granada, Spain

**91P** – The significance of DNA methylation of estrogen receptor alpha (ERa) expression in primary breast cancer (BC)

Klearchos Desiris, Thessaloniki, Greece

**92P** – Downregulation of Med19 gene expression inhibited the growth of breast cancer cells

Lihua Li, Wuxi, Jiangsu, China

**93P** – A novel approach using the telomerase-selective adenoviral marker for detection of circulation tumor cells in breast cancers

Seung Jin Kim, Suita, Japan

**94P** – The influence of TYMS and MTHFR gene polymorphisms on toxicity and response in breast cancer patients treated with 5-fluorouracil-based chemotherapy

Elzbieta Nowara, Gliwice, Poland

**95P** – Hedgehog signalling is active in biliary tract cancer and amenable to pharmacological inhibition

Tobias Kiesslich, Salzburg, Austria

MONDAY

**96P** – Sorafenib mediates apoptosis in hepatocellular carcinoma cells through kinase-independent inhibition of signal transducers and activators of transcription 3  
Kuen-Feng Chen, Taipei, Taiwan

**97P** – Involvement of microRNAs in the invasion of esophageal cancer cells  
Kayoko Matsushima, Nagasaki, Japan

**98P** – HB-EGF-CTF nuclear translocation induces gastric cancer invasion  
Takaya Shimura, Nagoya, Japan

**99P** – Amphiregulin nuclear translocation might reduce chemosensitivity in gastric cancer  
Michihiro Yoshida, Nagoya-city, Aichi Prefecture, Japan

**100P** – Plasma M30 and M65 levels in patients with advanced gastric cancer: Is there an impact on survival of patients?  
Ahmet Bilici, Istanbul, Turkey

**101P** – The development of the novel photodynamic therapy with glycoconjugated chlorine for stomach and colon cancer  
Mamoru Tanaka, Nagoya, Japan

**102P** – Metastasis suppressing/promoting microRNA expression in primary and metastatic colorectal cancer  
Michael Vickers, Ottawa, ON, Canada

**103P** – Detection and functional analysis of miRNAs in peripheral blood exosomes from cancer patients  
Masato Komoda, Fukuoka, Japan

**104P** – Expression of XIAP and miRNA-21 as predictor factors for lymph node invasion in rectum cancer  
Fernanda Peria, Ribeirão Preto, Brazil

**105P** – The p53 status affects the prognosis of patients with colorectal adenocarcinoma depending on the protein expression of NFY-C (Nuclear Factor Y, subunit C)  
Anastasia Kottorou, Patras, Greece

**106P** – Glutathione S-transferase Pi (GSTPi) for prediction of chemotherapy response and survival in stage IV colorectal cancer  
Wei Chua, Sydney, Australia

**107P** – Predictive value of molecular markers expression in locally advanced rectal cancer (LARC) treated with neoadjuvant bevacizumab (BEV) and capecitabine (CAPE) + standard radiotherapy (RT)  
Francesco Torino, Rome, Italy

**108P** – Extensive characterization of EGFR pathways may help in integrating the use of EGFR-targeted therapies in patients with squamous cell anal cancer  
Sara De Dosso, Bellinzona, Switzerland

**109P** – Differential effect of oxaliplatin and irinotecanin KRAS mutant colon carcinoma in vitro  
Zsuzsanna Bago-Horvath, Vienna, Austria

**110P** – TRAP1 and Sorcin cooperate in a survival pathway responsible for inducing drug-resistance in human colorectal carcinoma (CRC)  
Matteo Landriscina, Foggia, Italy

**111P** – Antitumor activity of Toll-like Receptor 9 agonist IMO overcomes K-Ras mutation and cooperates with cetuximab in colon and pancreatic cancers  
Giampaolo Tortora, Naples, Italy

**112P** – The potential of molecular-targeted therapy with EGFR and VEGFR signaling inhibitors against biliary tract cancer  
Daitaro Yoshikawa, Asahikawa, Japan

**113P** – The influence of SLC01B3 polymorphisms on docetaxel disposition in Asian nasopharyngeal carcinoma patients  
Sin-Chi Chew, Singapore

**114P** – Combined modalities of resistance in a cisplatin-driven human betel-associated oral squamous cell carcinoma  
Yen-Ting Cheng, Tainan, Taiwan

**115P** – Differential expression patterns of MMPs and the role in invasion in epithelial premalignant tumors and invasive squamous cell carcinoma  
Mi Ryung Roh, Seoul, South Korea

**116P** – Merkel cell polyomavirus (MCPyV) DNA present in non small cell lung cancer (NSCLC)  
Joongho Joh, Louisville, KY, USA

**117P** – Possible involvement of CXCL14 in anchorage-independent growth and bone metastasis from lung cancer  
Soichi Takiguchi, Fukuoka, Japan

**118P** – Some PPAR ligands sensitize human non-small lung cancer cells to ionizing radiation-induced apoptosis through up-regulation of OS generation  
Sung Hee Hong, Seoul, South Korea

**119P** – Preclinical and clinical activity of BMS-690514 in the treatment of non-small cell lung cancer (NSCLC)  
Eric Sbar, Princeton, NJ, USA

**120P** – Nilotinib enhances the cytotoxic effect of doxorubicin through selectively inhibiting the activity and cellular expression of the multidrug resistance protein P-glycoprotein in soft tissue sarcomas  
Regina Alemany, Palma de Mallorca, Spain

**121P** – PML expression in soft tissue sarcoma: Prognostic value in alkylating agents/anthracyclin based first-line therapy  
Bruno Vincenzi, Rome, Italy

**122P** – The hypermutagenetic role of overexpressed DNA polymerase iota and its variant in bladder cancer  
Jin Yang, Chongqing, China

**123P** – Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC)  
Michael Jeffers, Montville, NJ, USA

**124P** – Pharmacokinetics (PK) of sunitinib and its metabolite in patients with castrated refractory prostate cancer (CRPC) enrolled in the French multicenter PROSUT phase II study  
Marie-Christine Etienne-Grimaldi, Nice, France

**125P** – HPV infection in epithelial ovarian cells of women at high risk of developing ovarian cancer  
Olena Bilyk, Kiev, Ukraine

**126P** – Synergistic cytotoxic and apoptotic effect by AT-101 and cisplatin combination through DNA methyltransferase and histone deacetylase enzymes in human ovarian cancer cell lines  
Burcak Karaca, Izmir, Turkey

**127P** – Diagnostic approach in patients with unknown primary cancer  
Blanca Homet, Madrid, Spain

**128P** – Prognostic significance of gene expression profile in patients with carcinomas of unknown primary (CaUP)  
John Souglakos, Heraklion, Greece

**129P** – Determination of molecular markers for BRCA1/2 heterozygosity using gene expression profiling  
Asher Salmon, Jerusalem, Israel

**130P** – Carboxyl Terminus of Hsc70-Interacting Protein (CHIP) mediates degradation of C-MET receptor  
Ji Won Park, Daejeon, South Korea

**131P** – Quantitative high-dimensional monitoring of proteins in response to anti-cancer agents  
Satoshi Nishizuka, Morioka, Japan

**132P** – Nilotinib and sorafenib are more potent inhibitors for exon 11/17 c-Kit mutants than sunitinib: Results of incorporating cell-based screening platform and virtual molecular modeling study  
Yuan-Shuo Hsueh, Tainan, Taiwan

**133P** – Preclinical and clinical anti-angiogenic activity of BMS-690514  
Tai Wong, Princeton, NJ, USA

**134P** – Preclinical evaluation of trabectedin in patient derived tumor xenografts in vitro and in vivo, and identification of a predictive gene signature  
Heinz-Herbert Fiebig, Freiburg, Germany

**135P** – Radiotherapy may potentiate immunotherapy through presentation of novel tumor antigens  
Lotta von Boehmer, Zurich, Switzerland

**136P** – Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin (PLD) formulations in preclinical models: Is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of PLD products?  
Rao N. V. S. Mamidi, Raritan, USA

**137P** – Assessment of neuropathy-inducing effects of eribulin mesylate versus paclitaxel and ixabepilone in mice  
Krystyna Wozniak, Baltimore, MD, USA

**138P** – Immuno-positron emission tomography (PET) of Lewis Y (Ley) expressing xenografts using 89Zr-labelled humanised antibody hu3S193  
Fook Lee, Heidelberg, Australia

**139P** – Speckle tracking echocardiography identifies cardiac dysfunction induced by the anticancer Erb-B2 blocker lapatinib  
Carlo Tocchetti, Naples, Italy

**140P** – Analysis of time-to-progression (TTP) and progression-free-survival (PFS): Possible implications for optimizing the development, approval, costs and consequences of cancer therapies  
Franz Porzsolt, Ulm, Germany

**141P** – p53 responsive PIG3 gene polymorphism seems not associated with cerebral, colorectal and lung cancer  
Donatella Bianchessi, Milan, Italy

## Biomarkers

Chair: Antonella Isacchi, Milan, Italy

**178P** – Association of epigenetic inactivation of the ESR1 gene by aberrant methylation promoter with prognostic factors in breast cancer patients  
Joaquina Martinez-Galan, Granada, Spain

**179P** – Clinical significance and functional relevance of MAGED-4B in breast cancer  
Serena Germano, Dublin, Ireland

**180P** – Clinical significance of soluble vascular endothelial growth factor receptor-3 as a candidate biomarker for breast cancer patients  
Akihiko Takeda, Saitama, Japan

**181P** – SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nab-P)/carboplatin (C)/bevacizumab(B) for triple negative metastatic breast cancer (TNMBC)  
Kimberly Blackwell, Springfield, IL, USA

**182P** – A novel, simple and cost-effective KRAS mutation detection method, Luminex® assay: Results from a multicenter, prospective clinical trial  
EIJI Shinozaki, Tokyo, Japan



**183P** – A biopsy-driven and biomarker discovery clinical trial in metastatic colorectal cancer led by a new Quebec-wide translational research network, to identify signatures of clinical resistance

Gerald Batist, Montreal, QC, Canada

**184P** – Clinical validation of a 26-gene signature predicting response to cetuximab in wild type K-ras metastatic colorectal cancer

Vincent Vuaroqueaux, Riehen, Switzerland

**185P** – Integrative omics based next-generation molecular markers and targets in colorectal cancer

Debmalya Barh, Nonakuri, Purba Medinipur, India

**186P** – Circulating endothelial cells (CECs) and their apoptotic fraction (APO-CECs): Mutually independent biomarkers during bevacizumab-based treatment for advanced colorectal cancer patients

Mariangela Manzoni, Pavia, Italy

**187P** – Clinical value of circulating VEGFR2+pAKT+ cells as a functional surrogate biomarker in metastatic colorectal cancer treated with bevacizumab and chemotherapy

Sang Joon Shin, Seoul, South Korea

**188P** – Evaluation of ERCC1, BRCA1, thymidylate synthase (TS), class III beta tubulin (bTubIII), p53R2, RRM2 in stage I-III non-small cell lung cancer (NSCLC): A tissue microarray (TMA) study

Francesco Grossi, Genoa, Italy

**189P** – Overexpression of mTOR a novel marker for poor survival in early stage NSCLC: A validation study

Kathy Gately, Dublin, Ireland

**190P** – Localization, expression and impact on outcome of CXCR4 expression in resected early stage on small cell lung cancer

Dafydd Gwyn Bebb, Calgary, AB, Canada

**191P** – KRAS mutations differing for aminoacid substitution confer different drug sensitivity and resistance in NSCLC

Mirko Marabese, Milan, Italy

**192P** – The usefulness of measuring circulating tumor cells in patients with small-cell lung cancer

Tateaki Naito, Shizuoka, Japan

**193P** – Serum M30 AND M65 values in patients with advanced stage non-small cell lung cancer compared with healthy control group

Basak Oven Ustaalioglu, Istanbul, Turkey

**194P** – Proteomic analysis of large cell neuroendocrine carcinoma, small cell lung carcinoma and large cell carcinoma from formalin-fixed paraffin embedded samples and validation by immunohistochemical staining

Masaharu Nomura, Tokyo, Japan

**195P** – Detection of circulating tumor cells in gastric cancer patients using telomerase-specific replication-selective adenoviral agent: Prospective feasibility study

Hiroaki Ito, Yokohama, Japan

**196P** – Biomarker results from ARQ 197-114:

A phase Ib trial evaluating the cMET inhibitor ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC)

Carlos Rodriguez-Lope, Barcelona, Spain

**197P** – Loss of immunolabeling of Kruppel like factor 10 is associated with advanced stage and rapid progression of pancreatic cancer

Hui-Ju Ch'Ang, Tainan, Taiwan

**198P** – Circulating endothelial cells and their clinical manifestation in pancreatic cancer patients treated with gemcitabine based chemotherapy

Shunsuke Kondo, Tokyo, Japan

**199P** – Enhancing detection of BRAF-mutated circulating melanoma cells by pre-PCR cleavage of wild-type sequences

Alberto Fusi, Berlin, Germany

**200P** – Promoter hypermethylation of tumor suppressor genes in urine sediment from prostate cancer patients

Raluca Dumache, Timisoara, Romania

**201P** – Usefulness of noninvasive biomarkers to predict prognosis in bladder cancer

Raluca Dumache, Timisoara, Romania

**202P** – Determination of a new RECIST threshold using everolimus treatment in metastatic renal cell carcinoma: Evaluation from the RECORD-1 study

Rokhaya Thiam, Paris, France

**203P** – Co-administration of pazopanib and simvastatin increases the incidence of transaminase elevations in patients with cancer

Chun-Fang Xu, Harlow, UK

**204P** – Expression of the gastrin-releasing peptide receptor in hepatocellular carcinomas and its role as a prognostic biomarker

Nicolas Lazaretti, Passo Fundo, Brazil

**205P** – Value of bone resorption marker N-telopeptide crosslinks in predicting skeletal related events and response to zoledronic acid in bone metastases

Nermine Kamal, Cairo, Egypt

## Chest tumors

Chair: Rafal Dziadziuszko, Gdansk, Poland

**376P** – Third CECOG consensus on the systemic treatment of non small cell lung cancer

Tudor-Eliade Ciuleanu, Cluj-Napoca, Romania

**377P** – Outcomes of phase II clinical trials in advanced/metastatic non-small-cell lung cancer published within the last decade

Filip Janku, Houston, TX, USA

**378P** – Lung cancer in never-smokers

Yoichi Naito, Minato-ku, Japan

**379P** – Prospective study of host cell reactivation assay (HCRA) in non-small-cell lung cancer (NSCLC) patients (p)

Pedro Mendez, Badalona, Spain

**380P** – Alcohol drinking and risk of lung cancer

Arthur Klatsky, Oakland, CA, USA

**381P** – Mutations and beyond: Identification of predictors of outcome in randomized clinical trials (RCT) of 1st-line gefitinib (G) in advanced non small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFR-M)

Emilio Bria, Rome, Italy

**382P** – Validation study of epidermal growth factor receptor (EGFR) mutation tests using DNA from control admixture samples and formalin-fixed paraffin-embedded (FFPE) samples in non-small cell lung cancer (NSCLC) in the diagnostic setting

Koichi Goto, Kashiwa City, Chiba, Japan

**383P** – AXL mRNA overexpression correlates with lung metastases in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

Carlota Costa, Barcelona, Spain

**384P** – Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

Rafael Rosell, Badalona, Barcelona, Spain

**385P** – Validation study of epidermal growth factor receptor (EGFR) mutation tests using bronchofiberscopic brushing cytology samples and pleural effusion from non-small-cell lung cancer (NSCLC) patients in the diagnostic setting

Miyako Satouchi, Hyogo, Japan

**386P** – Does the type of EGFR activating mutation impact outcomes with erlotinib treatment?

David Heigener, Grosshansdorf, Germany

**387P** – Stem cell marker nestin expression correlates with proliferation and cell cycle in non-small cell lung cancer

Chen Zhenguang, Guangzhou City, China

**388P** – LACE-Bio: Results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration

Elisabeth Brambilla, Grenoble, France

**389P** – LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and

expression by immunohistochemistry (IHC) in patients with resected non-small cell lung cancer (NSCLC)

Stephen Graziano, Syracuse, NY, USA

**390P** – ERCC1, RRM1, TYMS and BRCA1 profiling for predicting response to chemotherapy in patients with non-small cell lung cancer (NSCLC)

Vassiliki Kotoula, Thessaloniki, Greece

**391P** – Serum tumor markers CEA, CYFRA and Ca125 are associated with worse prognosis in advanced non-small cell lung cancer (NSCLC)

Susana Cedrés, Barcelona, Spain

**392P** – A systematic review and consensus recommendations on the use of biomarkers in the treatment of non-small cell lung carcinoma (NSCLC)

Peter Ellis, Hamilton, ON, Canada

**393P** – Sorafenib activity in NSCLC cell lines seems related to a different type of K-RAS mutations

Massimo Broggin, Milan, Italy

**394P** – 1st-cycle rash as a clinical marker of outcome in patients with advanced non-small cell lung cancer (NSCLC) receiving 1st-line chemotherapy (CT) plus cetuximab: Analysis by histology

Ken O'Byrne, Dublin, Ireland

**395P** – Are primary tumour standardized uptake value (PT SUVmax), total lesion glycolysis (TLG) and metabolic volume (MV) measured on FDG PET (CT) predictors of survival in non-small cell lung cancer (NSCLC)?

Vanessa Terrones, Brussels, Belgium

**396P** – Prognostic significance of the maximum standardized uptake value on positron emission tomography according to histological subtypes for non-small cell lung cancer

Yasuhiro Tsutani, Hiroshima, Japan

**397P** – Biomarkers determination in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

Giorgio Cruciani, Ravenna, Italy

**398P** – The risk of lifelong DNA damage caused by lung cancer among rural male smokers who begin at teenage

Emmanuel Odiase, Abuja, Nigeria

**399P** – Reaction of plasma hepatocyte growth factor by administration EGFR-TKIs in lung cancer patients

Hidenori Tanaka, Osaka, Japan

**400P** – Mixed histology lung cancer – better or worse than pure histology lung cancer?

Courtney Krug, Huntington, WV, USA

**401P** – Prognostic factors of lung cancer patients with carcinomatous meningitis

Yukiko Nakamura, Shizuoka, Japan

**402P** – Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes  
Henrik Finnern, Ingelheim, Germany

**403P** – MAGE-A3 gene expression frequency and demography data of stage IB-IIIA NSCLC patients from ongoing MAGRIT phase III trial evaluating MAGE-A3 antigen specific cancer immunotherapeutic (ASCI) as adjuvant treatment

Joo Hang Kim, Seoul, South Korea

**404P** – A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC) (TORGO503)

Takuro Kometani, Fukuoka, Japan

**405P** – Oral vinorelbine (NVBo) + cisplatin (CDDP) as chemoradiotherapy (CT-RT) treatment (Trt) after induction in locally advanced non small cell lung cancer (NSCLC):

Results of a phase II study

Delphine Lerouge, Caen, France

**406P** – Multicenter phase II study of S-1 (S) plus cisplatin (P) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): West Japan Oncology Group (WJOG) 3706 trial

Haruko Daga, Osaka, Japan

**407P** – A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: Updated results of CALGB 30407

Ramaswamy Govindan, St. Louis, MO, USA

**408P** – Randomized phase II trial of uracil/tegafur (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601

Motoko Tachihara, Fukushima, Japan

**409P** – The result of percutaneous cryoablation for resectable primary lung cancer

Yoshikane Yamauchi, Tokyo, Japan

**410P** – Study B021247: A phase I feasibility trial of concurrent chemoradiation (CCRT) and bevacizumab (Bv) in patients (pts) with locally advanced non-squamous non-small cell lung cancer (NSCLC)

Robert Macrae, Ottawa, ON, Canada

**411P** – A randomized clinical trial of paclitaxel loaded polymeric micelle and cisplatin versus paclitaxel and cisplatin in advanced non-small cell lung cancer (NSCLC)  
Sung Lee, Seoul, South Korea

**412P** – A randomized, phase II study of paclitaxel (P) and carboplatin (C) ± conatumumab (CON) for first-line treatment of non-small cell lung cancer (NSCLC)  
Luis Paz-Ares, Seville, Spain

**413P** – A randomized trial of 1st line docetaxel and cisplatin (75/60 vs 60/60 mg/m<sup>2</sup>) for patients with stage IIIB or IV non-small cell lung cancer

Young-Chul Kim, Hwasungun, Jeonnam, South Korea

**414P** – Randomized phase II study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (GOIRC 02/2006): Preliminary results  
Marcello Tiseo, Parma, Italy

**415P** – Activity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harboring less common EGFR mutations

Jin-Yuan Shih, Taipei, Taiwan

**416P** – A phase II trial of linifanib treatment in non-small cell lung cancer (NSCLC) patients

Eng-Huat Tan, Singapore

**417P** – Randomized phase II study of sunitinib (SU) plus erlotinib (E) vs. placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC)

Harry J M Groen, Groningen, Netherlands

**418P** – Randomized, double-blind, placebo-controlled phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer (NSCLC) following 1st-line platinum-doublet chemotherapy

Myung-Ju Ahn, Seoul, South Korea

**419P** – Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small-cell lung cancer (NSCLC)

Jaafar Bennouna, Saint Herblain, France

**420P** – A phase II study of erlotinib plus capecitabine (XEL) as first-line treatment for Asian elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study)

Hong Yun Zhao, Guangzhou, China

**421P** – Pharmacokinetic (PK) evaluation of erlotinib with or without sunitinib to treat metastatic non-small cell lung cancer (NSCLC) in a phase II trial

Ana Ruiz-Garcia, San Diego, CA, USA

**422P** – Gemcitabine or erlotinib in combination with sorafenib in elderly patients with advanced non small cell lung tumor (GEST): A randomized phase II study

Cesare Gridelli, Avellino, Italy

**423P** – A final results of a phase II study of first-line gefitinib for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations; NEJ 003 study

Akira Inoue, Sendai, Japan

**424P** – Treatment of leptomeningeal metastasis from non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors  
Shigeki Nanjo, Kobe, Japan

**425P** – Clinical outcomes (COs) by sex in non-small cell lung cancer (NSCLC) patients (pts): Preliminary results from ARIES, a bevacizumab (BV) observational cohort study (OCS)  
Neal Fischbach, Fairfield, CT, USA

**426P** – The impact of tumor histology on effectiveness in bevacizumab (BV) treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a BV observational cohort study (OCS)  
Julie Brahmer, Baltimore, MD, USA

**427P** – Final safety outcomes by chemotherapy (CT) regimen for the M019390 (SAiL) trial: First-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC)  
Lucio Crino, Perugia, Italy

**428P** – Final safety data from patients (pts) who received maintenance (mnt) bevacizumab (Bv) in the M019390 (SAiL) trial: First-line Bv plus chemotherapy (CT) in advanced or recurrent non-small cell lung cancer (NSCLC)  
Janessa Laskin, Vancouver, BC, Canada

**429P** – Safety of first-line bevacizumab (Bv)-based therapy in the SAiL (M019390) trial: Central tumour location (CTL) and hypertension (HTN) in patients (pts) with advanced non-small cell lung cancer (NSCLC)  
Frank Griesinger, Oldenburg, Germany

**430P** – Maintenance bevacizumab (Bv) with or without pemetrexed (pem) following first-line Bv-cisplatin (cis)-pem in patients (pts) with advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary safety data from AVAPERL1 (M022089)  
Fabrice Barlesi, Marseille, France

**431P** – Bevacizumab (BV) treatment (Tx) to progression (BTP): Outcomes from a US community practice network  
Arlene Ravelo, San Francisco, CA, USA

**432P** – A Galician lung cancer group phase II study of bevacizumab (B), cisplatin and vinorelbine in chemo-naïve patients (p) with non squamous non small cell lung cancer (NSCLC)  
Maria Areses Manrique, Santiago de Compostela, Spain

**433P** – Clinical management patterns in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study  
Alfredo Carrato, Madrid, Spain

**434P** – Salvage chemotherapy (CT) with pemetrexed (PEM) for non small cell lung cancer (NSCLC): An implementation study  
Thierry Berghmans, Brussels, Belgium

**435P** – Compliance to vitamin supplementation and toxicity during 2<sup>nd</sup> line treatment with pemetrexed in patients with stage III/IV non small cell lung cancer (NSCLC) in daily practice  
Wolfgang Schuette, Halle, Germany

**436P** – Chemotherapy (CT) plus cetuximab as 1st-line treatment for advanced non-small cell lung cancer (NSCLC): Meta-analysis of individual patient data  
Nick Thatcher, Manchester, UK

**437P** – Meta-analysis of randomized phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC)  
Jean Pierre-Pignon, Villejuif, France

**438P** – Assessment of quality of life (QoL) in phase III trials in advanced non-small cell lung cancer (NSCLC)  
Krzysztof Adamowicz, Wejherowo, Poland

**439P** – Maintenance therapy of non-small cell lung cancer with erlotinib preserves quality of life  
E Juhász, Piheno, Hungary

**440P** – Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer  
Akitoshi Kinoshita, Ohmura, Japan

**441P** – Refractory vs sensitive relapsed SCLC: Validation of standard definition and assesment of alternative classification  
Andrea Ardizzoni, Parma, Italy

**442P** – Results of a randomized phase III study of single-agent amrubicin (AMR) versus carboplatin and etoposide (CE) in elderly patients with extensive-disease small cell lung cancer (ED-SCLC)  
Naoya Hida, Yokohama, Japan

**443P** – Results of a multicenter phase II trial with the deacetylase inhibitor (DACi) panobinostat in relapsed small cell lung cancer (SCLC) patients  
Filippo de Marinis, Rome, Italy

**444P** – Safety and pharmacokinetics of first-line AMG 479 (Mab to IGF1R) or AMG 102 (Mab to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC)  
Paul Lorigan, Manchester, UK

**445P** – Phase II study of belotecan and cisplatin as first-line chemotherapy for extensive disease of small cell lung cancer: Preliminary results  
Junshik Hong, Incheon, South Korea

**446P** – NGR-hTNF in combination with doxorubicin in relapsed small-cell lung cancer (SCLC)  
Vanessa Gregorc, Milan, Italy

**447P** – Meta-analysis of published randomized clinical trials (RCTs) comparing platinum/etoposide (PE) versus platinum/topoisomerase 1 inhibitors (PTIs) regimens for extensive-disease small-cell lung cancer (ED-SCLC)  
Olga Martelli, Rome, Italy

### Developmental therapeutics

Chair: James Spicer, London, UK

**504P** – Complete results from phase I dose escalation study of metMab, a monovalent antagonist antibody to the receptor met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies

Rebecca Moss, New Brunswick, NJ, USA

**505P** – Open-label phase Ib study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in combination with sorafenib or sunitinib in advanced renal cell carcinoma (RCC): Interim results

Leonard Appleman, Pittsburgh, PA, USA

**506P** – Cardiovascular adverse events (CV-AEs) in a pooled analysis of 1090 patients (pt) from phase 3 sunitinib (SU) trials  
Michael Ewer, Houston, TX, USA

**507P** – A phase I/II study of TKI258 (dovitinib), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer (mRCC): Preliminary phase II results  
Eric Angevin, Villejuif, France

**508P** – Phase I dose escalation trial of selective c-MET inhibitor ARQ 197 in Japanese patients with metastatic solid tumors  
Nobuyuki Yamamoto, Osaka, Japan

**509P** – A phase I dose escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumors

Alex Adjei, Buffalo, NY, USA

**510P** – Phase 1b dose escalation trial evaluating c-met inhibitor ARQ 197 and gemcitabine in patients (pts) with advanced solid tumors on schedules refined by in vitro mechanistic studies  
Shubham Pant, Oklahoma City, OK, USA

**511P** – Phase I study for KRN951 (AV-951), a selective VEGFR receptor 1, 2, 3 tyrosine kinase inhibitor in Japanese patients with metastatic solid tumors

Raizoh Yamaguchi, Shizuoka, Japan

**512P** – High inconsistencies among lists of cautioned & prohibited drugs in oncology phase I and phase II trials  
Benoit You, Pierre Benite, France

**513P** – An analysis of the risk of toxicity associated with participation in phase I oncology trials of novel molecularly targeted agents (MTA) at the Drug Development Unit, Royal Marsden Hospital  
Salma Alam, Sutton, UK

**514P** – Nature and subjectivity of dose-limiting toxicities in contemporary phase I trials: Comparison of cytotoxic versus non-cytotoxic drugs

Stephanie Clisant, Lille, France

**515P** – Public-private partnership in cancer drug development: A policy analysis

Richard Sullivan, London, UK

**516P** – Clinical outcome of patients with metastatic melanoma undergoing phase I clinical trials

Montserrat Blanco Codesido, Sutton, UK

**517P** – An international pooled analysis identifying predictive factors of serious side effects and DLTs during cycle 1 in patients included in phase I trials

Carlos Gomez- Roca, Villejuif, France

**518P** – Development of a new objective prognostic score for cancer patients treated in phase I trials

Ingrid Desar, Nijmegen, Netherlands

**519P** – Do patients on molecular targeted therapy suffer from sexual disorders?

Yohann Lorient, Villejuif, France

**520P** – A phase I dose finding study of the class 1 selective histone deacetylase inhibitor (HDACi) CHR-3996 in patients with treatment refractory metastatic cancer

Dionysis Papadatos-Pastos, Sutton, UK

**521P** – Updated results of a phase 1b/2 Study using a 30 min infusion of carfilzomib (CFZ) in patients (pts) with relapsed malignancies

Kyriakos Papadopoulos, San Antonio, TX, USA

**522P** – A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941  
Richard Baird, London, UK

**523P** – Results of a phase I, dose escalation study to assess the safety, efficacy and pharmacokinetics of siltuximab, an anti-IL-6 antibody in patients with solid tumors

Razelle Kurzrock, Houston, TX, USA

**524P** – Phase I study to assess the safety and tolerability of saracatinib (AZD0530) plus carboplatin (C) and/or paclitaxel (P) in patients with solid tumours

Steinar Aamdal, Oslo, Norway

**525P** – Complete phase IB study of TH-302 in combination with gemcitabine (G), docetaxel (D) or pemetrexed (P)

Mitesh Borad, Scottsdale, AZ, USA

**526P** – Antitumor immunity, efficacy and safety of CGTG-102 (Ad5/3-D24-GMCSF), an infectivity enhanced oncolytic adenovirus, in treatment of chemotherapy refractory solid tumors

Akseli Hemminki, Helsinki, Finland

**527P** – Clinical development of namitecan (ST1968), a novel camptothecin derivative: Phase I clinical data D1 Q3WK schedule  
Cristiana Sessa, Bellinzona, Switzerland

**528P** – Phase I and pharmacodynamic study of NGR-hTNF administered at high doses in refractory patients with solid tumors  
Paolo Zucali, Rozzano, Italy

**529P** – Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Safety run-in results from a randomized, controlled, phase II study (CORE)  
Tom Mikkelsen, Detroit, MI, USA

**530P** – Phase I study to assess the safety, tolerability, and pharmacokinetics of the specific Eg5 inhibitor AZD4877 in Japanese patients with solid tumours  
Taito Esaki, Fukuoka, Japan

**531P** – A phase I study of ridaforolimus, the oral mTOR inhibitor, as a single agent in Japanese patients with advanced solid tumors  
Yoshitaka Seki, Tokyo, Japan

**532P** – Targeting CD70 in non-Hodgkin lymphoma and renal cell carcinoma: A phase I study of the antibody-drug conjugate SGN-75  
Stephen Ansell, Rochester, MN, USA

**533P** – First report of the safety, pharmacokinetics (PK), and preliminary activity of PF299804 in Japanese patients (pts) with advanced solid tumors  
Toshiaki Takahashi, Shizuoka, Japan

**534P** – Preliminary results of a phase I study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging  
Joanna Pedersen, Sutton, UK

**535P** – A novel immunotherapy platform targeting paired cancer antigens through intra-lymph node immunization: Final results of two phase I clinical trials  
Mihail Obrocea, Valencia, CA, USA

**536P** – Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumours  
Penella Woll, Sheffield, UK

**537P** – Encouraging data from a phase I study of the first oral PARP inhibitor olaparib in Japanese patients with solid tumours  
Noboru Yamamoto, Tokyo, Japan

**538P** – A phase I study of AZD1152, an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia  
Shuichi Miyawaki, Tokyo, Japan

**539P** – Phase I/II trial of zoledronic acid plus interleukin-2 in patients with solid and hematological malignancies  
Volker Kunzmann, Wuerzburg, Germany

**540P** – Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small cell lung cancer: Safety run-in results of an open-label, randomized, phase II (CERTO) study  
Johan Vansteenkiste, Leuven, Belgium

**541P** – Natural history and management of everolimus (E) induced oral ulcers (OU)  
Charles Ferte, Lille, France

**542P** – Characterisation of the hepatic safety profile of trabectedin: Pooled analysis of 19 phase II clinical trials (CTs) in 1132 patients with solid tumours  
Jean-Yves Blay, Lyon, France

**543P** – Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors  
Binghe Xu, Beijing, China

**544P** – Effect of PF299804 on CYP2D6 activity in healthy volunteers (HVs) who are extensive metabolizers (EM)  
Carlo Bello, New York, NY, USA

**545P** – Cytotoxic activity of engineered 5-fluorouracil-loaded poly(butylcyanoacrylate) nanoparticles  
Radostina Alexandrova, Sofia, Bulgaria

**546P** – Pro-senescence therapy for neuroblastoma initiating stem cells  
Donatella Amendola, Rome, Italy

**547P** – A first in class AEMD to combat cancer  
Robert Shepard, Raleigh, NC, USA

**548P** – Accuracy of pulmonary function tests in patients treated in phase I trials  
Carlos Gomez-Roca, Villejuif, France

**549P** – Population pharmacokinetics of temsirolimus in pediatric patients with relapsed/refractory solid tumors  
Joe Boni, Collegeville, PA, USA

**550P** – Desensitization to different chemotherapy agents: A successful collaboration between oncology and immunoallergology  
Joana Caiado, Lisbon, Portugal

## Hematological malignancies

Chair: TBC

**1145P** – Long-term outcomes in early favourable Hodgkin's lymphoma treated with single modality ABVD: A single centre experience  
Bella Pajares Hachero, Málaga, Spain

**1146P** – Late relapses in Hodgkin's disease  
Blanca Cantos, Madrid, Spain

**1147P** – Vinorelbine, ifosfamide and prednisolone as a salvage regimen in relapsed Hodgkin's lymphoma  
Inas Abdel-Halim, Mansoura, Egypt



**1148P** – VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV): Final results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study  
Michele Spina, Aviano, Italy

**1149P** – Primary bone lymphoma  
Cristina Azevedo, Coimbra, Portugal

**1150P** – CNS prophylaxis and rituximab based regimen may improve the outcome and decrease the incidence of CNS relapse in poor risk patients with DLBCL  
Mervat Mahrous, El-Minia, Egypt

**1151P** – Investigation of the molecular basis of lenalidomide treatment in lymphoma cell lines  
Erica Ballabio, Oxford, UK

**1152P** – Modeling the pharmacokinetic/pharmacodynamic platelet response of inotuzumab ozogamicin, a novel antibody drug conjugate, administered alone or in combination with rituximab in patients with non-Hodgkin's lymphoma  
Joseph Boni, Collegeville, PA, USA

**1153P** – Non-random integration of Epstein-Barr virus (EBV) into chromosomes of Burkitt's lymphomas cell lines  
Eva Murga Penas, Hamburg, Germany

**1154P** – Prognostic significance of apoptosis-related proteins in diffuse large B-cell lymphoma (DLBL) patients (pts) treated with CHOP-based chemotherapy  
Jin Hyuk Choi, Suwon, South Korea

**1155P** – Morphological alterations in rats and rabbits after infection with bovine leukemia virus. In vivo laboratory model of a human viral T-lymphocytic leukemogenesis  
Petar Dimitrov, Sofia, Bulgaria

**1156P** – In vitro and in vivo synergistic anticancer effect of the HDAC inhibitor panobinostat (LBH589) plus zoledronic acid (ZOL) in human prostate cancer (PC) and multiple myeloma (MM) models  
Alfredo Budillon, Naples, Italy

**1157P** – Molecular cytogenetic characterization of chromosome 1 abnormalities in human multiple myeloma cell lines  
Snjezana Janjetovic, Hamburg, Germany

**1158P** – The study of pathogenetic mechanisms of thrombosis in patients with polycythemia vera syndrome  
Oana Badulescu, Iasi, Romania

**1159P** – BCR-ABL kinase mutations and imatinib resistance in chronic myeloid leukemia  
Satheesh Chiradoni Thungappa, Bangalore, India

**1160P** – Detection of BCR ABL fusion protein in CML and ALL by flowcytometric bead assay: An Indian experience  
Soma Mukhopadhyay, Kolkata, India

**1161P** – Early complete cytogenetic remissions in acute promyelocytic leukemia patients treated with arsenic trioxide as a first-line therapy  
Amol Akhade, Mumbai, India

**1162P** – Oral chemotherapeutic agent followed by aggressive chemotherapy improves overall outcome in adult acute myeloid leukemia (AML): A study from developing country  
Ashis Mukhopadhyay, Kolkata, India

**1163P** – Evaluation of hepatocyte growth factor (HGF) as a prognostic indicator in acute myeloid leukemia  
Hanan Mohamed, Giza, Egypt

**1164P** – Effect of arsenic trioxide on nucleostemin gene expression in acute promyelocytic leukemia patients  
Farzaneh Ashrafi, Isfahan, Iran

**1165P** – Criteria of prognosis for radiation-associated myelofibrosis with myeloid metaplasia following the Chernobyl accident  
Iryna Prokopenko, Kiev, Ukraine

**1166P** – Selective cytotoxicity of BIBR 1532 on acute promyelocytic leukemia cells through induction of P21 and suppression of C-Myc-dependent transcription of hTERT  
David Bashash, Tehran, Iran

## Psycho-oncology

Chair: TBC

**1201P** – Psychosocial care of Italian adult cancer patients: A large collaborative, hospital-based quality improvement project (HUCARE)  
Rodolfo Passalacqua, Cremona, Italy

**1202P** – The impression we give to patients when breaking bad news: A multicenter study in a Turkish cancer population  
Emel Yaman, Mersin, Turkey

**1203P** – Breaking bad news in a Greek regional hospital  
Apostolos Konstantis, Komotini, Greece

**1204P** – Job stress in health care professionals. A psycho-oncological analysis of the oncology division  
Guya Castellano, Treviglio, Italy

**1205P** – Influence of income and education on anticancer drug purchasing decisions in Hong Kong Chinese cancer patients  
Richard Epstein, Sydney, Australia

**1206P** – Psychological distress, fatigue, and pain in advanced breast cancer patients: Relationships with quality of life impairment  
Svetlana Kalyadina, Saint-Petersburg, Russian Federation

**1207P** – The effect of psychological support on quality of life in breast cancer patients  
Marina Maglakelidze, Tbilisi, Georgia

- 1208P – Phantom breast syndrome and psychological distress among breast cancer patients  
Nawal Ahbeddou, Rabat, Morocco
- 1209P – Breast cancer survivorship:  
A qualitative study from Iran  
Ali Montazeri, Tehran, Iran
- 1210P – Matrimonial risk factors in women with breast cancer  
Ivans Kuznecovs, Riga, Latvia
- 1211P – Fertility and sexuality concerns of cancer survivors  
Bogda Koczwara, Adelaide, Australia
- 1212P – Breast cancer treatment and sexuality. Moroccan women's perception  
Khoulia Slimani, Rabat, Morocco
- 1213P – Couple types and coping strategies: Difficulties of cooperation in conjoint drawing  
Veronica Tresoldi, Treviglio, Italy
- 1214P – The use of complementary and alternative therapies in cancer patients of Southeastern region of Turkey  
Mehmet Kucukoner, Diyarbakir, Turkey
- 1215P – Prospective study about depression in oncology and assessment of the medical decision making strategy  
Wadih Rhondali, Pierre Bénite, France
- 1216P – Surgery + radiotherapy vs. exclusive chemo-radiation therapy in oral and oropharyngeal cancer: Long term functional and psychological impact  
Marco Merlano, Cuneo, Italy
- 1217P – Psychiatric assessment in cancer patients: Preliminary results of cross sectional study  
Carola Locatelli, Rome, Italy
- 1218P – Burden of care. Positive and negative effects of caregiving  
Maria Luisa Bonetti, Treviglio, Italy
- 1219P – Initial attitudes of patients with lung cancer related to psychosocial rehabilitation  
Vasilios Heras, Nafplio, Greece
- 1220P – Do adult cancer survivors require psychotherapy? An experience from Eastern India  
Soma Basu, Kolkata, India
- 1221P – Influence of the family of oncological patients: An ethical problem?  
Luisina Onganía, Buenos Aires, Argentina
- 1222P – Psychological assessment and support to children and young adults with cancer in New Delhi  
Prakash Chitalkar, Kolkata, West Bengal, India
- 1223P – Repercussions of cancer on Moroccan adolescent and young adult lives  
Hassan Errihani, Rabat, Morocco

## Tuesday, 12 October 2010

08.00–09.00 **Yellow Hall 1**

**Challenge Your Expert session (Repetition)**

**Nasopharyngeal cancer**

Anthony Chan, Hong Kong, China

08.00–09.00 **Yellow Hall 2**

**Challenge Your Expert session (Repetition)**

**Multiple myeloma**

Joan Bladé, Barcelona, Spain

08.00–09.00 **Yellow Hall 3**

**Challenge Your Expert session (Repetition)**

**Advances of systemic treatment in metastatic melanoma**

Alexander M. M. Eggermont, Rotterdam, Netherlands

08.00–09.00 **Green Hall 3**

**Challenge Your Expert session (Repetition)**

**Advances in the treatment of metastatic or unresectable biliary tract cancer**

Juan W. Valle, Manchester, UK

08.00–09.00 **Green Halls 1+2**

**Patient Cases**

**Approaches to adjuvant treatment of small tumors**

Co-Chairs: Raimund Jakesz, Vienna, Austria and

Eric Winer, Boston, MA, USA

**08.00** The risk of stage and the risk of tumor biology: microscopic nodal tumor  
Raimund Jakesz, Vienna, Austria

**08.10** Triple negative small tumors  
Eric Winer, Boston, MA, USA

**08.20** Discussion

08.00–09.00 **Orange Halls 2+3**

**Patient Cases**

**Diagnosis and management of transformation**

Co-Chairs: Gianluca Gaidano, Novara, Italy and

Silvia Montoto, London, UK

**08.00** Richter's syndrome  
Gianluca Gaidano, Novara, Italy

**08.10** Transformed follicular lymphoma  
Silvia Montoto, London, UK

**08.20** Discussion

09.00–10.00 **Gold Hall**

**Controversy session**

**Anti-angiogenic agents should be used for the first-line treatment of ovarian cancer**

Moderator: Jonathan Ledermann, London, UK

- 09.00 Introduction and vote  
Jonathan Ledermann, London, UK
- 09.10 Pro Speaker  
Nicoletta Colombo, Milan, Italy
- 09.30 Contra Speaker  
Gordon Rustin, Northwood, UK
- 09.50 Vote and conclusions  
Jonathan Ledermann, London, UK

---

09.00–10.30 **Red Hall**

**Educational session (Repetition)**

**Towards an individualized approach of advanced non-small cell lung cancer**

Chair: Enriqueta Felip, Barcelona, Spain

Co-Chair: Rafal Dziadziuszko, Gdansk, Poland

- 09.00 Should we continue to use the term non-small cell lung cancer?  
Adi F Gazdar, Dallas, TX, USA
- 09.30 How to integrate current knowledge in selecting first-line therapy  
Enriqueta Felip, Barcelona, Spain
- 10.00 Consequences of targeted treatments for second-line therapy  
Federico Cappuzzo, Livorno, Italy

---

09.00–10.30 **Blue Hall**

**Educational session (Repetition)**

**Soft tissue sarcoma: From molecular diagnosis to selection of treatment**

Chair: Ian Judson, Sutton, UK

Co-Chair: Serge Leyvraz, Lausanne, Switzerland

- 09.00 Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies  
Eva Wardelmann, Bonn, Germany
- 09.30 Histology-driven chemotherapy of soft tissue sarcoma  
Mikael Eriksson, Lund, Sweden
- 10.00 Targeted therapies in soft tissue sarcoma  
Ian Judson, Sutton, UK

09.15–10.45 **Silver Hall**

**Special Symposium**

**Emerging concepts in head and neck cancer diagnostics and therapy**

Chair: Fortunato Ciardiello, Naples, Italy

Co-Chair: Lisa Licitra, Milan, Italy

- 09.15 Introduction  
Lisa Licitra, Milan, Italy
- 09.20 Biomarkers in molecular classification and diagnostics of head and neck squamous cell carcinoma  
Amanda Psyrri, Athens, Greece
- 09.40 New signalling pathway inhibitors and EGFR resistance  
Fortunato Ciardiello, Naples, Italy
- 10.00 Therapeutic implications of HPV positive tumors  
Maura Gillison, Columbus, OH, USA
- 10.20 Molecularly-targeted therapies in thyroid cancer  
Jean-Pierre Droz, Lyon, France
- 10.40 Conclusions  
Lisa Licitra, Milan, Italy

---

09.15–10.45 **Pink Hall**

**Special Symposium**

**The use of biomarkers to guide treatment in hematological malignancies**

Chair: Martin Dreyling, Munich, Germany

Co-Chair: Andreas Hochhaus, Jena, Germany

- 09.15 Introduction  
Andreas Hochhaus, Jena, Germany
- 09.20 Chronic lymphocytic leukemia The use of biomarkers to guide treatment in hematological malignancies  
Stephan Stilgenbauer, Ulm, Germany
- 09.40 Multiple myeloma  
Niels van de Donk, Utrecht, Netherlands
- 10.00 Mantle cell lymphoma  
Martin Dreyling, Munich, Germany
- 10.20 Chronic myelogenous leukemia  
Andreas Hochhaus, Jena, Germany
- 10.40 Conclusions  
Martin Dreyling, Munich, Germany

09.15–10.15 **Orange Hall 1**

**Multidisciplinary Interactive session (MIS)**

**Locally advanced laryngeal cancer**

Co-Chairs: Guy Andry, Brussels, Belgium and  
Jacques Bernier, Genolier, Switzerland

09.15 Surgery

Guy Andry, Brussels, Belgium

09.30 Radiotherapy

Jacques Bernier, Genolier, Switzerland

09.45 Discussion

---

10.15–13.00 **Gold Hall**

**Congress Highlights**

Chair: Rolf A. Stahel, Zurich, Switzerland

10.15 GLOBOCAN 2008: The worldwide burden of cancer

Eva Steliarova-Foucher, Lyon, France

10.30 Gastrointestinal tumors

David Cunningham, Sutton, UK

10.40 Colorectal cancer

Jean-Yves Douillard, St. Herblain, France

10.50 Head and neck cancer

Marco Merlano, Cuneo, Italy

11.00 Hematological malignancies

Lena Specht, Copenhagen, Denmark

11.10 Supportive & Palliative

Dorothy M. K. Keefe, Adelaide, Australia

11.20 Breast cancer, early

TBC

11.30 Breast cancer, advanced

Fatima Cardoso, Lisbon, Portugal

11.40 Sarcoma

Paolo G. Casali, Milan, Italy

11.50 Melanoma

TBC

12.00 Basic Science, biomarkers and TR

Giampaolo Tortora, Naples, Italy

12.10 Developmental therapeutics

James Spicer, London, UK

12.20 Gynecological cancer

Isabelle Ray-Coquard, Lyon, France

12.30 Genitourinary tumors

Maria De Santis, Vienna, Austria

12.40 Chest tumors

Lucio Crinò, Perugia, Italy

12.50 Congress closing remarks

Rolf A. Stahel, Zurich, Switzerland

11.00–12.30 **Red Hall**

**Educational session (Repetition)**

**Diagnostic and management issues in gastroesophageal cancer**

Chair: Florian Lordick, Hannover, Germany

Co-Chair: João Oliveira, Lisbon, Portugal

11.00 Is there any role for surgery in the multidisciplinary  
treatment of esophageal cancer?

Michael Stahl, Essen, Germany

11.30 Multimodality treatment for localized  
gastroesophageal cancer

David Cunningham, Sutton, UK

12.00 New trends for staging and therapy for localized  
gastroesophageal cancer: The role of PET scan

Florian Lordick, Hannover, Germany

---

11.15–12.45 **Blue Hall**

**Educational session (Repetition)**

**Advances in head and neck cancer**

Chair: Jan Vermorken, Edegem, Belgium

Co-Chair: Marshall Posner, New York, NY, USA

11.15 The role of papilloma virus infection

Stina Syrjänen, Turku, Finland

11.45 Integrating systemic agents into multimodality treatment  
of locally advanced diseases

Marshall Posner, New York, NY, USA

12.15 Optimal treatment for relapsing or metastatic disease

Jan Vermorken, Edegem, Belgium

---

11.15–12.45 **Silver Hall**

**Special Symposium**

**ESMO DCTF/UICC/WHO Joint Symposium: Meeting the challenge  
of managing cervical cancer in the developing world**

Co-Chairs: Eduardo Cazap, Buenos Aires, Argentina and

Andreas Ullrich, Geneva, Switzerland

11.15 What is the optimum screening method for cervical cancer  
in developing countries?

Rengaswamy Sankaranarayanan, Lyon, France

11.35 HPV vaccination: What practical experience tells us to date

Vivien Tsu, Seattle, WA, USA

11.55 Cervical cancer control: A global strategy

Eduardo Cazap, Buenos Aires, Argentina

12.15 The Health Minister's response to managing  
cervical cancer in low-income countries

Carlos Vallejos Sologuren, Lima, Peru

12.35 Conclusions

Eduardo Cazap, Buenos Aires, Argentina